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Abstract 
The overall aim of this project was to compare the int ractions of anti-arthritic 
gold(I) compounds and gold nanoparticles, with RAW264.7 macrophage cells and the 
redox protein thioredoxin reductase. Cytotoxicity studies showed that auranofin 
exhibited the greatest toxicity towards the macrophages, with an IC50 of 4 µM after 24 h 
treatment. Aurothiosulfate and aurothiomalate proved to be far less toxic than auranofin, 
whilst citrate-stabilised gold nanoparticles were non-toxic when administered at a 
concentration of 60 µM. Cellular gold uptake experim nts were performed using 
graphite furnace atomic absorption spectroscopy. The results of these experiments 
showed that treatment of the macrophages with gold nanoparticles led to greater levels 
of gold incorporation than treatment with aurothiomalate, aurothiosulfate or auranofin.  
The sub-cellular distribution of gold in macrophages treated with auranofin, 
aurothiomalate or gold nanoparticles was investigated using synchrotron radiation X-ray 
fluorescence microscopy. These experiments were performed using small numbers of 
macrophages at the Advanced Photon Source (Argonne National Laboratory, USA) and 
showed that gold was distributed throughout the cells that had been treated with 
auranofin. In contrast, treatment with aurothiomalate or gold nanoparticles led to 
discrete hotspots within cells, which was attributed o formation of lysosomal bodies 
dense with gold. Similar cellular gold distribution experiments were performed at the 
Australian Synchrotron using larger populations of macrophages. The results of these 
experiments showed that treatment with auranofin or aurothiomalate led to a non-
uniform uptake pattern across the cell populations, whilst treatment with gold 
nanoparticles resulted in a more uniform pattern of uptake. Scanning electron 
microscopy experiments provided supporting evidence that the gold associated with the 
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macrophages was internalised to varying depths within the cells, and not simply bound 
to their surfaces. 
A series of investigations were performed that examined the effects on 
macrophage production of various cytokines associated with the inflammation response, 
resulting from treatment with gold compounds or nanoparticles before activation using 
lipopolysaccharide. Treatment with aurothiomalate was shown to have a minimal effect 
on the production of nitric oxide, reactive oxygen species and tumor necrosis factor. In 
contrast, treatment of the cells with auranofin result d in much stronger inhibitory 
effects, with nitric oxide production reduced by 99%, reactive oxygen species 
production reduced by 94% and tumor necrosis factor pr duction reduced by 52%. 
Somewhat surprisingly, treatment of the macrophages with gold nanoparticles did not 
affect inflammation mediator production, despite evid nce from other experiments of 
extensive uptake and internalisation. A second serie  of investigations into 
inflammation mediator production was conducted using a number of commercially 
available gold nanoparticles, which varied in size and/or the composition of their 
protective outer shell. These experiments showed that none of the different types of 
gold nanoparticles were able to markedly affect the production of nitric oxide or 
reactive oxygen species. 
Mass spectrometric investigations were conducted into the ability of different 
gold(I) compounds to bind to thioredoxin reductase, an enzyme that may be an 
intracellular target of anti-arthritic gold complexes or gold nanoparticles. The results of 
these experiments showed that aurothiosulfate exhibited the most extensive binding to 
the enzyme, followed by auranofin, then aurothioglucose and aurothiomalate, and 
finally sodium dicyanoaurate. With the exception of s dium dicyanoaurate, multiple 
gold ions were observed to readily bind to the enzyme. In the case of auranofin, a 
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number of different adducts were observed in which one or more gold-triethylphosphine 
moieties were bound to thioredoxin reductase, indicating that the gold binding event 
involved displacement of the acetylthioglucose ligand in the initial coordination sphere 
of the metal complex. The differences in the extent of binding were attributed to each 
compound’s susceptibility to ligand displacement reactions. Experiments conducted 
with gold nanoparticles provided no evidence of binding of gold to thioredoxin 
reductase. This was attributed to either an inability of the nanoparticles to approach the 
active site of the enzyme owing to steric hindrance, or the interactions being too weak to 
survive the ionisation conditions present in the mass spectrometer. 
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Chapter 1:  
Introduction 
 
 
The usage of gold(I) compounds for the treatment of rheumatoid arthritis has a history 
that spans the 1930s until the present day. However, in modern times, these compounds 
have become less popular due to the rise of newer, more efficacious therapeutics with 
reduced side-effects. Intriguingly, recent studies have also shown that gold 
nanoparticles might have potential for the treatment of rheumatoid arthritis that exceeds 
that of the traditional gold(I) compounds. Consequently, this chapter provides a brief 
review of rheumatoid arthritis, with emphasis on the role of macrophages in disease 
progression, and the development of modern therapeutics. The discovery of clinical 
gold anti-arthritic drugs is presented, including descriptions of what is known about 
their mechanisms of action. A survey of research into the potential of new gold 
compounds as treatments for other diseases is also presented. The biological role of 
thioredoxin reductase, an enzyme thought to be an important biological target of gold(I) 
compounds, is discussed, along with the conflicting results of investigations into the 
biological interactions of gold nanoparticles. 
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1.1 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic autoimmune disease that typically arises 
as inflammation around the synovial joints of the body, causing discomfort and 
difficulty in movement. While joint swelling is often considered the defining 
characteristic of the disease, inflammation in the membranes around the heart or lungs, 
or in subcutaneous tissue is also observed in a large number of patients.1 The prevalence 
rate of RA in the developed world is estimated to be approximately 0.5 – 1%,2 with the 
disease usually presenting between ages 45 and 65,3 and occurring more frequently in 
women.4 Table 1.1 shows the prevalence rates of RA in selected countries, which were 
compiled from several studies performed between 1997 and 2003.5 In Australia, 
approximately 445,000 people reported having RA in 2014 giving a prevalence rate of 
1.85 per 100 inhabitants.6 Patients with RA have a lower life expectancy compared to 
the general populous, with men and women expected to live 4 and 10 years shorter, 
respectively.7 This increased mortality has not been linked directly to joint damage that 
occurs due to the disease, but is instead likely to be due to other complications such as 
heart attack.8,9 
Table 1.1: Prevalence rates of rheumatoid arthritis in selectd ountries.5 
Country 
Prevalence rate 
(per 100 inhabitants) Country 
Prevalence rate 
(per 100 inhabitants) 
Brazil 0.5 Japan 0.3 
China 0.2 – 0.3 Norway 0.4 – 0.5 
England 0.8 – 1.1 Netherlands 0.9 
France 0.6 Turkey 0.5 
Indonesia 0.2 – 0.3 United States 0.9 – 1.1 
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While direct causes of the disease have still not been definitively identified, both 
genetic and environmental factors are thought to play a role.2,10 The most important 
genetic factor centres on inheritance of a specific major histocompatibility complex 
antigen, known as HLA-DRB1.11 A number of environmental risk factors have been 
identified, with smoking being the primary one.2,12,13 There have also been a number of 
weaker links proposed between the incidence of RA and alcohol consumption, vitamin 
D intake, oral contraceptive usage and birthweight.14 It has been postulated that certain 
viral infections may also lead to development of the disease. For example, in one study, 
three types of herpes viruses were detected in higher levels in the serum and peripheral 
blood mononuclear cells (PBMCs) of patients with RA.15 However, a causal link has yet 
to be established, as the presence of the virus may also be due to the fact that the 
immune system of patients with RA is significantly compromised. Expression of auto-
antibodies, which are antibodies that target a person’s own proteins, are also thought to 
play a part in the disease. Between 50 – 80% of patients with RA have detectable levels 
of rheumatoid factor or anti-citrullinated protein a tibodies.2 This enables the presence 
of either of these two classes of protein to be used as biomarkers for disease diagnosis.2 
Disease progression is associated with increased severity of synovitis 
(inflammation of the synovial lining), and eventual loss of joint function. Synovitis is 
largely caused by proliferation of synovial fibroblasts and infiltration by macrophages, 
T and B lymphocytes, plasma cells, and dendritic cells.16 These cells all contribute to 
disease progression by producing pro-inflammatory cytokines and destructive proteases, 
which cause thinning of cartilage and degradation of bone. Progressive damage to the 
joints eventually leads to loss of function and personal disability in addition to 
decreased quality of life.17 The specific role macrophages play in the disease through 
cytokine emission is discussed in the following section. 
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1.1.1 The Role of Macrophages and Immune Mediators 
Macrophages are one of the major cell types involved in the progression of RA. 
The primary role of macrophages is to phagocytose cellular debris and pathogens; 
however, they also serve to produce inflammation and stimulate other immune cells. 
Macrophages can be differentiated into two different types, M1 and M2, which promote 
and reduce inflammation, respectively.18 They perform these roles by emitting a number 
of immune mediators. These include the pro-inflammatory cytokines tumour necrosis 
factor (TNF), interleukin (IL)-1, IL-6, IL-12, the anti-inflammatory cytokine IL-10, as 
well as reactive oxygen species (ROS) and nitric oxde (NO).16,19 A diagram depicting 
the relationship of macrophages with cytokine expression and joint destruction in RA is 
shown in Figure 1.1.20 
 
Figure 1.1: Key cytokine and cellular interactions in rheumatoid arthritis. Reprinted with permission 
from Macmillan Publishers Ltd: Nature Reviews Immunology, vol. 2, p. 364-371, copyright May 2002.20 
 
High levels of TNF expression in the synovial fluid is a characteristic feature of 
RA and strongly linked to progression of the disease. This is believed to be due to the 
ability of TNF to stimulate the release of a large number of other inflammatory 
cytokines.21 In addition to cytokine release, TNF can signal oxidative burst,22 stimulate 
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production of prostaglandins,23 and induce synthesis of matrix metalloproteinases.24,25 
Prostaglandins are a group of lipids that signal inflammation,26 while matrix 
metalloproteinases are enzymes that cause cartilage destruction and bone resorption.16 
 IL-1 refers to a subset of cytokines involved in immune and inflammatory 
responses. Two of the more prominent molecules in this group are IL-1α, which is 
primarily located intracellularly, and IL-1β, which is secreted from cells. A third, 
important member of this group of cytokines is IL-1Ra, which acts as an antagonist for 
IL-1α and IL-1β by competing for the same receptors.27 Like TNF, IL-1β has also been 
linked to the progression of RA, as it is expressed in greater quantities in the synovial 
fluid28 and plasma of patients with this disease.29 Further evidence of the importance of 
IL-1β is provided by observations of a correlation betwen plasma levels of this 
cytokine, with stiffness and pain scores in people suffering from RA. The functions of 
TNF and IL-1 seem to overlap. For example, IL-1 induces matrix metalloproteinase 
synthesis in a similar fashion to TNF.30,31 Some animal models seem to suggest that IL-
1 plays a larger role in joint destruction, while TNF is more important in production of 
inflammation.32 However, it is highly likely that both cytokines play important roles in 
both processes. This is highlighted by a study which showed that each cytokine can 
upregulate production of the other.27 
 The term ROS refers to a number of compounds containi g oxygen that are 
involved in cell signalling and homeostasis, and includes O2, O2‾, H2O2 and •OH.
33 
Oxidative stress occurs when these molecules are produced in increased quantities, and 
can lead to significant damage to deoxyribonucleic acid (DNA), proteins and lipids.34 In 
addition, ROS can degrade extracellular matrix materials such as collagens and 
proteoglycans,35 which directly leads to joint degradation and inflammation. In patients 
with RA, oxidative stress is observed in the synovial fluid along with a decrease in the 
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activity of anti-oxidant enzymes.36 This provides support for the conclusion that 
production of ROS is one of the main mechanisms of pathogenesis of the disease.37 
 NO is a free radical produced by a class of enzymes known as nitric oxide 
synthases. NO has a variety of biological roles as a signalling molecule in processes 
including vasodilation, neurotransmission and immune system regulation. Owing to its 
reactivity, NO is a very short-lived species (t1/2 = 6 s) and exhibits low bioavailability. 
This results in the actions of NO being restricted to near its site of synthesis.38 NO can 
form a number of related chemical species such as NO2, O2‾, NO3‾, N2O3 and 
ONOO‾. In addition, it may also react directly with biomlecules such as haem groups 
as part of its normal functions.39 Under general physiological conditions NO is 
considered to have an anti-inflammatory effect.38 In contrast, in certain inflammatory 
disorders such as RA, it is both a marker and pro-inflammatory mediator, particularly in 
macrophages.40 This is illustrated by studies that showed that NOproduction is linked 
to generation of inflammatory cytokines, enhanced bone resorption,38 diminished bone 
proliferation,38 and chondrocyte apoptosis.33 It is important to note that some studies 
have also shown that increased levels of cytokines result in enhanced production of 
NO.40 
1.1.2 Approaches to Treatment of Rheumatoid Arthritis 
Treatment of RA is usually in the form of a combinat on therapy involving 
administration of drugs belonging to two broad categories: nonsteroidal anti-
inflammatory drugs (NSAIDs) and disease modifying ati-rheumatic drugs (DMARDs). 
Corticosteroids are occasionally also used for providing relief from the inflammation 
associated with RA. However, their long term use is not recommended due to the severe 
side-effects associated with such treatment.41 NSAIDs are regularly used to treat 
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patients with RA owing to their analgesic and anti-pyretic effects, which result from 
inhibition of the cyclooxygenase class of enzymes.42,43 These enzymes catalyse the first 
two steps in the synthesis of prostaglandins.26 Although NSAIDs are very effective at 
providing relief from the pain associated with inflammation, there are concerns over 
their continued use for RA therapy as they can lower prostaglandin levels in the 
stomach, causing ulceration and bleeding. Lower prostaglandin levels may also result in 
kidney damage, leading to renal failure.26 
In comparison to NSAIDs, the DMARDs are used to treat RA with the intention 
of slowing or halting the disease. The structures of ome clinically used DMARDs are 
shown in Figure 1.2. Two examples of DMARDs are the anti-malarial compunds 
chloroquine and hydroxychloroquine (Figure 1.2 a and b), which have been used since 
the 1950s, and act by inhibiting the release of IL-1 by monocytes.44 D-Penicillamine 
(Figure 1.2 c) is another example of a DMARD and has been used since the 1970s. It is 
thought to act as a immunosuppressant, by decreasing proliferation of T lymphocytes 
and inhibiting macrophage function.41 The purine analogue sulfasalazine (Figure 1.2 d), 
also acts as a DMARD by reducing lymphocyte numbers,45,46 while cyclosporine 
(Figure 1.2 e), which was developed in the 1970s to prevent rejection of transplanted 
organs, is thought to work by inhibiting IL-1 release by monocytes and IL-2 release by 
T-helper cells.47 More recently, the biologics infliximab and etanercept were licensed 
for medical use in 1998, and reduce inflammation by specifically inhibiting TNF.48 Of 
all the DMARDs used by rheumatologists for the treatment of RA, methotrexate 
(Figure 1.2 f) is perhaps now the most popular.49–52 Methotrexate was originally 
developed as an anti-cancer compound in the 1950s, but is thought to also work as a 
DMARD by inhibiting purine metabolism.41,53 
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Figure 1.2: Structures of some typical disease modifying anti-rheumatic drugs used clinically for the 
treatment of rheumatoid arthritis: a) chloroquine; b) hydroxychloroquine; c) D-penicillamine;                 
d) sulfasalazine; e) cyclosporine; and f) methotrexate. 
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1.1.3 Therapeutic Usage of Gold in Rheumatoid Arthritis 
Another major class of DMARDs, that has been used successfully for treating 
RA are various gold(I) salts. Figure 1.3 shows the structures of some of these 
compounds. Their clinical usage is sometimes called chrysotherapy in recognition of the 
Greek word ‘chrysos’ for gold. The history of medicinal usage of gold metal dates back 
thousands of years.54 However, the usage of gold compounds for RA therapy can be 
traced to the discovery by Robert Koch in the late 1800s, that the gold complex 
K[Au(CN)2] powerfully inhibits the growth of the bacterium Mycobacterium 
tuberculosis,55–57 the causative agent of tuberculosis. Although the ability of this gold 
complex to treat tuberculosis subsequently proved to be limited in part due to its 
toxicity, in the 1920s and 1930s, Jacques Forestier performed a number of clinical 
studies into the ability of various simple gold compounds to treat RA.58–61 The impetus 
for these investigations was based upon the then erro eous understanding that RA was 
an infectious disease similar to tuberculosis.7,62,63 
In order to investigate the potential of gold compounds for treating RA, Forestier 
conducted an initial trial where 15 patients were given intramuscular injections of 
sodium aurothiopropanol sulfonate (Allochrysine, Figure 1.3 a) on a weekly basis for 
10-12 weeks.58 After completion of the trial, five patients had shown an excellent 
response, while a further five patients showed significant improvement in their 
symptoms, and the remaining five showed minimal to no response. Despite the overall 
positive results from this trial, Forestier warned of some toxic side effects from 
treatment with gold, including fever, diarrhoea and vomiting. A second trial into the 
effects of gold therapy on patients with RA was published by Forestier in 1930.59 This 
study involved optimised administration of Allochrysine to a total of 33 patients. 
Forestier noted that beneficial effects of gold trea ment were not seen until 3-6 months 
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after treatment had commenced. In 1934, Forestier published the results of a much 
larger trial, involving 500 patients with RA who were treated with a variety of gold 
salts.61 On this occasion a 70 – 80% success rate was reported for patients receiving 
gold salts via injection, with sodium aurothiomalate (brand name Myocrisin, Figure 1.3 
b) and aurothioglucose (brand name Solganol, Figure 1.3 d) being the most effective 
gold compounds. The successful treatment of patients with RA using gold compounds 
was confirmed in a number of subsequent papers,63–66 and led to the widespread clinical 
usage of gold for this purpose for several decades nd, to a lesser extent, the present. 
 
Figure 1.3: Structures of some typical gold(I) compounds used clinically for treatment of rheumatoid 
arthritis: a) sodium aurothiopropanol sulfonate; b) sodium aurothiomalate; c) sodium aurothiosulfate;      
d) aurothioglucose; and e) auranofin. 
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The clinical effectiveness of gold compounds for trea ing RA, not surprisingly, 
is often limited by the extent to which side effects occur. In approximately 40% of 
patients undergoing chrysotherapy a variety of side eff cts are observed, including 
mouth ulcers, skin rashes and dermatitis, anaemia, low platelet counts, elevated urine 
protein levels, kidney and liver damage, vomiting, diarrhoea and sometimes in the case 
of prolonged treatment, permanent grey/blue skin discolouration.57 In the 1980’s, a new 
orally administered Au(I) drug, auranofin (Figure 1.3 e, brand name Ridaura) was 
developed that was found to have fewer or less severe side-effects than the 
intramuscularly injected gold compounds.67 Another contrast between auranofin and 
many of the other widely used chrysotherapeutic agents is that it is a discrete 
mononuclear compound, which is bound to thioacetylglucose and triethylphosphine 
ligands. Although less toxic than many other clinically used gold compounds, auranofin 
also proved to be less efficacious, which has limited its popularity among 
rheumatologists.50,67 Today, the clinical use of gold(I) drugs for treatment of RA has 
largely been superseded by some of the aforementiond DMARDs, such as 
methotrexate, TNF inhibitors, and biologics. This is due to the increased efficacy 
observed at lower doses when patients are administered with these classes of therapeutic 
agents, as well as reduced side effects. Despite this, c rysotherapy continues to be used 
for treating refractory forms of RA. For example, a 2002 survey of Canadian 
rheumatologists reported that 40% use injectable god(I) salts frequently, and 56% use 
them occasionally.50 Similarly, a 2004 survey of British rheumatologists reported that 
20 – 40% use injectable gold(I) compounds as the third or fourth choice in therapy.51 
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1.1.4 Potential Uses of Gold Compounds for Treatment of Other 
Diseases 
While gold compounds have only found clinical use for the treatment of RA, 
their potential for treatment of other diseases hasbeen noted, and is being widely 
investigated. This section will briefly discuss some other areas of interest for medicinal 
gold complexes, commencing with the search for new anti-cancer agents. 
The potential of Au(I) compounds for the treatment of cancer was highlighted 
by studies which demonstrated the cytotoxicity of auranofin towards the HeLa cervical 
cancer cell line in vitro68 and leukaemia cells in vivo.69 This was followed by the 
development and screening of a number of auranofin analogues, which exhibited strong 
in vitro activity against a melanoma cell line, having half maximal inhibitory 
concentration (IC50) values less than 5 µM.
70 However, the in vivo anti-cancer activity 
of these complexes in mice with leukaemia proved limited.70 A series of gold(I) dppe 
(dppe = 1,2-bis(diphenylphosphino)ethane) complexes has also been prepared and was 
found to show promising in vitro anti-cancer activity, with [Au(dppe)2]Cl having an 
IC50 of 2 µM against melanoma cells.
71 However, these complexes also exhibited 
cardiovascular toxicity that precluded further development.72 A number of gold(III) 
complexes featuring the dimethylaminomethylphenyl (damp) ligand have shown 
promising anti-cancer activity,73 as well as other complexes containing N-
methylimidazole, 2-methylbenzoxazole, or 2,5-dimethylbenzoxazole as ligands.74 The 
structures of some of these complexes are shown in Figure 1.4. More recent efforts in 
this area have focussed on gold(I) phospholes or complexes containing N-heterocyclic 
carbene ligands, as well as a variety of Au(III) compounds designed to act as inhibitors 
of the enzyme thioredoxin reductase. This enzyme will be discussed in more detail in 
Section 1.3. 
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The potential of using gold complexes for the treatment of human 
immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) was first 
sparked by a report regarding an AIDS patient that w s receiving auranofin for 
treatment of psoriatic arthritis. The patient was refusing treatment for their HIV, yet 
showed a significant increase in the number of CD4+ T lymphocyte cells, when a 
decrease would have been expected with progression of the illness.75 Subsequently, it 
has been shown that dicyanoaurate inhibits proliferation of HIV in a strain of CD4+ T 
lymphocytes,76 and that aurothioglucose can inhibit HIV reverse transcriptase.77 
Unfortunately aurothioglucose proved ineffective in cell culture tests of HIV-inoculated 
lymphoid and leukaemia cells owing to lower levels of uptake.74,77 
 
Figure 1.4: Structures of some gold(I) and gold(III) complexes investigated for anti-cancer activity: 
a) [Au(dppe)2]Cl;  b) [Au(damp)Cl2];  c) [Au(N-methylimidazole)Cl3];  
d) [Au(2-methylbenzoxazole)Cl3]; and e) [Au(2,5-dimethylbenzoxazole)Cl3] 
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Chloroquine (CQ, Figure 1.2 a) has been one of the most widely used 
compounds for the treatment of malaria.78 However, in recent years its effectiveness has 
diminished, owing to the development of resistance to the drug in the protozoan 
Plasmodium falciparum, one of the most important agents of the disease.79 As a result, 
researchers have been searching for derivatives of chl roquine that are still effective 
against malaria. This has led to the discovery that[Au(triphenylphosphine)(CQ)]PF6 
(Figure 1.5), containing gold(I), showed promising in vitro activity against three 
species of Plasmodium.80 When compared to the phosphate salt of chloroquine, the gold 
complex was found to have an IC50 twenty times lower towards Plasmodium berghei, as 
well as five times and ten times lower towards two strains of chloroquine-resistant 
Plasmodium falciparum. The complex also showed in vivo activity against rats infected 
with Plasmodium berghei, with rats treated with the Au-CQ complex exhibiting 3.5× 
lower numbers of parasites than rats treated with chloroquine iteself.80 
 
Figure 1.5: Structure of [Au(triphenylphosphine)(CQ)]PF6, investigated for anti-malarial activity. 
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1.2 Mechanisms of Action of Gold Anti-Arthritic Agents 
The mechanism of action of gold(I) salts used to treat RA remains an area of 
debate, but is generally thought to involve a number of effects. All of the clinically used 
gold drugs are considered prodrugs, and undergo changes in structure through either 
ligand loss or a change in oxidation state to form biologically active metabolites.57,74 
The latter include [Au(CN)2]‾, Au(III) complexes, Au(0), and a range of Au(I)-protein 
complexes that result from ligand displacement reactions. In considering the many 
reactions that are likely to occur in vivo, it is important to note that although Au(I) 
exhibits a high degree of thermodynamic affinity for S- and Se-containing ligands, it 
remains a kinetically labile metal ion. This lability allows frequent ligand exchange 
reactions to occur with biomolecules, especially considering the high concentrations of 
thiol-containing species present in plasma and cells. Some of the key features of gold 
drug metabolites are discussed in the following sections, followed by some of their key 
interactions with cells and biomolecules. 
1.2.1 Gold Metabolites 
The majority (80 – 95%) of the gold(I) administered to patients with RA rapidly 
loses a ligand and binds to human serum albumin (HSA), the most abundant protein in 
plasma.81 The HSA then functions as a de facto transport agent and carries the bound 
gold(I) fragments to a large variety of other binding sites in the body.74 In the case of 
auranofin, it is only the tetraacetylthioglucose ligand which is initially lost during the 
binding process with HSA,82 whereas the polymeric gold(I) compounds typically break 
apart to release a single gold ion which binds to the protein, and the original coordinated 
ligand.83 HSA contains 35 cysteine residues, all but one of which normally form 
intramolecular disulfide bonds. The one exception is Cys34; its thiol group is free to 
react with endogenous species,84 and has been shown by a variety of techniques, 
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including electrospray ionisation mass spectrometry (ESI-MS) to be the main residue to 
which gold(I) drugs bind.85–88 
One important set of reactions that occurs after gold(I) complexes are 
administered to patients are those leading to formation of [Au(CN)2]
‾. Thiocyanate 
(SCN‾) is a normal component of plasma owing to direct die ary intake, and may be 
converted directly to cyanide by the enzyme, myelopr xidase, which is found in 
plasma or polymorphic leukocytes.89 Owing to the higher affinity of gold(I) for cyanide 
compared to thiol ligands,90,91 it is highly likely that Au-HSA complexes in vivo might 
undergo one or more ligand displacement reactions to form a cyanoaurate-thiol 
complex, or the dicyanoaurate ion.57,92 The dicyanoaurate ion is thought to facilitate 
gold uptake into cells, as it has been shown to be rapidly taken up by both red blood 
cells76,93 and T lympocytes.76 Its importance as a metabolite of compounds used for 
chrysotherapy is highlighted by studies that showed patients who are also cigarette 
smokers have higher incidences of side effects resulting from an increased formation of 
[Au(CN)2]‾ and associated higher levels of gold uptake in cells.
93,94 
It is also likely that [Au(CN)2]‾ participates in redox chemistry in vivo. For 
example, it has been shown that [Au(CN)2]‾ undergoes oxidation in the presence of the 
biological oxidant, hypochlorite, to form trans-[Au(CN)2Cl2]‾.
95 The same study also 
showed that in the presence of excess cyanide ions, thi  species rapidly forms 
[Au(CN)4]‾. Further evidence of redox reactions involving various gold metabolites is 
discussed below. 
There is a large amount of evidence to suggest that formation of Au(III) is an 
important outcome of administration of Au(I) compounds to patients as part of a 
chrysotherapy treatment regime.89,95–99 For example, it has been demonstrated in vitro 
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that Au(I) may be oxidised to Au(III) by hypochlorous acid,100 which is generated in 
vivo by myeloperoxidase in phagolysosomes of activated macrophages and 
granulocytes.101 In another study that searched for evidence that gold(III) is formed in 
vivo, the proliferation of T-lymphocytes, which are adaptive immune cells, was 
measured using a popliteal lymph node (PLN) assay.96 This assay scores proliferation 
by comparing the weight of a treated PLN and an untreated PLN within the same 
animal. Proliferation of T-lymphocytes in response to exposure to a molecule is strong 
evidence of sensitisation, or prior exposure, to that chemical compound. For this 
experiment, mice were treated with aurothiomalate, nd 5-7 weeks later were exposed to 
gold(I) or gold(III) compounds. Six days later the PLN assay was performed to assess if 
proliferation had occurred. Neither aurothiomalate nor AuCl caused sensitisation, but 
exposure to either AuCl3 or HAuCl4 did cause T-lymphocyte proliferation. This 
suggests that there had been prior in vivo formation of Au(III) from the aurothiomalate 
initially given to the mice. 
Another investigation set out to test the hypothesis that mononuclear phagocytes 
are a significant source of oxidation of Au(I) compounds to Au(III) species.98 It was 
demonstrated that Au(III)-primed T-lymphocytes exhibited no sensitisation towards 
aurothiomalate, but did show sensitisation after exposure to HAuCl4, or to peritoneal 
cells containing mononuclear phagocytes that were isolated from aurothiomalate-treated 
rats. In the same study, mononuclear phagocytes were separated from peritoneal cells, 
then treated with aurothiomalate, prior to being exposed to Au(III)-primed T-
lymphocytes. Evidence of significant sensitisation was obtained, indicating that it was 
likely that the aurothiomalate had been oxidised to Au(III) compounds within the 
phagocytes, probably by hypochlorous acid produced by myeloperoxidase.98 
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To confirm these observations in humans, patients wi h RA who had been 
treated using chrysotherapy compounds and suffered adverse side effects, then had their 
T-lymphocytes collected, cultured in vitro, and exposed to either aurothiomalate or 
HAuCl4, or one of several copper, platinum or nickel salts.
97 Only treatment with 
HAuCl4 resulted in sensitisation, but only in patients who also suffered from dermatitis 
as a side effect. These findings reinforce the view that Au(III) species are metabolites of 
chrysotherapeutic agents, and also suggest that Au(III) formation may be associated 
with some of the adverse effects of treatment. 
The possibility of Au(III) metabolites causing some of the side effects associated 
with chrysotherapy is plausible in view of their hig ly reactive nature in biological 
environments.57 Au(III) compounds are strong oxidants and react readily with a host of 
biological reductants. For example, it has been shown that Au(III) compounds can 
oxidise thiols to sulfides,74 and thioethers such as methionine to sulfoxides.102 
Furthermore, they can even oxidise disulfides.103 Each of the above reactions can result 
in significant changes to the tertiary structure, and therefore, the function of various 
biomolecules. These events could be beneficial for the treatment of RA if they involve 
biomolecules that enhance inflammation or produce reactive oxidative species. 
Alternatively the reactions may result in harm if the altered biomolecules then interact 
with non-specific targets in other regions of the body, as is likely to be the case. 
Another notable metabolite that may be formed during chrysotherapy is 
elemental gold. Zou et al. used nuclear magnetic resonance (NMR) spectroscopy to 
study the reactions of [AuCl4]‾ with glycine under various conditions.
104 They indicated 
that Au(III) could oxidise the glycine, resulting in loss of NH4
+ and formation of 
glyoxylic acid. It was also suggested that another molecule of [AuCl4]‾ could further 
oxidise the glyoxylic acid to produce formic acid, CO2 and Au(0). These results follow 
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on from earlier work indicating that Au(0) is formed as a major product from the 
oxidation of disulfides by Au(III) complexes.103 While there has been a limited number 
of investigations into the likelihood and clinical importance of in vivo formation of 
Au(0) during chrysotherapy, a large amount of work has been performed examining the 
biological interactions of Au(0) in the form of gold nanoparticles. These will be 
discussed further in Section 1.4. 
There is a body of evidence which suggests that the majority of intracellular 
gold resulting from chrysotherapy is localised in lysosomal bodies that have a 
characteristic morphology.105,106 These special lysosomes have been termed aurosomes, 
and have been the subject of investigations using synchrotron radiation X-ray 
absorption spectroscopy.107,108 In these experiments, X-ray absorption near-edge 
structure spectroscopy and X-ray absorption fine structure measurements were 
performed. The results of these studies demonstrated that aurosomes isolated from the 
kidneys of rats treated with aurothiomalate contained Au(I), which was likely bound to 
two sulfur atoms.107 In addition, it was found that even when gold was administered as 
Au(III) (as Na[AuCl4]), the gold in the aurosomes existed as Au(I) and was probably 
bound to two sulfur atoms.107 Similar experiments performed with auranofin also 
showed that the gold in the aurosomes was bound to two sulfur atoms,108 indicating that 
the triethylphosphine group had been displaced, as expected.  
What is notable about the results discussed above is that despite many reports 
suggesting that formation of Au(III) occurs in vivo, and that production of Au(0) is also 
likely, there is no spectroscopic evidence available that shows the formation of either. 
This may be reflective of the short-lived nature of any Au(III) metabolites formed in 
vivo, as well as the overall complexity of the Au(III)/Au(I)/Au(0) redox system. Further 
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studies are therefore required to fully elucidate th  redox reactions that take place after 
administration of gold compounds to living organisms. 
1.2.2 The Sulfhydryl Shuttle Mechanism 
The sulfhydryl or thiol shuttle mechanism has been proposed as the most likely 
method of cellular uptake for gold metabolites. This mechanism is depicted in Figure 
1.6 and stems from studies of auranofin uptake.109 In biological media the first reaction 
that auranofin most likely undergoes is loss of the ac tylthioglucose ligand, resulting in 
a gold-triethylphosphine moiety, which may become bound to any number of 
membrane transport proteins containing sulfhydryl groups. These subsequently carry 
the AuPEt3 (PEt3 = triethylphosphine) moiety across cell membranes and release it into 
the cytoplasm, where it may cause a number of effects. Gold transport out of the cell 
also involves sulfhydryl-containing membrane transport proteins, and is notably an 
energy-independent process.109 In other words, the transport of gold into or out f a cell 
by the sulfhydryl shuttle mechanism is controlled by an equilibrium between 
intracellular and extracellular gold sources. The exist nce of this equilibrium was 
confirmed by an experiment in which additional serum was added to a culture medium 
containing macrophages.109 Extracellular gold became serum bound, resulting in a net 
movement of gold out of the macrophages and into the culture medium. This is 
consistent with expectations if an equilibrium exists between the intra- and extracellular 
regions.109 Similarly, red blood cells that had accumulated gold as a result of being 
treated with auranofin, showed a marked efflux of gld when resuspended in fresh 
serum.110 
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Figure 1.6: The sulfhydryl shuttle mechanism for auranofin uptake and efflux by cells. Adapted with 
permission from Chemical Reviews, 1999, vol. 99 (9), p. 2589-2600.74 Copyright 1999 American 
Chemical Society. 
The sulfhydryl shuttle mechanism is also believed to be the principal means by 
which other metabolites of chrysotherapy drugs, such as Au-HSA, and gold-cyanide 
complexes, enter cells.74 This is because the uptake mechanism is only contingent upon 
a ligand displacement reaction with a membrane transport protein, which can occur due 
to the kinetic lability of the Au(I) ion. In the case of gold-cyanide complexes, evidence 
for the importance of the sulfhydryl shuttle mechanism was provided by experiments 
where an anion channel did not alter gold uptake by red blood cells in culture.76 In 
contrast, addition of free CN‾ inhibited gold uptake, indicating that ligand dissociation 
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is required for gold transport to occur.76 This is consistent with what would be predicted 
if gold transport occurred via the sulfhydryl shuttle mechanism.76 
1.2.3 Intracellular Gold Targets 
This section will discuss some of the effects various gold metabolites have upon 
a broad range of cells and biomolecules. These include diminished proliferation and 
function of specific cell types, inhibition of cytokine expression and transcription 
factors, modification of receptor function, and diminished activity of specific protein 
targets. 
One major mode of action of gold metabolites is through alteration of cell to cell 
signalling. It has been shown that aurothiomalate cn interfere with receptor-mediated T 
lymphocyte signalling by inhibiting the cysteine residues at the active-site of a number 
of protein-tyrosine phosphatases essential for this signalling process.111 One proposed 
mechanism involves Au+ ions that form a Cys-Au-Cys bridge between cysteine residues 
either in the same protein, or between two separate prot in molecules.57  
Administration of injectable gold has been shown to lead to a decrease in 
immunoglobulin (Ig) levels in ~50% of patients with RA, whereby severe depletion can 
be a problematic side-effect in some cases.112 In particular, two studies have been 
performed which examined the effect of aurothiomalate upon B lymphocytes. The 
relevance of B lymphocytes to RA stems from the fact that they produce large quantities 
of extracellular IgM and rheumatoid factor.113,114 Treatment with aurothiomalate 
showed decreased production of both IgM and rheumatoid factor, consistent with 
decreased activation of B lymphocytes. In vitro assays have also shown that 
aurothiomalate is an inhibitor of the differentiation and development of monocytes 
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isolated from patients with RA.115 These processes are strongly linked to RA 
pathogenesis.115 
In recent years TNF has been recognised as a critical cytokine in the 
development of RA. Therefore it is not surprising that a number of studies of the effects 
of chrysotherapy compounds on TNF expression have be n performed. In one 
investigation, mononuclear cells were isolated from the synovial membranes of patients 
with RA that were undergoing aurothiomalate treatment. The levels of expression of IL-
1α, IL-1β, IL-6 and TNF were all reduced, as was the number of inflammatory 
monocytes.116 In another investigation, PBMCs were isolated from patients with RA 
and healthy individuals, and the effects of aurothiomalate with and without co-
administration of the ‘toll-like’ receptor (TLR) 4 ligand lipopolysaccharide (LPS), upon 
TNF production were determined.117 It was found that when PBMCs were pre-
incubated with LPS and subsequently treated with aurothiomalate, TNF production was 
inhibited regardless of whether the PBMCs were sourced from RA patients or healthy 
individuals. In contrast, treatment of PBMCs only with aurothiomalate caused a mild 
increase in TNF production. A subsequent investigation using PBMCs only from 
healthy individuals found significant heterogeneity in the samples, but still largely 
confirmed the results of the previous study.118 In particular, the authors highlighted that 
aurothiomalate could stimulate or inhibit production f TNF, depending on whether 
LPS was also absent or present, respectively.118 These results highlight the intricate 
balance present between inflammatory cytokine expression and inhibition.118 
As discussed earlier, the majority of gold present in cells isolated from patients 
with RA undergoing chrysotherapy is found in lysosomal bodies termed 
aurosomes,105,106 where it is bound to two sulfur atoms.107 This localisation of gold 
inhibits release of lysosomal enzymes that are otherwis  responsible for joint 
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degradation.57 In vitro experiments have shown that auranofin, aurothiomalate and 
aurothioglucose all inhibit resorption of bone by rat osteoclasts, and exhibit cytotoxicity 
towards an osteoblast-like cell line.119 Leukocyte infiltration of synovial joints is a key 
factor in RA pathogenesis, that is targeted and facilitated by the expression of adhesion 
molecules by endothelial cells. Aurothiomalate inhibits the cytokine-stimulated 
expression of some of these adhesion molecules.120 Similarly, the ability of cytokines to 
induce polymorphonuclear neutrophils to adhere to endothelial cells is inhibited by 
auranofin and aurothiomalate. The alternative DMARD sulfasalazine did not elicit 
similar results, indicating that the two classes of DMARDs may exhibit different 
mechanisms of biological activity.121 
Aurothiomalate also inhibits both the progesterone122 and glucocorticoid123 
transcription receptors, as well as the activator protein 1 transcription factor.124 In 
addition, auranofin, aurothiomalate, aurothioglucose and AuCl3 inhibited IκB kinase in 
RAW264.7 mouse macrophages that had been stimulated by LPS.125 This was a 
significant result because IκB kinase activates nuclear factor-κβ (NF-κβ), a transcription 
factor implicated in the expression of many inflammatory genes. The authors were also 
able to demonstrate that inhibition of IκB kinase by auranofin led to reduced NF-κβ 
activity, and suggested that inhibition was likely to be a result of blocking of the thiol 
group at the active site.  
While gold may interact with a large number of intracellular enzymes, two in 
particular have attracted attention in discussions of the modes of action of anti-arthritic 
gold drugs. These are thioredoxin reductase (TrxR), which will be discussed in more 
detail in Section 1.3; and the enzyme family, protein kinase C. The latter enzymes 
phosphorylate other proteins, as part of signalling pathways involved in a large number 
of processes.126 In a series of experiments investigating the effects of aurothiomalate, 
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aurothioglucose and auranofin on Jurkat cells, which are a line of T-lymphocytes, it was 
found that all three compounds inhibited proliferation of the cells and reduced 
production of the pro-inflammatory cytokine, IL-2.127 The authors also showed that 
treatment of Jurkat cells with aurothiomalate led to a decrease in overall protein kinase 
C activity that was most likely due to inhibition of thiol groups at the active site, 
indicating one potential pathway towards anti-inflammatory effects.127 
1.3 Thioredoxin Reductase 
One enzyme which has been implicated in a number of human diseases, 
including cancer and RA, is TrxR. As a result, this enzyme has been highlighted by a 
number of researchers in recent years as a target for metallodrugs, and in particular, 
gold compounds. The following sections will discuss the structure and functions of 
TrxR, and summarise evidence that shows that the binding of metallodrugs to the 
enzyme can affect its activity, and potentially lead to a therapeutic effect. 
1.3.1 Structure and Mechanism of Action 
TrxR is a homodimeric flavoprotein, with a similar structure to glutathione 
reductase (GSR). In humans, each monomer is approximately 55 kDa in size and 
contains a flavin adenine dinucleotide (FAD) and a nicotinamide adenine dinucleotide 
phosphate (NADPH) binding site.128 Both TrxR and GSR feature an identical active site 
disulfide sequence near the N-terminus, which is comp sed of Cys-Val-Asn-Val-Gly-
Cys.129 However, a key difference in the amino acid sequence of TrxR is the 16-residue 
extension at the C-terminus, which contains a penultimate selenocysteine (Sec) 
residue.130 The monomers in TrxR are arranged spatially such that he C-terminal 
selenocysteine of one monomer is oriented towards the active site disulfide of the other 
monomer. The structure of dimeric human TrxR, determined crystallographically by 
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Fritz-Wolf et al.,131 is shown in Figure 1.7. The Sec residue is found in all mammalian 
forms of TrxR, and is essential for the function of the protein. This has been confirmed 
by experiments that examined the effects of removing or modifying the Sec residue by 
carboxypeptidase digestion, or through alkylation. In both cases these changes led to 
inactivation of the protein.132 Two isoforms of TrxR have been identified in mammals: 
cytosolic TrxR (TrxR1) and mitochondrial TrxR (TrxR2). The two isoforms are very 
similar in sequence, with the mitochondrial form featuring a 33-residue N-terminal 
extension that functions as a mitochondrial import sequence.128 
 
Figure 1.7: Structure of the human thioredoxin reductase dimer, d termined crystallographically by Fritz-
Wolf et al.131 The two monomers are coloured dark orange (left) and orange (right). Bound FAD is 
coloured yellow and NADP+ is coloured blue. Active site sulfur atoms are indicated in green. Reprinted 
from Journal of Molecular Biology, vol. 370, p. 116- 27, with permission from Elsevier. 
TrxR is named for its ability to catalyse the reduction of the oxidised form of the 
12 kDa redox enzyme, thioredoxin (Trx), by NADPH. It is the only protein known that 
performs this function, and achieves this role by transferring electrons from a bound 
NADPH to the Trx bound at the active site via the FAD cofactor.128 The overall set of 
reactions that constitute what is known as the thiored xin cycle is depicted in Figure 
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1.8. The redox active centre of Trx is composed of a four amino acid sequence: Cys-
Gly-Pro-Cys.133,134 In its reduced form, the Cys residues exist as a pair of thiols (Trx-
(SH)2); however, in the oxidised form of the protein (Trx-S2) they form a disulfide 
bridge.  
 
Figure 1.8: Schematic illustration of the reactions of the thioredoxin cycle. 
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Insight into how TrxR catalyses the reduction of Trx has been gained through a 
number of studies, some utilising a mutant form of human TrxR1 (hTrxR1), where the 
selenocysteine residue was altered to a cysteine, and an N-terminal hexahistidyl tag was 
added to facilitate expression in E. coli.131,135 In other cases experiments have been 
performed with the native Sec-containing form of rat TrxR (rTrxR1).136 All of the above 
studies have helped to establish a probable mechanism of action for reduction of 
oxidised Trx (Trx-S2) by TrxR. In the first step, upon NADPH binding, the oxidised N-
terminal disulfide of the first hTrxR1 monomer, whic  is hidden from the surface of the 
protein, is reduced. The electrons released by this process are transferred to the FAD 
prosthetic group, reducing it to FADH2. A charge-transfer complex is then formed 
between the FADH2 and the second Cys residue in the N-terminal active s te of the first 
hTrxR1 monomer, reducing each residue to a thiol. At this stage, the oxidised C-
terminal active site of the second hTrxR1 monomer (hTrxR1′) containing the 
selenylsulfide bond, is oriented towards the N-terminal active site, allowing reduction to 
selenol and thiol residues. This reduction causes th  C-terminal active site to move 
away from the N-terminal disulfide, a process which s facilitated by a series of 
residues, Trp407′, Asn418′ and Asn419′, which form a flexible ‘guiding bar’ for the 
hTrxR1′ C-terminal chain. After Trx binds to hTrxR1, the C-terminal active site 
becomes exposed to surrounding solvent molecules, and the selenol residue forms an 
intermolecular bond with the first Cys residue of Trx, which subsequently promotes 
protonation and electron transfer from the remaining C-terminal hTrxR1′ Cys residue to 
form reduced Trx (Trx-(SH)2 . This reduced protein then departs the active sit of 
hTrxR1, leaving the oxidised form of the latter protein ready to restart the catalytic 
cycle. 
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1.3.2 Functions of Thioredoxin 
As TrxR is the only known enzyme capable of reducing Trx, the functions of 
Trx can be considered indirect functions of TrxR. This section will discuss some of the 
key functions that Trx plays both intra- and extracellularly. 
Thioredoxin is involved in a number of cellular processes in its reduced form, 
through regulating and regenerating other enzymes. As a consequence, Trx is 
considered critical for normal cellular function, and it has been referred to as a 
‘moonlighting’ protein due to its capacity to perform a variety of roles in cells.137 
Thioredoxin most commonly functions by reducing substrates through disulfide 
exchange reactions, or acting as a hydrogen atom donor t  maintain the activity of other 
enzymes. One important substrate for Trx is ribonucleotide reductase, which is an 
enzyme essential for DNA synthesis owing to its role in catalysing the formation of all 
four deoxyribonucleotides from ribonucleotides.134,138 Here, Trx reduces the enzyme 
ribonucleotide reductase by acting as a hydrogen atom donor. 
Trx has been linked to a large number of other biochemical processes,139,140 
including reducing a number of peroxiredoxins141 and thioredoxin peroxidase.142,143 
These are proteins that protect cells from oxidative stress and apoptosis by reducing 
H2O2. Trx also plays a role in regulating the activity of methionine sulfoxide reductases, 
which are enzymes that repair proteins by reducing methionine sulfoxide residues to 
methionine.144 Other roles of Trx include inhibition and activation of the transcription 
factors NF-κB and activator protein-1, respectively,145 and regulation of the 
glucocorticoid receptor,140,146 which can either upregulate anti-inflammatory proteins in 
the nucleus or down-regulate pro-inflammatory proteins in the cytosol.147 It also binds 
to the enzyme apoptosis signal-regulating kinase 1, which leads to the formation of a 
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complex which inhibits the enzyme from performing its function of initiating 
apoptosis.148 When secreted extracellularly Trx acts as a growth factor, stimulating 
cellular growth, proliferation and differentiation.140 It is secreted by lymphocytes, 
hepatocytes, fibroblasts, and a number of cancer cells.149–151 Trx has also been shown to 
increase the expression of cytokines such as IL-1, I 2 IL-6, IL-8 and TNF,152 and to 
increase TNF induced expression of the pro-inflammatory IL-6 and IL-8 by RA 
synovial fibroblasts.153 
1.3.3 Thioredoxin Reductase as a Drug Target 
In recent years, there has been interest in TrxR as a target for medicinal 
chemistry due its overall role in regulating the important regulatory redox enzyme Trx. 
In particular, the involvement of the Trx system in DNA synthesis and inhibition of 
apoptosis make it a compelling target for anti-cancer therapies, especially since Trx has 
been shown to be over-expressed in a number of cancer cell types, when compared to 
relevant control cells.154–158 Furthermore, TrxR expression levels have also been shown 
to be higher than normal in a number of classes of cancer cells, such as breast, skin, 
thyroid and colorectal cancer cells.158,159 Given the critical role of Trx for maintaining 
the redox state of cells, its involvement in signalli g the expression of IL-6 and IL-8, 
and the upregulation of TrxR in synovial cells160 and synovial fluid,161 the Trx system 
also poses a potential target for the treatment of RA. Many of the investigations into the 
potential of TrxR as a drug target have examined the ability of various classes of 
metallodrugs to inhibit the enzyme. These studies wre focussed upon the presence of 
the penultimate selenocysteine residue as the primary target for the metal complexes. A 
number of key chemical features of Sec differentiate t from Cys, and make it ideal as a 
target for some types of metal complexes. Firstly, free Sec has a lower pKa than Cys 
(5.2 vs 8.5), resulting in the former being negatively charged at physiological pH and 
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hence more nucleophilic. Secondly, Sec is a softer base than Cys, making it more 
attractive to softer metals with which it reacts more quickly and forms stronger 
bonds.162 
An example of a clinically-used metallodrug that may inhibit TrxR is arsenic 
trioxide (ATO), which is effective in the treatment of promyelocytic leukemia.163 A 
2007 study used a number of methods to investigate wh ther TrxR inhibition was a 
contributor to the anti-cancer activity of ATO,164 as it had been previously noted that 
arsenic(III) exhibits strong binding interactions with selenols.165 In one investigation the 
in vitro effects of ATO on the activity of rTrxR was studie spectrophotometrically by 
monitoring the reduction of 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB).164 It was 
shown that ATO binding to rTrxR was irreversible, with an IC50 value of 0.25 µM. 
Matrix-assisted laser desorption ionisation mass spectrometry (MALDI-MS) of a 
trypsinised sample of TrxR that had been previously reacted with ATO, indicated that 
the arsenic was bound to both the Cys and Sec residues at the C-terminus.164 In another 
experiment, human breast cancer cells were treated with ATO, then lysed, and the 
activity of the Trx/TrxR system in the lysates subsequently measured by following the 
reduction of insulin.164 The results of these experiments showed that a decrease in the 
activity of the Trx/TrxR system occurred as the ATO concentration was increased. All 
of the above results highlight the potential for anti-cancer activity exerted via 
interactions with TrxR. 
 It has also been shown that the thioredoxin system is a potential therapeutic 
target for platinum complexes. For example, cisplatin nd transplatin were both shown 
to inhibit the activity of calf TrxR in experiments where the ability of the enzyme to 
catalyse the reduction of insulin by NADPH was measured. The second order rate 
constants for reduction of insulin in the presence of cisplatin and transplatin were 21 ±
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3 M−1.s−1,  and 84 ± 22 M−1.s−1, respectively.166 A primary metabolite of cisplatin inside 
cells, bis-(glutathionato)platinum(II),  was also studied and shown to inhibit the 
mammalian Trx system but not a bacterial Trx system. Bacterial TrxR does not contain 
the penultimate Sec residue, indicating the potential importance of the selenol residue in 
the mechanism of inhibition of these platinum complexes.166 This is further 
demonstrated by another study, which showed that cisplat n could effectively inhibit 
calf TrxR, but not the structurally related GSR, which does not contain a selenocysteine 
residue.167 
Platinum(II) compounds containing the terpyridyl (terpy) ligand have also been 
investigated as potential anti-cancer drugs that exert their biological effects as a result of 
binding to TrxR. One study measured the activity of hTrxR after incubation with 
different platinum terpy compounds, in the presence of DTNB. It was found that six of 
the compounds had IC50 values below 10 nM.
168 In contrast, the level of activity 
towards GSR was found to be 3-4 orders of magnitude low r, again highlighting the 
specificity of platinum complexes for the selenol active site.168 In another study, a 
mutant form of TrxR1 was studied, where the Sec had been replaced by a Cys.169 The 
effect of Pt(terpy)2+ complexes on the ability of hTrxR1 to reduce DTNB was similarly 
assessed, and the IC50 values obtained were found to range from 55 – 80 nM. This is a 
lower level of inhibition than in the previous study, which is most likely attributable to 
replacement of the Sec residue with Cys, resulting in lower affinity towards the 
platinum complexes. The specific interactions betwen [Pt(terpy)(N-acetyl-4-
aminothiophenolato)]+, shown in Figure 1.9, and hTrxR1, were revealed in a crystal 
structure of the metal/protein complex. Further information about these interactions 
were derived by performing a tryptic digest on the adducts formed between the enzyme 
and the platinum complex, and analysing the resultant fr gments by MALDI-MS. Both 
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techniques provided evidence of terpyridineplatinum(II) moieties binding at the C-
terminal active site of the enzyme.  
 
Figure 1.9: Structure of [Pt(terpy)(N-acetyl-4-aminothiophenolato)]+.169 
 
1.3.4 Interactions of Gold Drugs with TrxR 
While impressive results have been obtained from studies of the binding 
interactions between TrxR and other metals, it was thought that gold(I) compounds 
might be even more potent TrxR inhibitors due to the metal ion being a typical soft acid, 
and as such being expected to bind strongly to thiol or selenol residues. Consistent with 
this, a study was published in 1998 that showed that e anti-rheumatic drugs, 
aurothioglucose and auranofin, strongly inhibited hTrxR, with IC50 values of 65 and 20 
nM, respectively.170 A high degree of specificity towards the enzyme was also 
demonstrated in this study, as the two gold(I) compunds had to be present at 1000 
times higher concentrations for comparable levels of inhibition of GSR to be observed. 
Another study used spectrophotometry to  directly compare the ability of gold(I) and 
gold(III) compounds to inhibit reduction of DTNB by rTrxR2, with that of other metal 
compounds.171 The structures of some of these compounds are shown in Figure 1.10, 
while the IC50 values of these compounds towards rTrxR2 are displayed in Table 1.2. 
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Figure 1.10: Structures of some metal complexes investigated as TrxR inhibitors: 
a) Au(pydmb) = [Au(2-(1,1-dimethylbenzyl)-pyridine)(CH3COO)2]; 
b) Au(bipydmb) = [Au(6-(1,1-dimethylbenzyl)-2,2’-bipyridine))(OH)](PF6); 
c) Au(bipydmb)(xyl) = [Au(6-(1,1-dimethylbenzyl)-2,2’-bipyridine))(2,6-xylidine)](PF6); 
d) Au(dien) = [Au(2,2’-diethylenediamine)Cl]Cl2;  and 
e) zinc pyrithione = [Zn(2-mercaptopyridine-N-oxide)2]. 
 
All of the gold complexes produced the same high degre  of inhibition of 
rTrxR2, but at much lower concentrations than the other metal compounds. Table 1.2 
also shows that gold(I) complexes containing a triethylphosphine ligand were 
particularly powerful inhibitors. The investigators also examined the ability of gold(I) 
and gold(III) compounds to inhibit the activity of  GSR, and found that negligible 
inhibition occurred when the concentration of gold was ≤ 10 µM. This further 
demonstrates the significant extent of enzymatic specificity exhibited by these 
compounds. It was also shown that the gold compounds could alter mitochondrial 
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membrane permeability and induce mitochondrial swelling, but they did not affect the 
mitochondrial respiratory chain as strongly as complexes of other metal ions. This may 
indicate that while TrxR is an extremely important enzyme, its inhibition does not 
necessarily affect the overall redox state of the organelle. 
Table 1.2: Comparison of IC50 values derived from a spectrophotometric examinatio  of the ability of 
metal complexes to inhibit reduction of DTNB by rTrxR2.171 
Metal Compound Metal Ion IC50 (µM) 
Aurothiomalate Au(I) 0.280 
Triethylphosphine gold Au(I) 0.065 
Auranofin Au(I) 0.020 
Au(pydmb) Au(III) 1.42 
Au(bipydmb) Au(III) 0.28 
Au(bipydmb)(xyl) Au(III) 0.21 
Au(dien) chloride Au(III) 0.42 
Tributyltin chloride Sn(IV) 76.1 
Cisplatin Pt(II) 36.9 
Cadmium acetate Cd(II) 23.5 
Zinc acetate Zn(II) 19.5 
Zinc pyrithione Zn(II) 11.8 
 
 A number of more recent studies have also investigated the ability of gold(III) 
compounds to act as anti-cancer compounds as a result of their ability to bind to and 
inhibit TrxR.172,173 The results of these studies, and those presented in Figure 1.10, all 
suggest that Au(I) compounds are more potent TrxR inhib tors than similar Au(III) 
compounds. This is most likely due to the softer nature of the Au(I) ion compared to 
Au(III), which would be expected to lead to more favourable binding interactions with 
the penultimate selenocysteine residue of TrxR.174 In view of these studies some 
researchers have investigated the in vitro effects of a range of Au(I) complexes in 
selected cell lines. The structures of some of these compounds are shown in Figure 
1.11. For example, a pair of Au(I)-phosphole complexes (Figure 1.11 a and b) that 
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were shown to be very potent inhibitors (IC50 < 10 nM) of both hTrxR and hGSR, were 
also found to exhibit significant toxicity (IC50 ~5-15 µM) against three glioblastoma cell 
lines, and strong binding interactions with single-stranded plasmid DNA.175 
 
Figure 1.11: Structures of some gold(I) complexes investigated s potential anti-cancer drugs that act by 
inhibiting TrxR: a) [Au(1-phenyl-2,5-di(2-pyridyl)phosphole)Cl];    
b) [Au(1-phenyl-2,5-di(2-thienyl)phosphole)Cl]; c) [Au(1,3-bis(di-2-pyridylphosphino)propane)2]Cl; and  
d) [Au(1,3-di-R-imidazol-2-ylidene)2]
+ 
 
The four-coordinate Au(I) complex, [Au(d2pypp)2]Cl (d2pypp = 1,3-bis(di-2-
pyridylphosphino)propane, Figure 1.11 c), has also been shown to affect rTrxR activity 
towards insulin reduction, and is cytotoxic towards human breast cancer cells.176 
Although it was less active against rTrxR than some f the compounds discussed above 
(IC50 = 1 µM for insulin reduction), it did show strong and selective toxicity against 
human breast cancer cells when administered at only 5 µM concentration. The latter 
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cells showed an 80% drop in cellular Trx activity and a 40% drop in cellular rTrxR 
activity. These results highlight the importance of c mparing ex vivo with in vitro 
results to fully investigate a compounds potential as an enzymatic inhibitor. 
Gold(I) complexes of N-heterocyclic carbene ligands have become an area of 
considerable focus recently, with many studies demonstrating these compounds can 
significantly inhibit TrxR.177–186 In many of these studies the toxicity of the compounds 
towards cancer cells was explored along with their ab lity to inhibit TrxR, or the overall 
Trx system. For example, one study showed gold compounds of this type (Figure 1.11 
d) were more toxic towards human breast cancer cellsthan healthy breast cells, and also 
exhibited greater affinity towards TrxR compared to the structurally related GSR.186 
This study also further highlighted the importance of the selenol residue in TrxR for the 
overall affinity of the enzyme towards metal complexes. This was demonstrated by 
kinetics experiments which showed that the reactions f the metal complexes with 
selenocysteine were 20-80 times higher than for the corresponding reactions with 
cysteine at physiological pH. 
1.3.5 Mass Spectrometric Investigations 
Various types of mass spectrometers have been used for studying the 
interactions between drug molecules and enzymes, with MALDI-MS and ESI-MS 
proving to be particularly useful. For example, MALDI-MS has been used to monitor 
the binding of auranofin and sodium aurothiomalate, s well as some gold(III) drugs, to 
intact rTrxR1.187 Figure 1.12 shows the MALDI mass spectra of reaction mixtures 
containing different ratios of the complex [Au(bipy)(OH)2][PF6] (bipy = bipyridine) and 
rTrxR1. Each spectrum shows a very broad peak, attributable to the presence of protein 
molecules containing many different numbers of bound solvent molecules and other low 
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molecular weight species. Broad peaks are commonly bserved in MALDI mass 
spectra, and limit the accuracy with which the molecu ar mass of a protein or protein 
complex can be determined. Addition of 3 and 10 equivalents of the gold complex 
resulted in increases in the mass of the species in solution of ~1200 and ~3000 Da, 
respectively (Figure 1.12 a and b). While this is strong evidence of binding of the gold 
complex to the protein, the number of bound moleculs and the structure of the bound 
fragments could not be accurately determined due to the broad peaks observed. Much 
more information about the nature of the gold/TrxR binding interaction could be 
derived if narrower signals could be obtained for free protein molecules and 
protein/drug adducts in the same spectrum. 
 
Figure 1.12: MALDI mass spectra of solutions containing different ratios of rTrxR1 and 
[Au(bipy)(OH)2][PF6]: a) Au : rTrxR1 = 10 : 1;  b) Au : rTrxR1 = 3 : 1; c) free rTrxR1. Reproduced from 
Medicinal Chemistry Communications, 2011, vol. 2(1), p. 50-54 with permission of The Royal Society of 
Chemistry.187 
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ESI-MS offers a number of potential advantages for researchers wishing to 
examine the binding of small molecules to proteins. This is because the technique 
examines protein samples present in solution, as opposed to a matrix as is the case for 
MALDI-MS. In addition, ESI-MS provides raw spectra consisting of an envelope of 
ions corresponding to protein molecules in different states of protonation. This is 
exemplified by the spectrum of HSA shown in Figure 1.13 a).88 The presence of so 
many ions, each differing by a single charge, enables more accurate determination of 
the molecular mass of the species in solution. This is also true for the transformed 
spectrum shown in Figure 1.13 b).  
 
Figure 1.13: ESI mass spectra of HSA in 3% acetic acid: a) raw spectrum of free HSA, with an inset 
showing a magnified view between m/z 1780 and 1860; b) spectrum of free HSA transformed to a mass 
scale; and c) spectrum of a solution containing AuPEt3Cl : HSA = 1 : 1 obtained after  4 h, transformed to 
a mass scale. Components a-f are free HSA, HSA + Cys, HSA + glucose, HSA + AuPEt3, HSA + glucose 
+ AuPEt3, HSA + 2AuPEt3, respectively. Reprinted from Journal of Biological Inorganic Chemistry, 
2006, 11 (5), p. 559-570, with kind permission from Springer Science and Business Media.88 
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Another advantage of the narrow signals observed in ESI mass spectra is that it 
provides greater opportunities to observe separate ions from free protein, and protein 
molecules with one or more drug molecules or drug fa ments bound. For example, in 
Figure 1.13 b) and c) additional ions are present, which were attributed to cysteine and 
glucose molecules bound to HSA. In addition, in F gure 1.13 c), there are also ions 
from protein molecules with a AuPEt3 moiety bound. Observation of these separate ions 
allowed the relative abundance of each species to be determined. Despite these 
impressive results, to date no one has used ESI-MS to explore the binding of gold 
complexes, or those of any other metal ions, to intact TrxR. 
1.4 Gold Nanoparticles 
Recent years have seen considerable research focussed pon the potential for 
gold nanoparticles (Au NPs) to be used for a wide range of purposes in biology and 
medicine, such as diagnostic agents, bio-sensors, dug-delivery platforms and 
pharmaceuticals.188 Gold nanoparticles have been known to humans since the times of 
ancient Rome as a material for staining glass.189 One hundred and fifty years ago 
colloidal suspensions of gold were prepared by Michael Faraday using a procedure 
involving reduction of Au(III) with phosphorus.189 In 1951 a simpler method for 
preparing Au NPs was described by Turkevich et al.,190 and developed further by Frens 
et al. in the 1970’s.191 In both cases, the synthetic method involved addition of sodium 
citrate to a hot solution of H[AuCl4], with the overall reaction scheme shown in F gure 
1.14. The citrate molecules reduce the gold complex to the +1 oxidation state, after 
which a disproportionation reaction occurs, regenerating a Au(III) ion and producing 
elemental gold atoms that act as a nucleation point f r further reactions forming Au(I). 
Excess citrate ions then act as a stabilizing agent for the resulting colloid, preventing 
gold atoms from aggregating and producing particles that are 10 – 100 nm in size.191 
 
Chapter 1 – Introduction  41 
 
Figure 1.14: Reaction scheme for formation of Au NPs by citrate reduction. 
 
A variety of methods now exist to produce Au NPs with different shells, sizes 
and stability in non-aqueous solvents.192–194 The methods generally all start with 
reduction of a Au(III) complex in aqueous solution in the presence of a stabiliser to 
form the initial colloid, before either replacing the shell or utilising phase-transfer 
chemistry to change the shell. The capacity to functio alise the stabilising outer shell 
with groups such as thiols or amines is a major focus in this area, with small 
biomolecules also often employed.188 
1.4.1 Treatment of Rheumatoid Arthritis Using Au NPs 
A small number of studies have shown that Au NPs have potential for the 
treatment of RA. For example, in 1997 a case report was published in the United States 
involving a group of ten chronic sufferers of RA, who exhibited minimal response to 
several different therapies. These patients were then given an oral formulation of Au 
NPs, called Aurasol, which was synthesised by the citrate method with several 
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undisclosed ‘proprietary modifications.’195 Nine of the ten patients had previously been 
administered either aurothiomalate or auranofin, which proved to be either clinically 
ineffective or, in the case of five of the patients, resulted in adverse side effects. Prior to 
treatment (in week 0) the patients had their tenderness and swelling symptoms assessed 
by a semi-quantitative scoring system, in which a higher score corresponded to a greater 
severity of the symptoms. In addition, the levels of several Igs (IgG, IgM and IgA), 
rheumatoid factor, and the cytokines TNF and IL-6 were all determined. The average 
values obtained for each of these clinical markers at various time points throughout the 
study are shown in Table 1.3. Within one week of commencing treatment there wasa 
pronounced reduction in tenderness and swelling sympto s, which continued with 
further treatment. A statistically significant drop in the levels of IgG, IgM, TNF, IL-6 
and rheumatoid factor was also observed by the end of the study. The authors also 
commented that the patients showed no evidence of toxicity in either clinical or 
laboratory tests. 
Table 1.3: Effects of an oral Au NPs treatment regime on some inflammation markers of ten patients with 
chronic RA.195  
Marker Week 0 Week 1 Week 4 Week 16 Week 24 Week 52
Tenderness 54.8 ± 16.2 19.2 ± 6.3 8.4 ± 4.5 9.5 ± 2.6 5.4 ± 2.0 5.9 ± 2.5 
Swelling 42.5 ± 10.5 15.9 ± 5.9 13.2 ± 5.8 4.5 ± 1.3 3.3 ± 1.2 3.6 ± 2.2 
IgG 34.6 ± 7.3 - - 21.4 ± 4.4 18.8 ± 3.0 19.9 ± 3.4 
IgM 24.0 ± 4.9 - - 15.6 ±3.1 16.0 ± 3.5 19.4 ± 2.9 
IgA 5.9 ± 0.81 - - 4.5 ± 0.79 5.6 ± 1 4.7 ± 0.91 
TNF 207 ± 33 - - 105 ± 30 74 ± 25 - 
IL-6 241 ± 66 - - 107 ±20 104 ± 25 - 
RF 143.6 ± 23.7 - - - 145.9 ± 22.1 117.9 ± 18.9 
Note: Reported numbers are the means for all 10 patients. Tenderness and swelling are mean scores and 
unitless. All other markers were reported without units. Week 0 is before treatment began. Errors are 
standard error of the mean. - indicates data for that parameter not reported. 
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A subsequent investigation in 2008 examined the effcts of citrate-stabilised Au 
NPs on two strains of rats in which polyarthritis had been induced by injections of either 
Mycobacterium tuberculosis, collagen or pristane, a saturated alkane.196 The 
effectiveness of treatment using Au NPs was compared to that involving injection with 
aurothiomalate, with the rats given a mean arthritis score based upon the extent of paw 
and tail swelling, paw inflammation, and general well-b ing. With this approach a 
higher mean arthritis score indicated greater severity of symptoms. Both rats treated 
with aurothiomalate, and those administered Au NPs exhibited significantly lower mean 
arthritis scores than the group of control rats, in which arthritis had been induced using 
Mycobacterium tuberculosis. However, only rats treated with Au NPs had statistically 
lower mean arthritis scores than control rats where arthritis was induced by collagen or 
pristane. There were no signs of adverse side effects r sulting from treatment with Au 
NPs. This study and the case report involving human p tients both highlight the 
potential for Au NPs to be used for the treatment of RA or other inflammatory diseases. 
However, many questions remain concerning how the Au NPs exerted their anti-
arthritic effects, and how their effectiveness compares to the traditional gold(I) drugs. 
1.4.2 In Vitro Investigations Involving Au NPs 
Chithrani et al. published a number of studies examining the cellular ptake 
characteristics of different types of Au NPs.197–199 For example, in 2006 they published 
the results of an investigation on the effect of particle size on the extent of uptake of Au 
NPs by HeLa cells. This study involved citrate-stabilised Au NPs that were 14, 30, 50, 
74 and 100 nm in diameter.197 The number of particles incorporated into cells increased 
as the size of the particles increased from 14 to 30 and finally 50 nm. However, 
increasing the size of the nanoparticles further result d in the extent of cellular uptake 
decreasing. In the same publication, it was also noted that a similar trend was apparent 
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for Au NPs coated with transferrin, a serum protein that is involved in regulating iron 
levels. Notably, the overall number of particles incorporated into cells was always 
approximately three times smaller for transferrin-coated Au NPs than those coated with 
citrate.197 It was also demonstrated that Au NPs were most likely incorporated by 
receptor-mediated endocytosis, a process where the particle binds to a receptor on the 
surface of a cell, and is subsequently internalised upon membrane invagination and 
release of the particle from the receptor.197 The authors also reported that spherical Au 
NPs were taken up by cells in larger quantities than t ose with a rod shape.197 
A subsequent investigation focussed solely on the uptake of Au NPs coated with 
transferrin by HeLa, STO (fibroblast) and SNB19 (brain tumour) cell lines.198 It was 
again shown that the nanoparticles entered the cells by receptor-mediated endocytosis. 
In addition, the membrane-bound protein clathrin was demonstrated to play a large role 
in this process, while the rate of exocytosis of the nanoparticles was shown to decrease 
with increases in particle size.198 Subsequently it was shown in another study that Au 
NPs are initially packaged into endosomes, then fused with lysosomes, before being 
exocytosed.199 A scheme depicting the mechanism of uptake of Au NPs revealed by 
these studies is illustrated in Figure 1.15. 
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Figure 1.15: Cellular uptake of Au NPs by receptor-mediated endocytosis. Adapted from Nanomedicine: 
Nanotechnology, Biology, and Medicine, 2009, vol. 5 (2), p. 118-127 with permission from Elsevier.199 
 
 The cytotoxicity of, and extent of uptake of citrate-stabilised Au NPs by 
MC3T3-E1 cells, a mouse osteoblast cell line, has been recently investigated by 
Mustafa et al.200 No change in mitochondrial activity was found after treatment of the 
cells with Au NPs; however, there was an increase in expression of lactate 
dehydrogenase (LDH), an enzyme which is released upon cell damage or lysis. Using 
transmission electron microscopy (TEM), Au NPs were observed becoming 
encapsulated by the plasma membrane, with nanoparticle clusters also observed in the 
cytoplasm. These images demonstrate that Au NPs are tr nsported into cells by 
endocytosis,200 as had been initially observed by Chithrani et al.197,198 Mustafa et al. 
also suggested that the observed release of LDH could be a result of the disturbance of 
membrane integrity caused by endocytosis, as opposed to being an indicator of the 
cytotoxicity of the Au NPs.200  
To evaluate the biocompatibility of Au NPs, murine RAW264.7 macrophages 
were used to investigate whether Au NPs coated withlysine and poly-L-lysine elicit 
inflammatory and cytotoxic effects.201 Macrophages were chosen for this study due to 
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their role in the inflammatory response. Evidence of significant amounts of cellular 
uptake of Au NPs was obtained, along with indications that this occurred via receptor-
mediated endocytosis. Despite this, there was no indication that mitochondrial activity 
had been affected, and the levels of reactive nitrogen and oxygen species did not change 
significantly. This was also true for the pro-inflammatory cytokines TNF and IL-1β, and 
the level of general cellular protein expression.201 Contrasting results were reported by 
Yen et al. in a 2009 study using Au NPs obtained from Global N notech Industries in 
Taiwan.202 These Au NPs were synthesised by what was described as physical 
manufacturing and did not contain surface modifying or stabilizing agents. The 
cytotoxicity towards and extent of secretion of thepro-inflammatory cytokines TNF, 
IL-1, and IL-6 by murine J774.A1 macrophages was investigated after treatment with 
Au NPs. The results obtained with this different macrophage line showed significant 
cytotoxicity and increased levels of production of these cytokines, which became even 
more severe as the particle size decreased.202 These two studies highlight some of the 
conflicting evidence available in the literature con erning the biological interactions of 
nanomaterials, and the need for further investigations into the effects of changes in the 
physical characteristics of Au NPs, such as the presence and identity of stabilising 
‘shell’ molecules, on their cytotoxicity and other biological effects. 
One area that remains controversial is whether or not Au NPs can prevent or 
reduce emission of inflammatory molecules in cells. A 2010 investigation by Ma et al. 
published in Nitric Oxide described 10 - 15 nm diameter Au NPs as having the capacity 
to attenuate production of NO by RAW264.7 macrophages.203 In this study the 
macrophage cells were pre-treated with Au NPs, after which the inflammation-
stimulating molecule, LPS, was added. The concentration of NO2
-, a decay product of 
NO, produced by the cells was subsequently determind and shown to decrease as the 
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concentration of Au NPs increased. This was attributed to decreased expression of 
inducible nitric oxide synthase.203 The authors of the study also showed that this could 
be due to suppression of the transcription factor NF-κB. In contrast, the Au NPs did not 
affect expression levels of the pro-inflammatory cytokines, TNF, IL-1β and IL-6.203  
In evaluating the significance of the above results it i  important to note that the 
abstract of the article indicated that the Au NPs used were coated with polyethylene 
glycol (PEG).203 In contrast, in the methods section it was stated that the nanoparticles 
were purchased from the company Natural F & P (Seoul, Korea), and synthesised using 
the citrate approach. A reference is provided for the synthetic procedure used; however, 
the methods section of that article did not indicate that PEG had been used.204 As 
discussed above, the synthetic method employed to prepare Au NPs, and the identity of 
any molecules in the surrounding ‘shell’ may play an important role in determining how 
the nanoparticles interact with biological systems. In the discussion section of their 
article, Ma et al. state that a prior investigation into the effects of Au NPs on J774.A1 
cells, conducted by Yen et al.,202 obtained evidence which indicated that exposure to 
gold resulted in attenuation of cytokine production. I spection of the original data, 
however, shows that the Au NPs had the opposite effect. Furthermore, a letter to the 
editor by Leroy et al. in 2011, also published in Nitric Oxide,205 questioned the 
significance of the results reported by Ma et al.,203 and highlighted the fact that the 
composition of the nanoparticles in the study was unclear. Furthermore, in their letter to 
the editor, Leroy et al. presented results that showed that Au NPs stabilised with either 
citrate or dihydrolipoic acid did not attenuate LPS-induced formation of NO in NR8383 
cells, a rat macrophage cell line.205  
It is clear that there are conflicting results in the literature concerning the effects 
of Au NPs on production of reactive nitrogen-contaiing species. Further confusion in 
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this area stems from the results of an investigation into the effects of 28 nm diameter Au 
NPs coated with PEG, on LPS-activated RAW264.7 macrophages.206 The Au NPs did 
not induce significant formation of NO or IL-6 in the cells when the latter were exposed 
only to the nanoparticles. However, treatment of the macrophages with both Au NPs 
and LPS led to a small but significant increase (10 – 20%) in NO and IL-6 levels, as 
well as increased expression of inducible nitric oxide synthase.206 These results contrast 
those from the 2010 study by Ma et al., and further highlight the importance  that the 
nanoparticle size and shell composition may have in determining biological effects such 
as inflammation. Therefore it is essential that researchers in this field unambiguously 
report the synthetic procedure they employ to prepare Au NPs, and fully characterise the 
resulting materials. 
1.4.3 Interactions of Gold Nanoparticles with Proteins, Including 
Thioredoxin Reductase 
There have also been a number of recent investigations nto the biological 
interactions of Au NPs with proteins. For example, the binding of Au NPs to bovine 
serum albumin has been studied using zeta potential me surements and quartz crystal 
microbalance techniques.207 It was tentatively concluded that electrostatic forces, 
possibly involving the carboxylate groups of citrate anions on the surfaces of the Au 
NPs, and protonated amines of surface lysine residu of the protein, were responsible 
for the observed interactions. In another study circular dichroism spectroscopy and 
dynamic light scattering were used to perform measurements on systems containing 
citrate-stabilized Au NPs of various sizes, and a range of proteins found in human 
blood.208 It was concluded that in these systems protein molecules formed an outer 
layer, or ‘corona,’ on the surface of the Au NPs, and the overall strength of interactions 
between the two components increased along with nanoparticle size. 
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To date there appears to be very little work reported in the literature describing 
interactions between Au NPs and TrxR. The lack of studies in this area is surprising 
considering the body of evidence demonstrating the potency of Au(I) and Au(III) 
compounds as TrxR inhibitors. In one recent study, evidence of interactions between 
TrxR and small nanoclusters composed of 25 gold atoms stabilized by a tridecapeptide 
was reported.209 The clusters inhibited the activity of TrxR directly, and in HeLa cells, 
leading to higher levels of ROS and apoptosis. Apart from this investigation, there 
appears to have been only one other study which has examined the interactions between 
Au NPs and the Trx system.210 The aim of this study was to determine whether Au NPs 
can induce oxidative stress in vivo in a marine organism, the mussel Mytilus edulis. The 
mussels were exposed to Au NPs over a 24 hour period. Subsequently, gold was 
detected primarily in the digestive glands of the mussels. The effect of exposure to gold 
on the level of activity of TrxR was also examined; however, no significant changes 
were detected. 
The above results contrast those obtained in a study where A549 lung cancer 
cells were exposed to silver nanoparticles (Ag NPs), and the effects of these 
nanoparticles on the synthesis of selenoproteins and activity of TrxR were monitored.211 
Treatment with the Ag NPs inhibited incorporation of selenium into selenoproteins, and 
inhibited TrxR activity in a dose-dependent manner. This was attributed to the effects of 
Ag+ ions leaching from the nanoparticles, as opposed to the direct effects of the 
nanoparticles themselves. Consistent with this hypothesis, the extent of inhibition of 
TrxR activity in A549 cells was ten times greater after exposure to Ag+ ions than Ag 
NPs.211 The researchers were also able to show in a cell-free system that TrxR1 is 
inhibited by Ag+ ions; however, they did not indicate if Ag NPs were also able to 
directly inhibit the enzyme. The results of this study may, therefore, imply that Ag NPs 
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are unable to interact with TrxR or the Trx system. As yet it has not been conclusively 
shown if this is also true for Au NPs. 
In summary, whilst a limited number of in vivo studies have suggested that Au 
NPs may have promising anti-inflammatory effects, this has not been supported by the 
results of laboratory experiments. It is also likely from a number of studies that have 
been performed, that the physical characteristics of Au NPs greatly contribute to their 
overall biological effects and interactions. Despite this, and the clear demonstration that 
gold compounds can significantly affect the activity of TrxR, there is still a gap in our 
understanding of how, if at all, Au NPs interact wih the thioredoxin system. 
1.5 Project Aims 
The overall aim of this project was to compare the biological activity and effects of 
gold nanoparticles, to that of gold(I) drugs used for the treatment of rheumatoid 
arthritis. The specific aims of the project were to: 
• compare the cytotoxicity of gold nanoparticles towards macrophages with that 
of gold(I) anti-arthritic drugs; 
• compare the extent of uptake of gold compounds and nanoparticles by 
macrophages; 
• investigate the intracellular fate of gold(I) drugs and gold nanoparticles in 
macrophages using microprobe synchrotron radiation X-ray fluorescence 
imaging; 
• compare the relative abilities of gold(I) drugs and gold nanoparticles to affect 
the production of pro- and anti-inflammatory cytokines, reactive oxygen species, 
and nitric oxide in macrophages; and 
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• investigate the binding of gold(I) drugs and gold nanoparticles to thioredoxin 
reductase using electrospray ionisation mass spectrome y. 
 
 
 
 
 
Chapter 2:  
Materials and Methods  
 
 
This chapter provides a detailed description of how the experiments described in this 
thesis were performed, along with details of where the many commercial reagents were 
obtained. 
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2.1 Materials 
All aqueous solutions were prepared using Milli Q™ water (18.2 MΩ, 
Millipore, Billerica, USA) unless otherwise specified. Sodium aurothiomalate, sodium 
aurothioglucose, auranofin, gold(III) chloride (99.%), dithiothreitol (99.0%, DTT), 
ethylenediaminetetraacetic acid (99%, EDTA) sodium citrate, caesium iodide (Fluka 
brand, 99.999%), trypan blue solution (0.5% w/v in phosphate-buffered saline, PBS), 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), sulfanilamide, N-
(1-naphthyl)ethylenediamine dihydrochloride (NED), sodium nitrite, trace metals pure 
NaCl (99.999%), conc. hydrochloric acid (HCl, 98%), rat thioredoxin reductase (batch 
#033M4083V) and lipopolysaccharide (Escherichia coli serotype 055:B5) were 
obtained from Sigma-Aldrich (St. Louis, USA). Sodium aurothiosulfate was obtained 
from Alfa Aesar (Ward Hill, USA). Sodium hydroxide pellets (98%), sodium chloride, 
potassium chloride, potassium dihydrogen phosphate, sodium hydrogen phosphate, 
polysorbate 20 (TWEEN) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) (all ACS grade) were obtained from Amresco (S lon, USA). Ammonium 
acetate (98%), glacial acetic acid (99.5%), isopropanol (99.0%), methanol (99.8%) and 
ethanol (99.5%) were obtained from Ajax Finechem (Seven Hills, Australia), while 
dimethylsulfoxide (DMSO, 99.98%) was obtained from Fisher Scientific (Waltham, 
USA). Ultrapur nitric acid (HNO3, 60% v/v) was obtained from Merck Millipore 
(Darmstadt, Germany), whilst a certified Au standard solution (997 mg/L Au, 10% HCl 
(v/v)) was obtained from PerkinElmer (Waltham, USA). u NPs were purchased from 
BBI (product codes EM.GC2, EM.GC20 and EM.GC100; diameters 2, 20 and 100 nm, 
respectively) and Sigma-Aldrich (product codes 741965 and 753610; both have 
diameters of 20 nm, stabilised in citrate buffer and PBS, respectively).* Mouse 
                                                 
* Sigma-Aldrich state that both contain a “proprietary surfactant as stabilizer.” 
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interleukin-10 and mouse tumour necrosis factor enzyme-linked immunosorbent assay 
(ELISA) kits (ELISA MAX™ Deluxe) were obtained from BioLegend (San Diego, 
USA). Invitrogen (Grand Island, USA) was used to obtain 2',7'-
dichlorodihydrofluorescein diacetate (DCFH2-DA), pre-cast NuPAGE 4-12% Bis-Tris 
gels, and Novex Sharp protein standards. Enzo Life Sci nces (Plymouth Meeting, USA) 
was used to obtain 7-aminoactinomycin D (7AAD). PBS tablets (Oxoid brand) were 
obtained from Thermo Fisher Scientific (Waltham, USA). Fetal bovine serum (FBS, 
heat-inactivated) was obtained from Bovogen Biologicals (East Keilor, Australia). 
GlutaMAX™ and Roswell Park Memorial Institute-1640 (RPMI-1640) cell culture 
medium powder were obtained from Life Technologies (Carlsbad, USA). Disposable 
pipettes, 6-mL round bottom polystyrene tubes and 96 well plates for MTT assays were 
obtained from BD (Franklin Lakes, USA). Cell culture flasks (75 cm2 surface area, T75 
flasks), cell culture dishes (60 mm), 24-well plates, 96-well plates for Griess assays and 
cell scrapers were obtained from Greiner Bio-One GmbH (Frickenhausen, Germany). 
15 mm diameter Nunc™ Thermanox™ coverslips were purchased from Emgrid 
Australia (The Patch, Australia). Silicon nitride (Si3N4) membranes (frame size = 5 mm 
× 5 mm; sample surface area = 1.5 mm × 1.5 mm; membrane thickness = 500 nm; and 
frame thickness = 200 nm) were obtained from Silson (Northampton, UK). 
2.2 Synthesis of Gold Nanoparticles 
A stock solution of gold nanoparticles was synthesis d according to the classical 
method described by Turkevich et. al.,190 but with some modifications. Milli-Q water 
(30 mL) was heated to near boiling and a solution of HAuCl4.3H2O (10.00 mM in 
water, 2.000 mL) was added.  This was followed by a solution of tri-sodium citrate 
(20.00 mM, 4.000 mL) and the resulting solution turned red (from colourless). The 
solution was subsequently heated for one hour, cooled to room temperature, and then 
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transferred to a volumetric flask (50.00 mL) to which Milli-Q water was added to 
produce a solution with a final concentration of 400 µM Au(0), assuming complete 
conversion of Au(III). More concentrated solutions of Au NPs required for nitric oxide 
formation experiments were prepared by centrifuging the above preparation of Au NPs 
(11000×g, 10 min), removing the top aqueous layer, and re-suspending the pellet 
containing the nanoparticles in a smaller volume of water. 
Absorption spectra of Au NPs were obtained using a Varian (Santa Clara, USA) 
Cary 500 UV-VIS-NIR spectrophotometer and quartz cuvettes. Particle size analysis 
was performed on Au NPs using a Malvern (Malvern, UK) Zetasizer Nano S, while 
field emission scanning electron microscopy (FESEM) images were obtained using a 
JEOL (Akishima, Japan) JSM-7500FA FESEM instrument. The FESEM samples were 
prepared by allowing small volumes of Au NP solutions to evaporate on carbon-copper 
films. 
2.3 Cell Culture 
The adherent RAW264.7 macrophage cell line was obtained from the American 
Type Culture Collection (Manassas, USA) as frozen permanents. The cells were 
maintained in Roswell Park Memorial Institute-1640 (RPMI-1640) medium containing 
10% (v/v) fetal bovine serum (FBS) and 2 mM GlutaMAX™ (complete medium) at 37 
°C and 5% CO2/95% air in a Revco (Twinsburg, USA) Ultima incubator.  Cells were 
subcultured at 90% confluence, and used between 3 and 30 passages. Cells were lifted 
from the surface of flasks by gentle scraping. Treatm nt solutions containing sodium 
aurothiomalate or sodium aurothiosulfate were prepared in RPMI-1640 medium 
containing 2 mM GlutaMAX™ (incomplete medium). Control cells were also treated 
with incomplete medium. Treatment solutions containing auranofin were prepared by 
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first dissolving the metal complex in DMSO, and then diluting to the desired auranofin 
concentration using incomplete medium. The final concentration of DMSO in auranofin 
treatment solutions was 1% (v/v).  Treatment solutins containing gold nanoparticles 
were prepared using a solvent consisting of 15% (v/v) water and 85% (v/v) incomplete 
medium. For inflammation assays (Section 2.9), gold nanoparticle treatment solutions 
were spiked with a small volume of concentrated Dulbecco’s phosphate-buffered saline 
(10×D-PBS, preparation described in Section 2.9.1) to counteract disturbance of 
isotonicity due to dilution of the incomplete medium. The gold nanoparticle treatment 
solutions for these experiments were prepared using a solvent consisting of 1.5% (v/v) 
10×D-PBS, 15% (v/v) water, 83.5% (v/v) incomplete mdium. 
2.4 Trypan Blue Assays 
Trypan blue assays were performed to assess the number of viable cells in a 
sample, and were performed by adding cell suspension (50 µL) to trypan blue solution 
(50 µL). The resulting solution was loaded onto a Neubauer-improved bright-line 
haemocytometer (Marienfield-Superior, Lauda-Königshofen, Germany) and the number 
of viable (colourless) and non-viable (blue) cells were counted according to the 
manufacturer’s instructions using a Motic (Causeway Bay, Hong Kong) AE20 light 
microscope at 10× magnification. 
2.5 MTT Assays 
 The cytotoxicity of the gold compounds and Au NPs was assessed using the 
MTT assay.212 This technique provides a measure of the cellular toxicity exhibited by a 
compound by spectrophotometrically quantifying the extent of mitochondrial enzymatic 
reduction of the yellow compound 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) to form the purple formazan, (E,Z)-5-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenylformazan.212 This reaction (Figure 2.1) occurs in living cells with functioning 
mitochondria.213 As such, the amount of purple formazan formed is drectly 
proportional to the number of viable cells. 
 
Figure 2.1: Reduction of yellow MTT to form a purple formazan compound. 
 
RAW264.7 cells in complete medium were seeded into a 96-well plate (5×104 
cells/100 µL/well) and incubated overnight (37 °C, 5% CO2). The cell medium was then 
removed by aspiration and the cells were washed twice ith incomplete medium (300 
µL) to remove any FBS. Freshly prepared treatment solutions containing gold 
compounds or Au NPs at the required concentrations were added to the wells (100 
µL/well) and incubated for either 4 h or 24 h. At the end of the treatment period, the 
treatment solutions were removed by aspiration, and the adherent cells were washed 
twice with incomplete medium (300 µL). For the 4 h treatments, the cells were 
incubated for an additional 20 h in incomplete medium (100 µL) before the addition of 
MTT solution (50 µL, 2 mg/mL in PBS) and subsequent incubation for 4 h. For the 24 h 
treatments, cells were incubated for 4 h with incomplete medium (100 µL) and MTT 
solution (50 µL, 2 mg/mL in PBS) immediately after washing the cells. At this time, the 
solutions were aspirated from the cells, and the resulting purple crystals dissolved in 
DMSO (200 µL/well). The absorbance of these solutions was then measured at 570 nm 
and 630 nm using a BMG Labtech (Offenburg, Germany) POLARstar Omega 
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microplate reader. The absorbance at 630 nm was used as a background subtraction, 
whilst the absorbance at 570 nm measured the amount of the formazan. In each assay 
six wells were allocated for each concentration of the gold compound or Au NPs being 
assessed, and eighteen wells were used for the control cells. The change in absorbance 
of each group of six or eighteen wells was averaged for calculations of the cell 
viabilities (Equation 2.1).  
 
Cell Viability % = 
A570– A630(treated cells)
A570– A630 (control cells)
×100 
    
 
Each experiment was performed three times, and the errors reported here are the 
standard deviations between calculated cell viabilities for a given concentration on each 
plate. 
2.6   Graphite Furnace Atomic Absorption Spectroscopy (GFAAS) 
 The quantity of gold associated with macrophages after treatment with gold 
compounds or Au NPs was determined by GFAAS.43,214 RAW264.7 cells in complete 
medium (5×106/5.00 mL/dish) were seeded into sterile 60-mm cell u ture dishes and 
incubated for 24 h. The cell medium was then removed, and the cells were washed once 
with PBS and once with incomplete medium to remove any FBS. Treatment solutions 
containing the Au compounds or Au NPs were then added to cells, which were then 
incubated for 24 h. At this point the treatment soluti ns containing any dying/lifted cells 
were collected in centrifuge tubes.  Incomplete medium (5 mL) was added to the dishes 
and the adherent cells were harvested by gentle scraping and added to the cells 
contained in the treatment solutions. The combined c lls were centrifuged (300×g, 5 
min) and washed twice with incomplete medium (5 mL) followed by further 
centrifuging (300×g, 5 min). The resultant cells were resuspended in incomplete 
2.1 
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medium (1.000 mL), and an aliquot (50.0 µL) then removed and the cell number and 
viability were assessed by the trypan blue method described in Section 2.4. The 
remaining cells were then centrifuged and washed twice with saline solution 
(preparation described in Appendix A:). The pellets were freeze-dried for 2 h and 
digested in nitric acid (10 - 100 µL Ultrapur, 60% v/v) overnight, whereby the volume 
of acid was dependant on the final dilution volume. The resulting solutions were 
subsequently diluted in 5.00 mL or 50.00 mL volumetric flasks with a final nitric acid 
concentration of 0.6% v/v. Triplicate cell samples were prepared for each concentration 
of gold compound or Au NPs examined. 
 GFAAS measurements were performed on the final solutions using a 
PerkinElmer AAnalyst 600 atomic absorption spectrometer equipped with the Winlab 
32 AA Furnace program, incorporating Zeeman-effect background correction, an AS-
800 autosampler, and an AA Accessory cooling system. A gold hollow cathode lamp 
(PerkinElmer) was employed that emitted radiation at a wavelength of 242.8 nm. A slit 
width of 0.7 nm was used to give an instrument energy reading of approximately 50 W. 
A certified Au standard solution (997 mg/L Au, 10% HCl (v/v)) was used to prepare the 
stock Au standard solution (50 µg/L, 0.6% HNO3 v/v) for generation of a calibration 
curve (correlation coefficients: 0.992 - 0.994). The analyte (20 µL) was mixed with 
matrix modifier solution (5 µL), and atomised from the surface of a pyrolytic graphite-
coated tube using the furnace operating conditions described in Appendix A:. Argon 
gas was used throughout the analysis, with absorption measurements conducted during 
the atomisation stage (1800 °C).  
Triplicate measurements were performed for each sample and averaged to give 
the gold content per unit of volume for that sample. This was then converted into the 
mass of gold per cell using the results of the trypan blue assay determined prior to 
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sample digestion. Errors are reported as the standard eviation of the mean, n = 3. 
Statistical significance was tested by one-way analysis of variance (ANOVA) with a 
Tukey post-test set at 95% confidence intervals, performed using GraphPad Prism 
version 5.03. These tests were performed on two subgro ps of samples based upon 
treatment concentration (2.5 µM and 60 µM). 
2.7 Microprobe Synchrotron Radiation X-Ray Fluorescence (SR-XRF) 
Imaging 
The spatial distribution of gold and other elements within macrophages that had 
been treated with either Au(I) compounds or Au NPs was determined by microprobe 
SR-XRF imaging.215–219 In this experiment, the sample is bombarded with focussed X-
rays from a synchrotron source. If the X-ray beam possesses high enough energy to 
excite core electrons of an atom of interest, these lectrons are ejected into the 
continuum producing an unstable ion with a vacancy i  the core shell. This vacancy is 
subsequently filled by an electron from an outer energy level, releasing an X-ray 
fluorescent photon. This principle, illustrated in Figure 2.2, results in emission of 
fluorescent photons that are characteristic of the elements analysed, due to the unique 
energy transitions between orbitals of different elements. As such it is possible to detect 
a range of elements present in a sample simultaneously without the need for additional 
treatment steps. 
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Figure 2.2: Illustration of X-ray fluorescence utilised in SR-XRF. 
2.7.1 Preparation of Samples 
Samples for both high and low resolution mapping were prepared on Si3N4 
membranes, which were initially washed once with ethanol (70% v/v), twice with sterile 
PBS, and finally once in cell growth medium, before b ing placed in a 60 mm cell 
culture dish. RAW264.7 cells in complete medium (5×106/5 mL) were seeded into the 
dishes and incubated overnight. After confirming that the cells had grown to a sufficient 
confluence on the Si3N4 membranes, the medium was removed and the cells were
washed twice with incomplete medium to remove any FBS. Treatment  solutions (5.00 
mL), containing the appropriate concentrations of Au(I) compounds or Au NPs, were 
then added to the dishes prior to incubation for 24 h. Following this period the 
membranes were removed from the dishes, and washed by sequentially dipping in two 
solutions of PBS and then three solutions of ammonium acetate (200 µM) to remove 
any excess phosphate or chloride ions.220,221 The cells were then fixed by dipping once 
in methanol.222,223 The membranes were freeze-dried overnight and stored in a 
desiccator until analysed. 
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2.7.2 High Resolution Mapping 
Microprobe SR-XRF analysis of individual cells was performed on the 2-ID-D 
beamline at the Advanced Photon Source (APS), Argonne National Laboratory 
(Chicago, United States) using a monochromatic 13.45 keV X-ray beam focused to 
0.3 μm2 using two stacked zone plates. The silicon nitride (Si3N4) membranes were 
mounted on a high precision XYZ motorised stage (PM20076), and the fluorescent X-
rays were detected using a Vortex EM (Radiant Detector Technologies, LLC, 
Northridge, USA, 165-VTX-EM) silicon drift detector perating in fluorescence mode. 
High resolution elemental maps were acquired over pr -determined scan areas using a 
0.5 µm step size and 0.5 s/point dwell time. The elem nts were quantified with the aid 
of corresponding measurements from the thin film standards NBS-1832 and NBS-1833, 
obtained from the National Bureau of Standards (Gaithersburg, USA). 
2.7.3 Low Resolution Mapping 
Elemental mapping of large cell areas (120 µm × 120 µm) with lower resolution 
was performed at the XFM beamline at the Australian Synchrotron (AS, Clayton, 
Australia) to compare gold uptake across a large population of cells. These experiments 
were performed using a monochromatic 12.055 keV X-ray beam focused to 2 μm in the 
horizontal and vertical dimensions using a Kirk-Patrick Baez mirror and a silicon drift 
diode detector operating in fluorescence mode.216 Elemental maps were acquired using a 
2 µm step size and 1 s/point dwell time. 
2.7.4 Data Analysis 
The full fluorescence spectra obtained at either th APS or AS were fitted to 
modified Gaussians and the data was processed usingthe MAPS software package, 
version 1.7.1.03, provided by Dr Stefan Vogt at APS. 
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2.8 Scanning Electron Microscopy of Cells 
Samples were prepared on 15 mm diameter Nunc™ coverslips, which were 
initially washed with ethanol (70% v/v) and then complete medium, before being placed 
in a 60-mm cell culture dish. RAW264.7 cells in complete medium (3×106/5.00 
mL/dish) were seeded into the dishes and incubated ov rnight. After confirming that the 
cells had grown to a sufficient confluence on the coverslips, the medium was removed 
and the cells were washed twice with incomplete medium to remove FBS. Treatment 
solutions (5.00 mL) containing the appropriate concentrations of Au NPs were then 
added to the dishes prior to incubation for 24 h. Following this period the coverslips 
were removed from the dishes, washed in PBS twice and then placed into 
glutaraldehyde solution (2% v/v in PBS) for 2 h at room temperature. At the end of this 
period, the coverslips were washed twice in PBS, then dehydrated by incremental 
increases of ethanol solution (30% × 2, 50% × 2, 70% × 2; v/v; 10 min/solution) and 
refrigerated overnight in 70% ethanol. The coverslips were cut to size, then further 
dehydrated by incremental increases of ethanol solution (70% × 1, 80% × 1, 90% × 1, 
100% × 3; v/v; 10 min/solution).  
At this point, the samples were dried by critical point drying (CPD) using an EM 
CPD030 instrument (Leica, Wetzlar, Germany). Briefly, the samples were submerged in 
ethanol at 8 °C in the chamber of the instrument, ad liquid CO2 added until the 
chamber was full. After 15 min, the chamber was partially drained and refilled with 
liquid CO2, which was repeated three times. The chamber was then heated to 40 °C and 
CO2 gas slowly drained to dry the samples. At this point, the samples were mounted in a 
sample holder, coated with 10 nm of platinum and analysed using a JEOL JSM-6490LV 
FESEM instrument for general images and a JEOL JSM-7500FA FESEM instrument 
for variable accelerating voltage and electron disper ive X-ray (EDX) images. 
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2.9 Inflammation Assays 
2.9.1 Solutions 
Investigations into the formation of inflammation markers required a number of 
different solutions and cell media, prepared as described in Appendix A:. Their names 
and components are briefly described here. Dulbecco’s phosphate-buffered saline (D-
PBS) consisted of KCl (2.67 mM), KH2PO4 (1.47 mM), NaCl (138 mM) and Na2HPO4 
(8.10 mM). 10×D-PBS contained KCl (26.7 mM), KH2PO4 (14.7 mM), NaCl (1.38 M) 
and Na2HPO4 (81.0 mM). Enzyme-linked immunosorbent assay (ELISA) wash buffer 
contained 0.5% v/v TWEEN/D-PBS. Incomplete NaCl medium contained KCl (5 mM), 
HEPES (10 mM) and NaCl (145 mM), while complete NaCl medium was prepared by 
adding glucose (5 mM) to incomplete NaCl medium. 
Solutions containing commercial Au NPs, required for NO and ROS formation 
experiments were administered to cells using the Au NPs vehicle, which consisted of 
1.5% (v/v) 10×D-PBS, 15% (v/v) water, 83.5% (v/v) incomplete medium. The 
concentration of Au NPs in treatment solutions prepa d from commercial nanoparticle 
solutions was generally 40 µM. The only exception t this was stock solutions 
containing 2 nm Au NPs which were originally obtained from BBI. In this case, the 
final concentration of the stock solution was 9 µM. 
2.9.2 Assays 
The initial preparation of samples for determining the extent of inflammation 
marker formation was performed using the following, similar steps. RAW264.7 cells 
were seeded into a 24-well plate (5×105/ .000 mL/well) and incubated overnight. The 
medium was removed by aspiration and the cells were washed three times with 
incomplete medium (1 mL). The relevant vehicle (500 µL/well) containing LPS (a 
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positive control treatment), gold compounds or Au NPs was added and incubated with 
the cells for 24 h. In other experiments, cells in incomplete medium (500 µL/well) were 
pre-incubated with gold compounds or Au NPs for 4 h, after which LPS (100 ng/mL) 
was added and the cells were incubated for a further 20 h.   
Sections 2.9.3 - 2.9.5 describe the procedures used to determine the extent of 
inflammation marker formation after the treatment described above. 
2.9.3 Nitric Oxide Formation 
The production of reactive nitrogen species including nitric oxide (NO) was 
assessed by measuring total nitrite concentration usi g the Griess assay.203,224 Nitrite 
(NO2
-) is a major cellular decay product of NO, an inflammation mediator that has a 
short biological half-life. As a consequence, the amount of NO2‾ released from cells is 
commonly used to infer relative amounts of NO production.224 In the presence of nitrite 
and acid, sulfanilamide and N-(1-naphthyl)ethylenediamine (NED) combine to form the
Griess reagent, an azo compound that is pink in colour (Figure 2.3). 
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Figure 2.3: Reaction scheme for formation of the Griess reagent in assays used to detect nitrite. 
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Prior to commencement of an assay, a stock solution of sulfanilamide was 
prepared by dissolving 1.0 g in 100 mL of 5% (v/v) HCl. In addition, a stock solution of 
NED was prepared by dissolving the dihydrochloride salt (0.1 g) in Milli-Q H2O (100 
mL). Macrophages were first treated with gold compounds or Au NPs as described in 
Section 2.9, after which the resulting solutions were removed by aspiration and 
centrifuged (300×g, 5 min) to obtain cell-free supernatants. Triplicate liquots (50 µL) 
of each supernatant or freshly prepared NaNO2 standards (0 – 100 µM, in 10 µM 
increments) were added to the wells of a 96-well plate. The sulfanilamide stock solution 
(25 µL) was added to each well using an 8-channel micropipette, followed by NED 
stock solution (25 µL). The plate was then incubated at room temperature for 10 min. 
Wells containing nitrite changed to a pink colour. The absorbance at 540 nm (A540) was 
measured using a Molecular Devices (Sunnyvale, USA) pectraMAX Plus 384 
microplate reader. The mean absorbance of the triplicates for each sample or standard 
were calculated and the concentration of nitrite in ach sample was interpolated from a 
linear standard curve (0 – 100 µM, 11 points, 10 µM increments) using GraphPad Prism 
version 5.03 (GraphPad Software, Inc., La Jolla, USA). The experiment was performed 
three times, with the errors reported being the standard error of the mean for each 
replicate experiment.  
2.9.4 Reactive Oxygen Species Formation 
The production of reactive oxygen species (ROS) was assessed by measuring the 
extent of cellular conversion of 2',7'-dichlorodihydrofluorescein diacetate (DCFH2-DA) 
to 2',7'-dichlorofluorescein (DCF).225,226 DCFH2-DA is readily taken up by cells and 
subsequently converted in two steps to a fluorescent dye. Intracellular esterase enzymes 
remove the two acetyl groups of DCFH2-DA to form DCFH2, which is subsequently 
oxidised to the conjugated fluorescent molecule DCF by cellular ROS (Figure 2.4). By 
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targeting cells with a laser, it is possible to excite and then detect any DCF present 
within cells and thus infer the amount of ROS that s been formed. 
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Figure 2.4: Reaction scheme for conversion of DCFH2-DA to DCF employed for the detection of ROS. 
 
The following describes a typical experiment assessing the extent of ROS 
production using DCF. Stock solutions containing DCFH2-DA were dissolved in 
DMSO to obtain a concentration of 5 mM and were stored frozen at -20 °C in 30 µL 
aliquots. Experiments were performed in minimal light to prevent photodecay of the 
fluorescent dyes. After macrophages were treated with gold compounds or Au NPs as 
described in Section 2.9, the treatment solution was removed by aspiration and the cells 
were washed three times with incomplete NaCl medium (1 L). DCFH2-DA (500 µL, 
10 µM in complete NaCl medium) or DMSO for autofluorescence control samples (500 
µL, 0.2% in complete NaCl medium) was added to the wells and the plate was 
incubated for 30 min. The cells were then washed three times with incomplete NaCl 
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medium (1 mL) before being harvested by gentle scraping in complete NaCl medium 
(500 µL). The cell suspensions were then transferred to 6 mL round bottom polystyrene 
tubes and centrifuged (300×g, 5 min) to produce a pellet. The supernatant was decanted 
and the resuspended cells (<50 µL) were incubated with 7-aminoactinomycin D 
(7AAD, 1 µL, 1 mg/mL) at room temperature for 5 min. Complete NaCl medium (300 
µL) was added and the suspension analysed using a Becton Dickinson (San Jose, USA) 
LSR II flow cytometer. The samples were excited using a blue laser (488 nm) with 
emissions measured at 515 nm and 695 nm corresponding to DCF and 7AAD 
fluorescence, respectively. 10000 events were counted for each sample. Instrumental 
fluorescence compensation was applied in some experiments to account for ‘bleeding’ 
of one high intensity fluorescent marker into the other. 
The data was analysed using FlowJo (Tree Star, Ashland, USA), with ROS 
production reported as the median fluorescence intensity at 515 nm for viable cells. 
Viable cells were gated initially on the basis of frward scatter and side scatter, and 
secondly on the basis of fluorescence at 695 nm, to exclude 7AAD high (non-viable) 
cells. The median fluorescence intensity (MFI) at 515 nm for DMSO-treated 
autofluorescence control samples was subtracted from that of the relevant sample 
treated with DCFH2-DA to determine the amount of ROS production following each 
treatment. The experiment was performed five times with the errors reported as the 
standard error of the mean. For the LPS-induced ROS production experiment, final 
median fluorescence intensity values were normalised to the control sample (incomplete 
medium only) and reported as percentages. 
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2.9.5 IL-10 and TNF Release 
The extent of production of the cytokines IL-10 and TNF was assessed by 
ELISAs performed using pre-packaged kits obtained from BioLegend. These kits 
contained all the buffers, standards, antibodies and high-binding 96-well plates required 
to perform the assays, with the exception of the wash buffer, which was prepared as 
described in Appendix A.5. The protocol for performing the ELISAs was provided by 
the manufacturer and is described in the following sections. All wash steps were 
performed by inverting the plate, blotting the plate dry on paper towel and adding 
approximately 300 µL of wash buffer. Prior to use, c ll treatment supernatants were 
removed and centrifuged (300×g, 5 min) to pellet any floating cells.  
Wells of a high-binding 96-well ELISA plate were incubated overnight at 4 °C 
with the specific capture antibody required for theELISA to be performed, which was 
present in coating buffer (100 µL). Wells were then washed three times with wash 
buffer and blocked with the assay diluent (200 µL) for 1 h at room temperature. The 
ELISA plate was then washed once with wash buffer, and duplicate aliquots (100 µL) of 
each sample or respective cytokine standard were add d to each well and incubated at 
room temperature for 2 h. The wells were then washed fiv  times with wash buffer, the 
respective detection antibody was added (100 µL), and the wells incubated at room 
temperature for 1 h. The wells were then washed with ash buffer five times and 
Avidin-HRP (100 µL) added prior to incubation at room temperature for a further 30 
min. At this point, the wells were washed (seven times for TNF and twelve times for IL-
10) with wash buffer, substrate solution (100 µL) then added to each well and the 
resulting mixtures incubated at room temperature fo a further 15 min. Finally, H2SO4 
(1 M, 50 µL) was added to each well and the absorbance of each well was measured at 
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450 nm and 570 nm using a Molecular Devices SpectraMAX Plus 384 microplate 
reader.  
The absorbance at 570 nm was used as a background subtraction, whilst the 
absorbance at 450 nm corresponded to the blue colour arising from the presence of 
either cytokine. The absorbance of duplicate wells for each sample or standard was 
averaged and used for calculations. The concentration of cytokine in each sample was 
interpolated from a standard curve (0 – 2000 pg/mL for IL-10, 0 – 500 pg/mL for TNF; 
8 points per curve, 2 fold increments), which was tr nsformed to the log scale on both 
axes using GraphPad Prism version 5.03. Each experiment was performed three times, 
with the errors reported as the standard error of the mean for each replicate experiment. 
2.9.6 Statistical Analyses 
Statistical significance was tested by using either a one-way ANOVA with a 
Tukey post-test set at 95% confidence intervals, or a two-tailed unpaired t-test with a 
95% confidence interval. The tests were applied on subgroups of samples based on what 
vehicle was used. Specifically, both concentrations f aurothiomalate-treated samples 
were sub-grouped with their vehicle (incomplete medium) and tested by one-way 
ANOVA, whilst both concentrations of Au NP-treated samples were sub-grouped with 
the Au NPs vehicle and also tested by one-way ANOVA. Samples treated with 2.5 µM 
auranofin were grouped with the auranofin vehicle treatment and tested by t-test. The 
auranofin and Au NPs vehicles were both grouped with incomplete medium and tested 
by one-way ANOVA. As such, significance reported for a sample refers to when it is 
compared to its relevant vehicle. All statistical analyses were performed using 
GraphPad Prism version 5.03.  
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2.10 Expression and Purification of Human TrxR 
A plasmid containing human thioredoxin reductase (hTrxR), pET46-(His)6-
hTrxR1, was obtained from A. Wang.169 The expressed protein had the codon for 
selenocysteine-498 mutated to a cysteine to facilitte bacterial expression and contained 
an N-terminal His6 tag to assist purification. E. coli BL21(λDE3)/pLysS containing the 
TRXR+ plasmid was grown in lysogeny broth (tryptone (7.5 g), yeast extract (3.75 g), 
NaCl (7.5 g) in Milli-Q H2O (750 mL)) at 37 °C to A600 = 0.6. The culture was cooled to 
23 °C, and TrxR production was induced with isopropyl-β-D-thiogalactoside (IPTG, 1 
mM) overnight. Cells were collected by centrifugation (10000×g, 15 min) and 
resuspended in buffer A (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10 mM imidazole), 
before being lysed using a French press. The lysate w s then clarified (28000×g, 30 
min) and the supernatant loaded onto a Ni2+-affinity column (HisTrap HP, GE 
Healthcare).  
The column was eluted with imidazole (12 mL, 25 mM), followed by a linear 
gradient (30 mL) of imidazole (25 – 350 mM) in buffer A. Fractions containing the 
purest preparation of TrxR, as assessed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE, described below) were combined, dialyzed into buffer B 
(30 mM Tris-HCl, pH 8.0, 2 mM DTT, 1 mM EDTA), and loaded onto an anion-
exchange column (8-mL MonoQ GL, GE Healthcare). Purified hTrxR was eluted with 
NaCl (12 mL, 120 mM) followed by a linear gradient (160 mL) of NaCl (120 – 300 
mM) in buffer B. Fractions containing ≥ 90% purified hTrxR were pooled, frozen in 
liquid nitrogen and stored at –80 °C. 
Assessment of protein purity was performed using denaturing SDS-PAGE. 
Protein samples were mixed with SDS loading buffer (300 mM Tris base, 50 mM DTT, 
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2% (w/v) SDS, 10% (v/v) glycerol and 0.03% (w/v) bromophenol blue) and heated to 
90 °C for 5 min before loading into a pre-cast NuPAGE 4-12% Bis-Tris gel. Loaded 
gels were electrophoresed at 200 V for 1 h using an Xcell4 Midi-Cell (Invitrogen, 
Grand Island, USA) apparatus. Following electrophoresis, the gels were stained with 
hot Coomassie staining solution (40% (v/v) methanol, 10% (v/v) acetic acid, 0.3% (w/v) 
Coomassie brilliant blue) for 20 min, then destained with hot destaining solution (25% 
(v/v) methanol 10% (v/v) acetic acid). De-stained SDS-PAGE gels were imaged using a 
Molecular Imager Gel Doc XR+ system (Bio-Rad, Hercules, USA). Protein band 
positions were compared to a Novex Sharp protein sta dard. 
2.11 Electrospray Ionisation Mass Spectrometry 
The following section describes how a typical investigation into the reactivity of 
gold compounds towards either human or rat TrxR was undertaken using ESI-MS.88,227 
Frozen TrxR (200 µL) was thawed on ice, and dialysed for 3 h against ammonium 
acetate (100 mM or 500 mM, pH 7.2) containing DTT (1 mM) using tubing with a 
molecular weight cut off of 12 000 mass units. The dialysis was performed twice more 
(3 h each) using the same solutions but without DTT present. The absorbance of the 
solution at 280 nm was determined using a Thermo Scientific (Waltham, USA) 
NanoDrop 2000 spectrophotometer and the final protein concentration was determined 
using the Beer-Lambert law and extinction coefficients calculated using the ExPASY 
ProtParam tool228,229 (ε = 65165 L.mol
-1.cm-1 for hTrxR and ε = 58330 L.mol
-1.cm-1 for 
rTrxR). 
Stock solutions of each gold complex or Au NPs were freshly prepared on the 
day that they were used. The required volumes were add d to the protein sample to give 
reaction mixtures containing the desired molar ratios of gold drug : TrxR, with the 
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protein concentration diluted with H2O to approximately 1 µM. The reaction mixtures 
were left on ice to react for the pre-determined periods of time, after which glacial 
acetic acid was added (final concentration of 5% (v/v) for hTrxR, 1% (v/v) for rTrxR). 
For rTrxR, methanol was also added (final concentration 10% (v/v)) to assist ionisation. 
The reaction mixtures were then immediately analysed using the mass spectrometer.  
Experiments investigating gold binding at different time points were performed 
similarly. The reaction mixtures were prepared and t the required time point an aliquot 
was removed and acetic acid or acetic acid/methanol dded to it. The solution was then 
immediately analysed using the mass spectrometer. 
Spectra were acquired using a Waters (Manchester, UK) Q-ToF Ultima ESI 
mass spectrometer operating in positive ion mode using a nanospray source, over the 
m/z range 1000–6500, with at least 50 acquisitions combined to give the final spectrum. 
The instrument was calibrated using a caesium iodide solution (10 mg/mL in 70% 
isopropanol/water). Raw spectra were background subtracted and smoothed using a 
Savitsky-Golay algorithm, and the charge series ion were transformed to a mass scale 
using MassLynx software (Waters, Manchester, UK). Stated masses and their errors 
were also calculated using MassLynx software. 
2.12 Protein Identification by Proteomics 
Experiments to definitively identify either human or rat thioredoxin reductase 
were performed by a collaborator, Dr. Matt Padula (University of Technology, Sydney). 
The procedure used is broadly described here. Purified TrxR samples were analysed by 
gel electrophoresis and bands of interest excised. The protein band was then buffered 
and digested using trypsin, and the resultant peptid s chemically extracted from the gel. 
The peptides were then separated and analysed by liquid chromatography/mass 
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spectrometry (LC/MS). The detected peptides were compared to a protein database 
using the search engine Mascot (Matrix Software, Boston, USA)230 and the proteins 
present in the sample subsequently identified. 
 
 
 
 
Chapter 3:  
Cellular Toxicity, Uptake and 
Localisation of Gold Complexes and 
Nanoparticles 
 
 
This chapter compares the uptake and final distribution of a selection of anti-arthritic 
gold(I) compounds and gold nanoparticles within RAW264.7 macrophages. The 
toxicity of the gold compounds and nanoparticles wa also investigated using the MTT 
assay, whilst quantification of the amount of gold incorporated into the cells was 
determined by graphite furnace AAS. The distribution f gold within individual 
macrophages and across a population of macrophages was investigated by performing 
microprobe SR-XRF imaging at the Advanced Photon Source, Argonne National 
Laboratory, and the Australian Synchrotron. Scanning electron microscopy was also 
used in an attempt to provide evidence that gold nanop rticles were internalised by the 
macrophages, and that they were not simply associated with the exterior cell surfaces. 
Parts of the work presented within this chapter were published in: James, L. R. A; et al., 
J. Inorg. Biochem., 2015, 142, 28-38. 
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3.1 Introduction 
One of the core aims of this research project was to compare the cellular 
toxicity, uptake and localisation of gold compounds and Au NPs. The cell line chosen 
for this and all other cellular experiments in this project was the murine macrophage 
line, RAW264.7. Macrophages phagocytose cellular debris and pathogens, and are 
heavily involved in RA progression as they promote inflammation and stimulate other 
immune cells through emission of various mediators.18 Due to the controversies noted in 
Section 1.4.2 regarding the biological interactions of Au NPs, those used in this project 
were characterised prior to use. In addition to allwing comparisons of cytotoxicity, the 
results of the MTT assays also provided the concentrations of the gold compounds and 
Au NPs to be used in all subsequent experiments. All statistical analyses presented in 
this chapter were performed using a one-way analysis of variance, with a Tukey-Kramer 
post-test set at 95% confidence intervals. 
3.2 Characterisation of Gold Nanoparticles 
The physical and electronic properties of Au NPs, prepared as described in 
Section 2.2, were characterised by absorption spectrophotometry, FESEM and particle 
size analysis. This facilitated comparisons with similar materials for which the 
biological properties had been previously reported, as it was noted earlier (Section 
1.4.2) that differences in the physical or chemical characteristics of Au NPs can impact 
dramatically upon their biological interactions. Figure 3.1 shows the absorption 
spectrum of a sample of the Au NPs. The spectrum featur d one broad surface plasmon 
resonance band centred at 522 nm as well as significa t absorbance at higher energies. 
The overall spectrum is consistent with that of other samples of gold nanoparticles.231–
233 
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Figure 3.1: UV-visible absorption spectrum of a solution contai ing 400 µM Au NPs. 
 
A FESEM image of a solution of Au NPs is shown in F gure 3.2. These were 
prepared by evaporation on a copper grid to produce particles that were generally 
spherical in shape and relatively uniform in size, with diameters ranging from 10 – 20 
nm. These results were then compared with those obtained from particle size analysis 
performed using a zetasizer. This instrument assesse  the distribution of particle sizes in 
a suspension by periodically shining a laser into the sample and measuring scattered 
light, a process known as dynamic light scattering.234 Measurements performed using 
the zetasizer were analysed to reveal an average dimeter of 23 ± 7 nm for the Au NPs, 
which is in good agreement with the results obtained from FESEM (Figure 3.2).  
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Figure 3.2: Field emission scanning electron micrograph of Au NPs evaporated on a copper membrane. 
A 100-nm scale bar is shown at the bottom of the image. The pink box indicates the area that was used to 
obtain an EDX spectrum. 
 
EDX spectroscopy was performed simultaneously with FESEM, and afforded 
the spectrum shown in Figure 3.3. This technique operates on a similar principle to SR-
XRF to allow simultaneous detection of a number of different elements present in a 
sample. The chief difference between the two methods is that EDX uses electrons to 
excite the sample, whilst SR-XRF uses X-rays. EDX spectroscopy detects the presence 
of any impurities, such as other metals in the nanop rticles. In addition to signals arising 
from gold, the spectrum in Figure 3.3 contained intense peaks consistent with the 
presence of large quantities of carbon and copper, which are the main components of 
the carbon-copper support grid. Importantly, the spctrum did not reveal the presence of 
other metals, such as iron and manganese, which were viewed as potential 
contaminants.  
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Figure 3.3: Energy-dispersive X-ray spectrum of Au NPs deposited on a carbon-copper membrane. Peaks 
highlighted in blue are the major signals arising from that element. 
 
3.3 Cytotoxicity 
The toxicity of a selection of gold(I) compounds with anti-arthritic activity, and 
Au NPs towards macrophages was compared for two reasons. First of all, while similar 
studies have been conducted previously using either gold compounds or Au NPs, none 
had previously directly compared the cytotoxicity of the two classes of gold species. 
Secondly, the results of these studies were needed to determine the concentrations of 
gold compounds and Au NPs to be used for subsequent cellular uptake and localisation 
experiments, as well as studies examining their effects on the expression of 
inflammation markers. 
Since the gold compounds used in these experiments have different solubilities, 
a number of control cytotoxicity experiments were also performed to determine if any 
of the solvents or other reagents used had any significant toxicity. For example, while 
most of the gold compounds examined were soluble in water, this was not true for 
auranofin, which was instead very soluble in both et anol and DMSO. Ethanol is a 
known cytotoxic substance,235 whilst DMSO is better tolerated by cells and accordingly 
features in many tissue culture protocols.236 As such, solutions of DMSO and 
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incomplete medium were selected for preparing solutions of auranofin to enable its 
administration. Therefore, it was necessary to assess the cytotoxicity of solutions 
containing varying amounts of DMSO and incomplete medium towards the 
macrophages. Figure 3.4 presents the results obtained from this investigation. 
 
Figure 3.4: Cytotoxicity of solutions containing increasing amounts of DMSO dissolved in incomplete 
medium, towards RAW264.7 cells, as assessed by the MTT assay. The macrophages were incubated with 
the solutions at 37 °C under an atmosphere of 5% CO2 for 24 h. The error bars represent one standard 
deviation calculated from triplicate plates. 
 
Inspection of the graph shows that introduction of 1% (v/v) DMSO into 
complete medium resulted in cell viability falling to 85%, while increasing the amount 
of DMSO to 2% (v/v) resulted in cell viability falling much further to 30%. Further 
increases in the amount of DMSO present resulted in cell viability falling to ≤ 7%. 
Therefore cytotoxicity studies involving auranofin were performed with solutions 
prepared using a solvent consisting of 1% (v/v) DMSO in incomplete medium. 
Solutions of all other gold complexes were prepared using incomplete medium alone. 
The results of initial cytotoxicity experiments performed by exposing the 
macrophages to gold compounds for 4 h are shown in Figure 3.5. It is clear from 
examining the figure that auranofin was the most toxic gold compound, with an IC50 of 
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5 µM. The next most toxic compound was dicyanoaurate,  notable chrysotherapy 
metabolite, with an IC50 of 35 µM. The other two compounds investigated, 
aurothiosulfate and aurothiomalate, did not show any signs of toxicity even in solutions 
containing the maximum concentrations of these two complexes, 100 and 10000 µM, 
respectively. 
 
Figure 3.5: Cytotoxicity of some anti-arthritic gold compounds towards RAW264.7 cells, as assessed by 
the MTT assay. The macrophages were incubated with the gold compounds at 37 °C under an atmosphere 
of 5% CO2 for 4 h. The error bars represent one standard deviation calculated from triplicate plates. 
 
Investigations into the toxicity of the gold compounds towards macrophages 
after a 24-h treatment period were also performed, with the results obtained shown in 
Figure 3.6. Once again, auranofin proved to be the most toxic compound, with a 
slightly lower IC50 of 4 µM, compared to that obtained from the 4-h treatment. 
Dicyanoaurate exhibited significantly greater cytotoxicity as a result of the longer 
exposure period to the cells, as its IC50 value decreased to ~9 µM, compared to the 
value of 35 µM obtained after a 4-h treatment period. Figure 3.6 shows that 
aurothiosulfate exhibited very low levels of cytotoxicity, with an IC50 of 650 µM. In 
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contrast, aurothiomalate remained non-toxic towards the macrophages, even when 
present at a concentration of 1000 µM. 
 
Figure 3.6: Cytotoxicity of some anti-arthritic gold compounds towards RAW264.7 cells, as assessed by 
the MTT assay. The macrophages were incubated with the gold compounds at 37 °C under an atmosphere 
of 5% CO2 for 24 h. The error bars represent one standard deviation calculated from triplicate plates. 
 
The low IC50 values determined for auranofin with the RAW264.7 macrophages 
at both treatment periods are consistent with the results of previous investigations into 
the toxicity of this drug. For example, auranofin was found to have an IC50 of 1.5 µM 
towards a B16 mouse melanoma cell line, using a clonogenic assay,70 and an IC50 of 
1.06 µM against a human ovarian cancer cell line using a 24-h MTT assay.237 The small 
difference between the IC50 values obtained using 4- and 24-h treatment times suggests 
that there was little additional cellular uptake of this compound as a result of the 
increase in exposure time, or that the compound acts quickly. Support for the latter 
conclusion is provided by a study that showed that m ximum uptake of auranofin by 
RAW264.7 cells exposed to a 5 µM solution of the drug occurred after 20 min.109,238 
The lack of difference in cytotoxicity indicates dam ge caused by a rapid mechanism of 
action, but may also in part be a result of the cells treated for 24 h having no recovery 
time prior to addition of the MTT. 
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The toxic nature of sodium dicyanoaurate has been noted previously in the 
literature,57,239 including the nephrotoxic effect that acute doses produce in vivo.240 In 
addition, a recent study reported the anti-proliferative effects of K[Au(CN)2] on four 
cancer cell lines, with IC50 values ranging from 0.10 – 0.13 µg/mL (0.34 – 0.45 µM).
241 
Despite the large differences between these values and those obtained in the present 
study, it is important to note that the aim of the lit rature study was to assess the anti-
proliferative activity of dicyanoaurate, not its cytotoxicity. Similarly, there do not 
appear to have been many investigations into the in vitro toxicity of aurothiosulfate. 
This most likely stems from the lack of clinical interest the compound received 
following initial human trials that investigated its effectiveness for the treatment of 
tuberculosis in the 1920’s.242 However, one study that was published in 2006 used th  
MTT assay to measure the effect of aurothiosulfate on human THP1 monocytes. It was 
reported that the cells showed no observable signs of cytotoxicity when exposed to 
aurothiosulfate at the relatively low concentration of 5 µM.243 
The results presented in Figure 3.5 and Figure 3.6 show that aurothiomalate 
exhibited no toxicity towards the macrophages at all concentrations examined (from 1 
to 1000 µM), for both exposure times. This is in direct contrast with the outcomes of a 
previous study conducted by Mirabelli et al.70 The latter study reported that 
aurothiomalate showed significant toxicity towards the B16 mouse melanoma cell line, 
with an IC50 of 60 µM. The difference between these results could be due to variations 
in the experimental methodology employed. In the lit rature report, a clonogenic assay 
was used to assess toxicity towards the melanoma cell line, whereas in the present work 
the MTT assay was used to perform experiments with a macrophage cell line. An 
additional difference is that the previous study used the free acid form of aurothiomalate 
as opposed to the sodium salt used in the current study. It is important to note that the 
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results of the present investigation are generally consistent with those of a number of 
other studies.120,243 For example, aurothiomalate showed no significant toxicity towards 
a human umbilical vein endothelial cell line in studies performed using both a 51Cr 
release assay and an MTT assay, even at concentratio s of up to 1000 µM.120 In yet 
another study, aurothiomalate exhibited no toxicity towards THP1 monocytes when 
administered at a concentration of 500 nM, although this is significantly lower than the 
maximum value of 1000 µM used in the current study.243 
The Au NPs used in cytotoxicity experiments were synthesised as a colloidal 
suspension in water, and were diluted using incomplete medium prior to administration 
to the macrophages. As a consequence, control experiments were first performed to 
determine the cytotoxicity of solutions containing i creasing ratios of water in the cell 
medium. The results of these experiments are present d i  Figure 3.7, and show that 
cell viability was not significantly affected until the amount of water present in the 
solvent mixture reached 30% H2O (v/v). Therefore it was decided to use solutions 
consisting of 15% H2O/85% incomplete medium (v/v) for all in vitro experiments 
involving Au NPs. 
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Figure 3.7: Cytotoxicity of solutions containing increasing amounts of water relative to incomplete 
medium towards RAW264.7 cells, as assessed by the MTT assay. Macrophages were incubated with the 
solutions at 37 °C under an atmosphere of 5% CO2 for 24 h. The error bars represent one standard 
deviation calculated from triplicate plates. 
 
Figure 3.8 compares the toxicity towards the macrophages of different 
concentrations of Au NPs, to that of the reagents used to synthesise the nanoparticles, 
including H[AuCl4] and trisodium citrate. Neither the Au NPs or trisodium citrate 
showed toxicity at the highest concentrations studied (60 µM and 1000 µM, 
respectively), whereas H[AuCl4] proved to be mildly cytotoxic, exhibiting an IC50 of 
200 µM. The effect of higher concentrations of Au NPs could not be explored, as this 
would have necessitated using solutions that are hypotonic. Furthermore, stock 
solutions of Au NPs containing higher concentrations of nanoparticles than 400 µM 
could not be prepared, owing to aggregation of the particles. 
There have been only a few studies that have examined the cytotoxicity of 
H[AuCl4]. However, one investigation showed the corresponding sodium salt, 
Na[AuCl4], is cytotoxic towards a number of cancer cell lines.
244 These studies assessed 
cytotoxicity using the sulforhodamine B assay, and lso explored the biological activity 
0.1 1 10 100
0
20
40
60
80
100
120
Ratio of Water In
Incomplete Medium (v/v %)
C
el
l V
ia
bi
lit
y 
(%
)
 
Chapter 3 – Cellular Toxicity, Uptake and Localisation 86 
of some gold(III) compounds with anti-cancer activity. The IC50 values for Na[AuCl4] 
ranged from 11.0 – 42.0 µM for 7 different cell lines (11.0, 12.6 17.7, 22.5, 26.5, 35.5 
and 36.3 µM), which indicates that the sodium salt w s appreciably more toxic towards 
those cells than the macrophages examined as part of the current work.  
 
Figure 3.8: Cytotoxicity of Au NPs, and the reagents used in their preparation, towards RAW264.7 cells, 
as assessed by the MTT assay. The macrophages were incubated with the nanoparticles and compounds at 
37 °C under an atmosphere of 5% CO2 for 24 h. The error bars represent one standard deviation 
calculated from triplicate plates. 
 
It was noted in Section 1.4.2 that the toxicity and biocompatibility of Au NPs 
has been a relatively controversial area of the literature, possibly as a result of their 
biological activity being strongly dependent upon nanoparticle composition and size. 
Despite this, the results shown in Figure 3.8 are consistent with those presented in some 
key literature studies. For example, in one investigation the toxicity of Au NPs prepared 
by the citrate reduction method towards PC-3 and MCF-7 cells was measured by both 
an MTT assay and an LDH release assay.245 Significant decreases in cell viability were 
only observed when the concentration of Au NPs reach d 558 µM. The same type of Au 
NPs were also shown to have little effect on the metabolic activity of MC3T3-E1 cells, 
even when the latter were exposed to solutions containi g nanoparticle concentrations 
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of up to 1020 µM.200 However, increases in LDH release were detected when t e cells 
were exposed to solutions with Au NP concentrations f 508 µM or higher.200 The lack 
of cytotoxicity observed in the current study is alo consistent with a report by Shukla et 
al.,201 who observed only minor decreases in cell viability, as determined by an MTT 
assay, when RAW264.7 cells were treated for 24 h wit solutions containing 10–100 
µM Au NPs coated with a poly-L-lysine shell. 
Table 3.1 summarises the IC50 values obtained from experiments where the 
macrophages were exposed to gold compounds and Au NPs for 24 h. Using these 
results, the following order of increasing cytotoxicity is obtained: 
aurothiomalate < aurothiosulfate < H[AuCl4] < Na[Au(CN)2] < auranofin 
It was not possible to determine the absolute position of Au NPs within this series 
owing to the inability to prepare solutions with hig er concentrations of nanoparticles to 
facilitate comparisons.  
Table 3.1: Summary of IC50 values of gold compounds and Au NPs towards RAW264.7 cells.  
Compound IC50 (µM) 
Auranofin 4 ± 0.3 
Aurothiomalate > 1000 
Aurothiosulfate 650 ± 46 
Na[Au(CN)2] 9 ± 0.3 
H[AuCl4] 200 ± 40 
Au NPs > 60 
Note: Cells were treated at 37 °C and under an atmosphere of 5% CO2 for 24 h. Cytotoxicity was 
assessed by the MTT assay. 
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By using the cytotoxicity information obtained from these experiments, it was 
possible to determine the optimum concentrations of ome of the gold compounds for 
use in other biological experiments performed using a treatment period of 24 h. For 
example, experiments with auranofin were performed using solutions containing 2.5 
µM gold complex, which is slightly less than the total concentration of gold found in the 
serum of chrysotherapy patients, which typically ranges from 8 – 20 µM.246–248 It was 
not possible to carry out experiments using higher concentrations of auranofin, 
however, owing to the extensive levels of cell death observed (Figure 3.6). In contrast, 
experiments were able to be performed using solutions containing 60 µM Au NPs, 
without affecting cell survival. Although this concentration is significantly higher than 
that of gold in the serum of chrysotherapy patients, it ensured that sufficient gold was 
incorporated into the macrophages to enable the gold uptake and distribution 
experiments to provide useful data. Similarly, experim nts were successfully performed 
by incubating macrophages with solutions containing 1000 µM aurothiomalate, owing 
to the lack of toxicity of this gold compound at tha  concentration. 
The trypan blue assay was also used to assess the impact of exposure of 
RAW264.7 macrophages to gold compounds or Au NPs. The benefit of this study was 
that it measured membrane integrity as an endpoint, and therefore provided information 
essential for interpreting the results of the gold uptake experiments presented later in 
this chapter. After exposure of the macrophages to various gold compounds or Au NPs 
for 24 h, cell viability was assessed by exposing the cells to trypan blue, an organic dye 
that can only enter cells that have compromised membranes. The results of these trypan 
blue studies are shown in Figure 3.9, and confirm that the vast majority of the 
macrophages exposed to Au NPs, aurothiosulfate or aur thiomalate remained viable as 
they retained intact cellular membranes. This is demonstrated by low proportions of 
 
Chapter 3 – Cellular Toxicity, Uptake and Localisation 89 
non-viable cells (< 9%) in each case where the macrophages were exposed to a gold 
complex or Au NPs. In contrast, for macrophages exposed to auranofin (2.5 µM), the 
number of viable and non-viable cells was significantly different (P < 0.001) to that of 
cells treated with the auranofin control solution (vehicle used for treatment). 
Importantly, the results of the trypan blue assay are consistent with those derived from 
the MTT assay (Figure 3.6), as both indicate that auranofin is significantly more toxic 
than any of the other gold compounds examined. In addition, the results of the 
experiments performed here are similar to those from another study where MCF-7 cells 
were exposed to auranofin at cytotoxic concentrations, and showed significant levels of 
compromised membrane integrity when examined using the trypan blue assay.249 
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Figure 3.9: Membrane integrity of RAW264.7 cells after exposure to gold compounds or Au NPs, as 
assessed by the trypan blue assay. Macrophages were incubated with the gold compounds or Au NPs at 
37 °C and under an atmosphere of 5% CO2 for 24 h. The error bars represent one standard deviation 
calculated from triplicate samples. *** = Statistically significant (P < 0.001) compared to corresponding 
vehicle; ns = not significant compared to corresponding vehicle (P > 0.05). 
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3.4 Gold Uptake 
A fundamental question that arises from the cytotoxicity results, is whether the 
observed variations between the drugs stems primarily from differences between the 
level of cellular uptake of the gold compounds or Au NPs. To address this question, 
GFAAS was used to determine the extent of uptake of gold by RAW264.7 cells exposed 
for 24 h to Au NPs, aurothiosulfate, auranofin or au othiomalate at 2.5 and/or 60 µM 
concentrations. The results of these experiments are presented in Figure 3.10. 
 
Figure 3.10: Cellular gold content (fg/cell) of RAW264.7 cells after exposure to gold compounds or 
nanoparticles as determined by GFAAS. Macrophages were incubated with the gold compounds or Au 
NPs at 37 °C under an atmosphere of 5% CO2 for 24 h. The error bars represent one standard deviation as 
calculated from triplicate samples. *** = Statistically significant (P < 0.001) compared to corresponding 
vehicle; ns = not significant compared to corresponding vehicle (P > 0.05). 
 
Data was also obtained for three different control samples consisting of the 
vehicles used for the treatment solutions. For insta ce, the vehicle used for 
aurothiomalate and aurothiosulfate (incomplete medium) was different to that for 
auranofin, and both of these solvents varied from that used for the Au NPs. As 
expected, the extent of incorporation of gold by macrophages exposed to each of the 
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vehicles was extremely low (< 4 fg/cell). Furthermoe, there was no significant 
difference (P > 0.05) between the amounts of gold incorporated into cells exposed to the 
different vehicles. Inspection of Figure 3.10 also reveals that there was very little 
incorporation of gold by macrophages exposed to 2.5µM aurothiomalate or 
aurothiosulfate. In both cases, the level of cellular gold present was not statistically 
different (P > 0.05) from that of macrophages exposed to the corresponding vehicle. In 
contrast, macrophages exposed to 2.5 µM solutions of either auranofin or Au NPs did 
show levels of gold uptake that were statistically significantly higher (P < 0.001) than 
that of cells exposed to the corresponding vehicle. 
The ability of macrophages to incorporate auranofin is ot surprising, in view of 
the distinctly different structure of this complex compared to aurothiomalate and 
aurothiosulfate. Auranofin has a more lipophilic struc ure owing to the presence of the 
triethylphosphine moiety, that facilitates its transport across cell membranes,250 and 
therefore contributes to its higher cytotoxicity. Conversely, the lower cytotoxicity of 
aurothiomalate and aurothiosulfate may be due to their poorer ability to enter cells, at 
least when present at low concentrations. 
Increasing the concentration (to 60 µM) of aurothiomalate, aurothiosulfate or Au 
NPs in the treatment solutions resulted in enhanced levels of gold incorporation by the 
macrophages. For cells treated with aurothiomalate or aurothiosulfate, the amount of 
gold incorporated was statistically higher (P < 0.001) than that of vehicle-treated cells. 
In the case of aurothiomalate a ~70-fold increase in the amount of cellular gold (8.3 ± 
0.3 to 520 ± 50 fg/cell) occurred as a result of increasing the concentration of the metal 
complex. An even more substantial increase in the lev l of gold uptake to 1420 ± 70 
fg/cell was observed following treatment with 60 µM aurothiosulfate. This is 100 times 
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the value of 14.5 ± 0.4 fg/cell obtained when the cells were exposed to 2.5 µM 
aurothiosulfate. 
Exposure to 60 µM Au NPs resulted in a greater level of cellular gold uptake 
compared to that observed when the macrophages wereexposed to the same 
concentration of aurothiosulfate or aurothiomalate (P < 0.001). Furthermore, the amount 
of gold incorporated (3300 ± 200 fg/cell) was 33 times greater than that observed for 
cells treated with just 2.5 µM Au NPs (100 ± 20 fg/cell). As discussed in Section 1.4.2, 
it has been shown that Au NPs can enter a variety of cells (ovarian, brain, cervical and 
breast cancer cells; osteoblasts, and fibroblasts) via a receptor-mediated, clathrin-
dependent endocytosis pathway,197–200 and that the rate of uptake increases with 
decreasing nanoparticle size.198 In contrast, auranofin enters cells by the sulfhydryl 
shuttle mechanism (Section 1.2.2), in which the Au(PEt)3
+ fragment binds to a 
membrane transport protein through a thiol group, and is subsequently transported 
through the membrane.109 If the other gold drugs are incorporated into the macrophages 
by a similar mechanism to that used by auranofin, or one which is inhibited by their 
polymeric structures, then this might explain the differences between the amounts of 
gold incorporated by the gold(I) compounds compared to the Au NPs, that are shown in 
Figure 3.10. 
It is instructive to compare the relative cytotoxicities of the various gold 
compounds and Au NPs as determined by the MTT assay, with the degree of cellular 
uptake. For example, if cytotoxicity was dependent on the amount of intracellular gold, 
then cytotoxicity would be expected to increase in the following order: 
aurothiomalate < aurothiosulfate < auranofin < Au NPs. 
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 Whilst the results of the MTT assays showed broad correlation with gold uptake for the 
gold compounds as listed in the above ordering, it was not possible to definitively 
determine whether or not Au NPs are more toxic than either aurothiosulfate or 
aurothiomalate due to the restricted concentration range of Au NP solutions that could 
be prepared. However, the cytotoxicity data obtained using treatment solutions 
containing 2.5 µM gold compounds or Au NPs strongly supports the hypothesis that Au 
NPs are far less toxic than auranofin. Furthermore, th  data shown in Figure 3.10 
demonstrates that Au NPs were taken up in comparable or even larger quantities than 
auranofin by the macrophages without a noted cytotoxic effect. Since the results of the 
trypan blue assay indicate that Au NPs do not affect membrane viability, this further 
supports the conclusion that the quantity of gold incorporated into cells is not the sole 
determinant of cytotoxicity. Furthermore, since Au NPs were readily incorporated into 
macrophages without affecting their membrane integrity, it would appear that their 
incorporation occurs predominantly via a specific cellular mechanism, rather than as a 
consequence of membrane compromise. In contrast, macrophages treated with 
auranofin showed significant levels of membrane compro ise. Further work will be 
required to determine if this is a direct consequence of the sulfhydryl shuttle mechanism 
of uptake proposed for this compound, or if membrane disruption occurs as a later 
necrotic event. 
3.5 Intracellular Distribution of Gold 
Insight into the molecular mechanisms of the cytotoxicity of drugs can often be 
obtained through identifying which parts of a cell the drug accumulates to the greatest 
extent. Therefore microprobe SR-XRF was used to determine the location of gold in 
single cells and small clusters of cells, after exposure to different concentrations of a 
variety of gold compounds or Au NPs for 24 h. Micropr be SR-XRF is particularly 
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well-suited for analysis of metal compounds in cells, as it does not require modification 
of the drug or addition of an imaging agent, and allows simultaneous detection of many 
other biologically relevant elements.215,219 The results from these experiments are 
presented as elemental distribution maps. In the following sub-sections, selected 
examples of elemental maps derived from data obtained at the Advanced Photon Source 
and the Australian Synchrotron are presented and discussed. Experiments were 
performed at two synchrotrons to provide complementary information. Data obtained at 
the Australian Synchrotron was used to obtain images of large numbers of cells to 
determine the degree of homogeneity of gold uptake cross a large number of 
macrophages. Experiments performed at the Advanced Photon Source provided higher 
resolution images of single macrophages or small groups of macrophages, which 
enabled the subcellular distribution of gold in themacrophages to be determined. The 
full set of results obtained from experiments performed at both synchrotrons is 
presented in Appendix B:. This includes the integrated XRF spectra used to derive the 
elemental distribution maps. 
3.5.1 High Resolution Maps of Single or Small Numbers of Cells 
Elemental distribution maps for a macrophage exposed only to incomplete 
medium are shown in Figure 3.11. The elemental distribution maps for chlorine, 
potassium and calcium can often be used to infer th overall size and shape of a cell, 
whilst only low concentrations of iron and copper are expected as a result of their 
essential roles in many metalloenzymes. The distribution maps for phosphorus and zinc 
can sometimes be used to identify the location of the cell nucleus, owing to the presence 
of these elements in the phosphate backbone of DNA, and zinc-fingers motifs of DNA-
binding proteins, respectively. However, this approach is sometimes problematic for 
experiments performed with whole cells, as compression of the data obtained using a 
 
Chapter 3 – Cellular Toxicity, Uptake and Localisation 95 
three-dimensional sample into a two-dimensional image can result in an inability to 
resolve sub-cellular features. This problem can generally be overcome by obtaining 
images of thin-sectioned cell samples. However, this option was not explored as part of 
this project since locating Au NPs in the various thin sections can be time-consuming 
and there was very limited APS beamtime available for these experiments. Sulfur maps 
may be used to infer the location of proteins due to the predominance of thiol residues 
in protein molecules. A scatter map is also often included to show the degree of X-ray 
scattering occurring at a specific location, which is an indication of the overall amount 
of matter present at that site. 
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Figure 3.11: Microprobe SR-XRF elemental maps for RAW264.7 cells incubated with incomplete 
medium at 37 °C under an atmosphere of 5% CO2 for 24 h. Scan dimensions (H x V) were 18.5 µm × 
18.5 µm. All elemental concentrations are µg/cm2. 
Inspection of the P, S, K and Zn elemental maps shown in Figure 3.11 reveals 
the presence of a cell with a rounded morphology. The Ca, Cl and Cu maps are 
relatively uninformative, as they reveal only slightly higher concentrations of these 
elements within the cell. In addition, the Cl map shows significant amounts of this 
element outside the cell, owing to the presence of this element in the cell medium used. 
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The Fe map reflects the approximate shape of the cell, but also exhibits localisation in a 
crescent shaped region around the inside edge of the rig t side of the cell. The Au map 
is consistent with the gold signal being essentially due to background noise, as there is 
effectively no gold present in the mapped area. This was an important result, as any 
gold identified as being present in greater quantities in macrophages treated with gold 
compounds or Au NPs could then be concluded to arise solely from the treatment. In 
view of the above discussion, only the S, K, Zn and Au maps have been shown in 
subsequent sections of this chapter as they are the most informative. 
Elemental maps of RAW264.7 cells treated with 2.5 µM auranofin are shown in 
Figure 3.12. Each of the S, K and Zn maps clearly show four separate macrophages 
within the mapped area. This includes one in both the top-left and bottom-right corners 
that have a round morphology, as well as a third prominent cell in the middle of the 
image that instead shows a fibroblastic morphology. There is a fourth cell present in the 
image near the top-centre, which also has the same fibroblastic appearance, but which is 
fainter than the first three cells. The fibroblastic morphology is normal for RAW264.7 
cells, while the rounded morphology is commonly associated with non-viable cells, 
such as those that have previously been exposed to acute cytotoxins.251 It is therefore 
notable that examination of the Au map reveals thate gold is not evenly distributed 
between the cells. In contrast, both of the rounded c lls have gold distributed 
throughout, while this element is completely absent from the fibroblastic cells. These 
observations are consistent with the cytotoxic nature of auranofin discussed previously, 
and the low treatment concentration used.  
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Figure 3.12: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 2.5 µM auranofin at 
37 °C under an atmosphere of 5% CO2 for 24 h. Scan dimensions (H x V) were 50.5 µm × 50.5 µm. All 
elemental concentrations are µg/cm2. 
 
This distribution of gold and, in particular, its co-localisation with sulfur, is 
highlighted in the co-localisation map shown in Figure 3.13. In this map, the round 
cells are pink/purple in colour as a result of the combination of red from the sulfur map 
and blue from the gold map. Gold was not uniformly incorporated into all macrophages 
due to the relatively low concentration of gold that the cells were exposed to. Those that 
did incorporate the gold compound were compromised owing to its cytotoxicity, and 
hence lost membrane integrity and subsequently their s ape as they died. 
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Figure 3.13: Individual elemental microprobe SR-XRF maps, and co-localisation map for RAW264.7 
cells treated with 2.5 µM auranofin at 37 °C under an atmosphere of 5% CO2 for 24 h. Scan dimensions 
(H x V) were 50.5 µm × 50.5 µm. 
 
Figure 3.14 shows elemental maps for cells treated for 24 h wit  1000 µM 
aurothiomalate. Examining the maps reveals the presence of two fibroblastic cells in 
close proximity to each other. The Au map shows the metal is primarily located in 
discrete areas within the cell at the bottom of the figure. In contrast, there are only two 
gold ‘hotspots’ in the upper cell, indicating that there has been less extensive 
incorporation of this metal. The region where gold is present in the highest amounts also 
happens to be the area where sulfur is most abundant, suggesting some co-localisation 
of these two elements. 
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Figure 3.14: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 1000 µM 
aurothiomalate at 37 °C under an atmosphere of 5% CO2 for 24 h. Scan dimensions (H x V) were 20.5 
µm × 52.5 µm. All elemental concentrations are µg/cm2. 
 
The elemental maps for cells treated with 100 µM H[AuCl4] for 24 h are shown 
in Figure 3.15. The S and Zn maps reveal the presence of a single cell with a round 
shape, whilst the Au map suggests that gold is present in relatively low concentrations 
throughout the cell. Comparison of the Au and S maps also provides evidence that there 
may be some co-localisation of these two elements within the cell.  
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Figure 3.15: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 100 µM HAuCl4 at 
37 °C under an atmosphere of 5% CO2 for 24 h. Scan dimensions (H x V) were 30.5 µm × 28.5 µm. All 
elemental concentrations are µg/cm2. 
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Elemental maps for cells treated with 60 µM Au NPs for 24 h are shown in 
Figure 3.16. Examination of the K map reveals a single fibroblastic cell, whilst the Au 
map shows a number of very discrete hotspots for this metal, primarily in the bottom 
part of the cell. Comparison with the S and Zn maps suggests that there is a high degree 
of co-localisation of the latter two elements with each other, as well as with gold. 
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Figure 3.16: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 60 µM Au NPs at 37 
°C under an atmosphere of 5% CO2 for 24 h. Scan dimensions (H x V) were 13.5 µm × 50.5 µm. All 
elemental concentrations are µg/cm2. 
The images presented in Figure 3.12 – Figure 3.16 all provide evidence that 
suggests there is some degree of cellular co-localisation of gold with sulfur. This is 
particularly striking in the case of cells treated with Au NPs. In the case of cells treated 
with sodium aurothiomalate, auranofin, or H[AuCl4] a probable explanation for this 
observation is that the gold has become associated wi h sulfur that is endogenous to the 
cell, such as glutathione or sulfur-containing proteins. In addition, co-localisation might 
be accounted for by proposing that the sulfur-containing ligands present in sodium 
aurothiomalate and auranofin were not displaced upon uptake into the cell. However, 
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this explanation is unlikely, since it has been repo ted that the original sulfur-donor 
ligands associated with the gold complexes rapidly undergo ligand exchange reactions 
when the complexes are introduced into biological systems.250 In addition, the results of 
the TrxR binding experiments described in Chapter 5 also reveal rapid loss of the S-
containing ligands initially present in the coordination sphere of the gold complexes 
under study. 
Figure 3.16 suggests that the degree of co-localisation of Au and S within the 
cell treated with Au NPs is much greater than in the case of cells treated with the 
various gold compounds. Whilst it is very likely tha  the gold incorporated into the cell 
has become associated with endogenous sulfur, the co-localisation suggested by the 
results shown in Figure 3.16 is largely the result of an issue arising from them thod 
used to detect S and Au in the macrophages, which centres on the intense Au M line. 
Figure 3.17 shows the integrated XRF spectrum of the elemental maps presented in 
Figure 3.16. Inspection of the spectrum reveals that the gold M line (2.1 keV) is in 
close proximity to the phosphorus (2.0 and 2.1 keV) and sulfur (2.3 and 2.4 keV) K 
lines. Owing to the intensity and breadth of the gold M line, overlap with the 
phosphorus and sulfur K lines is so extensive that it contributes significantly to the 
intensity of the latter signals. 
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Figure 3.17: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated with 60 µM Au NPs at 37 °C under an atmosphere of 5% CO2 for 24 h. 
Vertical lines indicate the expected positions of gld L and M lines. 
The overlap of the gold M line with the phosphorus and sulfur K lines is 
highlighted in Figure 3.18, which shows the integrated, fitted, background an ssigned 
XRF spectra for the region from 1.5 keV to 3 keV. The integrated spectrum is 
essentially raw data, whilst the fitted spectrum is the integrated spectrum after modified 
Gaussians have been applied to it. The background spectrum is subtracted from the 
fitted to then produce the assigned spectrum, which is used to produce the elemental 
maps. Examining the spectra obtained for cells treated with incomplete medium (Figure 
3.18 a), there is not much difference between the integrat d/fitted spectra and the 
assigned spectrum. In the case of cells treated with auranofin (Figure 3.18 b), whilst 
there is a gap between the integrated/fitted spectra and the assigned spectrum at the 
position of the gold M line (2.12 keV), there is no major difference at the position of the 
sulfur K line (2.30 keV), indicating no effect upon assignment of that element. 
However, when examining the spectra for cells treated with aurothiomalate and Au NPs 
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(Figure 3.18 c and d) there is a clear peak present at the position of the gold M line that 
is large enough to overlap both the phosphorus and sulfur K lines. Although correction 
was attempted through subtraction of the background from the fitted spectrum (to 
produce the assigned spectrum), it is not possible to know how successful the 
subtraction was in removing the contribution of thegold M line to the spectral intensity 
of the surrounding elements. 
  
a) b) 
  
c) d) 
Figure 3.18: Integrated (black), fitted (green), background (blue) and assigned Kα lines (red) of 
microprobe SR-XRF spectra of RAW264.7 cells treated for 24 h at 37 °C under an atmosphere of 5% 
CO2 with: a) incomplete medium; b) 2.5 µM auranofin; c) 1000 µM aurothiomalate; and d) 60 µM Au 
NPs. The vertical grey line indicates the expected position of the gold M line. 
This analysis leads to the conclusion that some of the spectral intensity 
previously attributed to sulfur for the Au NPs-treated cells in Figure 3.16 was due to 
the presence of gold. In contrast, the gold elemental maps shown in Figure 3.16 and 
elsewhere were derived from the intensity of the gold L signal, which is present in a 
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different region of the spectrum (11.9 keV) where th re are no overlapping spectral 
lines from other elements. Therefore it is possible to conclude that all the gold elemental 
maps presented in this thesis accurately reflect th cellular distribution of this element. 
As such, it is not possible to conclude that the Au NPs had become associated 
with either exogenous or endogenous sulfur containing species on the basis of the XRF 
data. This issue is most striking in the case of cells treated with Au NPs, because the 
extent of incorporation of gold into the macrophages was significantly greater compared 
to when the cells were treated with the gold compounds (Figure 3.10). This is also 
evident from inspection of Table 3.2, which shows the maximum concentration of 
different elements observed in the individual elemental maps. Table 3.2 also shows that 
the maximum concentration of gold in the maps of macrophages treated with Au NPs is 
much greater than that for the macrophages treated with discrete gold compounds. It is 
also evident that the maximum concentrations of phos rus, sulfur and zinc in 
elemental maps of macrophages treated with Au NPs are approximately 1.7×, 4× and 
1.8× higher than for the cells treated with incomplete medium only. This is also most 
likely due to the overlap of the Au XRF spectral lines with those from the P, S and Zn, 
and therefore contributing to the intensity of the latter. In contrast, the maximum 
concentrations of the latter three elements in cells treated with the gold complexes were 
very similar to that found in the case of macrophages treated with incomplete medium 
only (Table 3.2). In the case of these samples, the intensity of the gold M line was 
relatively low (Appendix B:) as a result of lower levels of gold uptake, and so did not 
overlap significantly with the spectral lines used to produce the maps for other 
elements. Therefore it may be concluded that co-localization of Au and S in the case of 
macrophages treated with the Au complexes was due to interactions between the gold 
complexes and sulfur-containing amino acids and proteins, most likely inside the cells. 
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It should also be noted that whilst it is possible to compare levels of gold uptake using 
the data presented in Table 3.2, it should be viewed with caution as this data was 
obtained from measurements performed on single cells only. In contrast, the gold 
uptake data presented in Figure 3.10 was obtained from experiments performed on bulk 
cellular samples. 
Table 3.2: Maximum concentrations of elements derived from microprobe SR-XRF maps of RAW264.7 
cells. 
 
Maximum Elemental 
Concentration (µg/cm2) 
Treatment P S Zn Au 
Control 6.28 2.50 0.0615 0.0186 
Auranofin (2.5 µM) 2.33 1.53 0.0420 0.698 
Aurothiomalate (1000 µM) 3.70 2.51 0.0358 8.06 
H[AuCl 4] (100 µM) 1.97 1.87 0.0530 14.5 
Nanoparticles (60 µM) 10.9 10.3 0.116 87.4 
Note: Macrophages were treated at 37 °C under an atmosphere of 5% CO2 with various gold compounds 
and Au NPs for 24 h. The concentrations of auranofin and H[AuCl4] used to treat the cells were chosen as 
they were close to their respective IC50 values. All other concentrations were chosen as they were 
expected to result in significant gold uptake by the cells. 
The presence of discrete localised areas containing gold in the elemental maps of 
macrophages treated with Au NPs, is consistent with previous studies that used TEM to 
show that gold accumulated in structures known as endosomes, as well as lysosomes, 
following exposure of cells to Au NPs.199,200 It has also previously been reported that 
macrophages treated with aurothiomalate show evidence of gold being packaged into 
lysosomes to form structures sometimes termed aurosome , owing to their high gold 
content.105,106 The size of the spots are approximately 0.5 – 1 µm in diameter, which is 
approximately 30 – 65 times the size of an administered nanoparticle. Therefore it is 
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likely that the gold hotspots observed in Figure 3.16 are also attributable to aurosomes, 
formed as a result of endocytosis of Au NPs bound to the surface of the macrophage 
membrane. This is particularly consistent with macrophage behaviour, as one of their 
primary roles is to engulf foreign materials within their plasma membrane and 
invaginate them as vesicles.252 These vesicles are combined into endosomes and 
eventually lysosomes.252 
3.5.2 Low Resolution Maps of Large Numbers of Cells 
In this section, elemental maps obtained at the Australian Synchrotron are 
presented to show the localisation of elements in samples consisting of large numbers of 
macrophages treated with the various gold compounds or Au NPs. The images are of 
much larger scan areas than those obtained at the APS, and allow comparisons to be 
made regarding the homogeneity of gold uptake across a larger percentage of the total 
cell population. Examples of characteristic X-ray spectra used to produce these maps 
are shown in Appendix B:. Figure 3.19 shows the elemental maps for cells exposed to 
‘incomplete medium’ only. The S, K and Zn maps provide a good overview of the 
overall appearance and location of cells in the mapped area, whilst the Au map shows 
that only a very small amount of this element was present, as expected, owing to its 
absence from the treatment solution. The maps show roughly 40–50 cells in total, which 
have grown together in dense clumps, and vary in morphology from fibroblastic to 
round. 
Elemental maps showing cells treated with 2.5 µM auranofin are presented in 
Figure 3.20. The S, K and Zn maps show a lower population density of cells than was 
present in the control sample. This is most likely due to a significant percentage of the 
cells dying owing to the cytotoxicity of auranofin, and being washed off the silicon 
nitride membrane. Examination of the mapped area reveal d the two distinct 
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morphologies for these cells noted earlier, namely fibroblastic and rounded cells. 
Examination of the Au map shows that this element was only present in significant 
amounts within the rounded cells, which is consistent with the results presented earlier 
in Figure 3.12, and the cytotoxic nature of this compound revealed in Section 3.3. This 
is further highlighted by the co-localisation map shown in Figure 3.21, in which only 
the rounded cells feature the pink/purple colour indicative of the presence of gold, 
potassium and sulfur in the same regions. 
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Figure 3.19: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with incomplete medium 
at 37 °C under an atmosphere of 5% CO2 for 24 h. Scan dimensions (H x V) were 120 µm × 120 µm. 
Values are relative quantifications and are unitless. 
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Figure 3.20: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 2.5 µM auranofin at 
37 °C under an atmosphere of 5% CO2 for 24 h. Scan dimensions (H x V) were 120 µm × 120 µm. 
Values are relative quantifications and are unitless. 
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Figure 3.21: Individual elemental microprobe SR-XRF maps, and co-localisation map for RAW264.7 
cells treated with 2.5 µM auranofin at 37 °C under an atmosphere of 5% CO2 for 24 h. Scan dimensions 
(H x V) were 120 µm × 120 µm. 
Elemental maps for cells treated for 24 h with 2.5 µM and 1000 µM 
aurothiomalate are shown in Figure 3.22 a) and b), respectively. Examination of the S, 
K and Zn maps corresponding to cells treated with 2.5 µM aurothiomalate shows a 
significant number of macrophages. Inspection of the Au map reveals that the metal is 
randomly distributed throughout the entire mapped area at low concentrations, in a 
similar manner to that observed for the control sample. These observations indicate that 
little gold uptake occurred at this low treatment con entration. When the concentration 
of aurothiomalate in the treatment solution was increased to 1000 µM (Figure 3.22 b), 
the S, K and Zn maps showed a more dense population of macrophage cells. The Au 
elemental map now showed that the majority of cells contained regions of low gold 
concentration comparable to that seen with the control sample. However, some regions 
of the gold map feature ‘hot spots’ of gold corresponding to much higher concentrations 
of the metal that were associated with cellular materi l. 
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Figure 3.22: Microprobe SR-XRF elemental maps for RAW264.7 cells treated at 37 °C and under an 
atmosphere of 5% CO2 for 24 h with: a) 2.5 µM aurothiomalate and b) 1000 µM aurothiomalate. Scan 
dimensions (H x V) were 120 µm × 120 µm. Values are relative quantifications and are unitless. 
This non-uniform pattern of gold uptake is similar to what was observed for 
auranofin, and was also observed for cells treated with 2.5 µM aurothiosulfate (Figure 
3.23 a). When the concentration of aurothiosulfate was increased to 500 µM, the 
elemental maps (Figure 3.23 b) provided evidence of cellular rupture, as there was a 
large amount of cellular debris distributed throughout the image area. This is possibly 
due to the treatment concentration of 500 µM resulting in significant cytotoxicity for the 
macrophages, leading eventually to membrane rupture and lysis. 
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Figure 3.23: Microprobe SR-XRF elemental maps for RAW264.7 cells treated at 37 °C under an 
atmosphere of 5% CO2 for 24 h with: a) 2.5 µM aurothiosulfate b) 500 µM aurothiosulfate. Scan 
dimensions (H x V) were 120 µm × 120 µm. Values are relative quantifications and are unitless. 
Maps of macrophages exposed to Au NPs at concentratio s of 2.5 µM and 60 
µM are shown in Figure 3.24 a) and b), respectively. In contrast to the gold(I) 
compounds discussed previously, exposure of the macrophages to either concentration 
of Au NPs resulted in gold elemental maps that showed a homogenous distribution of 
the metal across the cell population. This is consistent with the results of GFAAS 
studies presented earlier (Figure 3.10), which showed higher levels of gold 
incorporation into Au NP-treated cells. Comparison of the S and Au images suggests a 
high degree of co-localisation of these elements along with Zn within the cells. 
However, this is once again due to issues discussed earlier, which arise due to overlap 
of the gold M line with the sulfur K line and the gold L line with the zinc K line. Further 
evidence of this is provided by the integrated SR-XF spectrum shown in Appendix 
B:, Figure B.30. 
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Figure 3.24: Microprobe SR-XRF elemental maps for RAW264.7 cells treated at 37 °C under an 
atmosphere of 5% CO2 for 24 h with: a) 2.5 µM Au NPs, and b) 60 µM Au NPs. Scan dimensions (H x 
V) were 120 µm × 120 µm. Values are relative quantifica ons and are unitless. 
3.6 Scanning Electron Microscopy Studies 
Whilst the GFAAS gold uptake experiments described in Section 3.4 provided 
evidence of extensive cellular uptake of Au NPs by macrophages, they did not afford 
any clues to the distribution of the gold throughout these cells. In contrast, whilst 
images obtained by microprobe SR-XRF in Section 3.5 clearly showed association of 
gold with whole cells, these experiments were unable to discern whether the gold had 
been internalised, or was simply extracellularly bound. In order to definitively show that 
Au NPs had been incorporated into the cells, FESEM was employed. Figure 3.25 
shows the FESEM images for cells treated with incomplete medium or Au NPs. 
Examination of Figure 3.25 a), the image of cells treated with incomplete medium, 
reveals a number of cells grown in close proximity to each other. Most have a rounded 
morphology, with one cell towards the top right of the image featuring extensive 
blebbing, indicating that it is late apoptotic or necrotic. 
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Figure 3.25: FESEM image of RAW264.7 macrophages treated at 37 °C under an atmosphere of 5% CO2 
for 24 h with: a) incomplete medium; and  b) 60 µM Au NPs. Image a) was collected at ×2700 
magnification, and b) at ×2200 magnification. Both were obtained using a accelerating voltage of 15 kV. 
Figure 3.25 b) shows a scanning electron micrograph of macrophages treated 
with 60 µM Au NPs. Again, a number of cells are visible, featuring a mixture of 
rounded and fibroblastic morphologies. In contrast to Figure 3.25 a), a number of 
bright white spots are now also visible, mostly located on the edges of the cells in the 
dendrites. Gold deposits are easily identified by FESEM owing to their pronounced 
electron scattering properties.253 Scrutiny of Figure 3.25 b) also suggests that some 
5 µm 
10 µm 
 
Chapter 3 – Cellular Toxicity, Uptake and Localisation 113 
cells are extending their membranes to phagocytose the Au NPs, which is consistent 
with suggestions in the literature that Au NPs are taken up by cells through 
endocytosis.199,200  
Confirmation that the white spots are gold was provided by comparing the 
FESEM image of a cluster of macrophages treated with Au NPs, to a gold elemental 
map of the same cells, obtained by EDX spectroscopy (Figure 3.26). Whilst there 
appears to be a fairly low signal-to-noise ratio in the gold EDX map, there are clearly 
hotspots corresponding to regions where there are higher concentrations of gold in the 
cell in the top-right quadrant. Figure 3.26 c) shows an overlay of the FESEM image and 
EDX gold map, and provides support for the conclusion that the hotspots in the EDX 
map correspond to the white spots of the FESEM image, identifying the latter as gold. 
a) 
 c) 
 b) 
 
Figure 3.26: EDX and FESEM images of RAW264.7 cells treated with 60 µM Au NPs at 37 °C under an 
atmosphere of 5% CO2 for 24 h. Images were collected at 4300× magnificat on with an accelerating 
voltage of 25 kV. EDX was collected for 90 min.  a) FESEM image; b) EDX map for gold; c) overlay of 
a & b. 
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Figure 3.27 shows a series of FESEM images of an identical group of cells that 
had been treated with 60 µM Au NPs. Each image was collected using a different 
accelerating voltage. Higher voltages provide electrons with greater penetrating power 
through the sample thereby allowing detection of gold that is deeper below the surface 
of the cell. Figure 3.27 a) was collected at the highest accelerating voltage and shows 
three cells with many white spots most likely corresponding to Au NPs. The more 
diffuse spots are thought to be internalised gold below the membrane surface, whilst the 
more sharply defined spots, such as the one highlighted by a red arrow, are more likely 
to correspond to surface-bound gold. These surface-bound spots were visible at all 
accelerating voltages used. Inspection of all images in Figure 3.27 reveals that as the 
accelerating voltage was decreased, the number of diffuse spots also decreased. This is 
consistent with the hypothesis that the diffuse spots c rrespond to gold particles located 
below the surface of the cell. Therefore, it can be concluded that a significant proportion 
of the cellular gold uptake measured by GFAAS, and gol  observed in the microprobe 
SR-XRF images, is due to internalised Au NPs, and not simply due to particles located 
on the cell membrane. The results here are generally consistent with those of an earlier 
study, in which FESEM was used to show that 10 nm Au NPs were incorporated within 
macrophages to varying depths.254 
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a) b) 
  
c) d) 
  
e)  f) 
Figure 3.27: FESEM images of RAW264.7 macrophages treated with 60 µM Au NPs at 37 °C under an 
atmosphere of 5% CO2 for 24 h. The images are of the same group of cells collected at ×4300 
magnification and were obtained with accelerating voltages of: a) 25 kV  b) 20 kV  c) 18 kV  d) 15 kV  
e)12 kV  f) 10 kV. 
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Chapter 4:  
Effects of Gold Compounds and Gold 
Nanoparticles on the Cellular Production 
of Inflammation Mediators 
 
 
The investigations described in this chapter expand upon those of Chapter 3, by 
comparing the ability of anti-arthritic gold compounds and gold nanoparticles to exert 
anti-inflammatory effects, by altering the cellular expression of three pro-inflammatory 
mediators in macrophages. These were nitric oxide, reactive oxygen species and tumor 
necrosis factor. In addition, the ability of the gold compounds and nanoparticles to alter 
the production of the anti-inflammatory mediator interleukin-10 in macrophages was 
examined. The chapter concludes with an exploration of the effects of changing the size 
and composition of gold nanoparticles upon production of nitric oxide and reactive 
oxygen species in the same type of macrophages. 
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4.1 Introduction 
The toxicity and cellular uptake of a number of gold complexes and Au NPs was 
compared in the previous chapter. The results of these studies showed that there was a 
higher level of incorporation of the Au NPs by macrophages, as well as a different pattern 
of cellular distribution compared to the gold compounds. To see how these differences 
might affect anti-inflammatory activity, the level of expression of a number of 
inflammation mediators after exposure of macrophages to gold compounds or Au NPs was 
compared. The mediators studied were NO, ROS, TNF and IL-10. Each was selected 
because of its known involvement in the inflammatory response associated with RA 
(Section 1.1.1). However, murine RAW264.7 macrophages do not constitutively produce 
appreciable quantities of these mediators, and as such the cells require ‘activation.’ The 
TLR4 ligand, LPS, was chosen to activate the macrophages, as it has also been used 
previously for similar studies.201,203,206,255–260 
The results presented in this chapter follow a similar structure for each mediator 
studied, and were obtained from experiments performed as described in Section 2.9. First, 
experiments showing how mediator production by macrophages is affected by the addition 
of gold compounds or Au NPs are presented, with the eff cts of addition of LPS as a 
positive control also included. Following this, the results of experiments that investigated 
the ability of the gold compounds or Au NPs to attenuate LPS-induced mediator 
production are shown.  
To focus the scope of the experiments, only the effcts of addition of the anti-
arthritic gold(I) compounds auranofin and aurothiomalate were compared to that of adding 
Au NPs. These two compounds were selected because they are the most broadly studied, 
and remain the most clinically relevant. In order to facilitate comparison with the toxicity 
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results presented in the previous chapter, the effects of adding 2.5 µM Au NPs, auranofin 
and aurothiomalate on the production of the inflammation mediators was explored. In 
addition, the effects of adding a higher concentration (60 µM) of aurothiomalate or Au NPs 
were also examined. As aurothiomalate was water soluble, its control solution (vehicle 
used for treatment) was incomplete medium. The auranofin control solution (vehicle) 
consisted of 1% DMSO/99% incomplete medium, while for Au NPs the control solution 
(vehicle) was 1.5% 10×D-PBS/15% H2O/83.5% incomplete medium.  
Statistical evaluations of the data were performed by using one-way ANOVA on 
sample subgroups to compare the gold compounds or Au NPs with their respective vehicle. 
One subgroup consisted of the auranofin vehicle, th Au NPs vehicle and incomplete 
medium. A second subgroup consisted of 2.5 µM and 60 µM aurothiomalate treatments as 
well as incomplete medium. Similarly, a third subgroup consisted of 2.5 µM and 60 µM 
Au NP treatments and the Au NPs vehicle. All one-way ANOVA tests were performed 
using a Tukey-Kramer post-test set at 95% confidence i tervals. Results obtained from 
experiments performed using 2.5 µM auranofin were grouped only with the auranofin 
vehicle. Since this group consisted of only two samples, statistical analysis of the results 
was instead performed using a two-tailed unpaired t-test set with a 95% confidence 
interval. The tests were performed in these subgroups as the predominant interest in each 
experiment was whether a compound could cause inhibition or stimulation of inflammation 
mediator production, relative to its vehicle (solvent). This was a particularly important 
consideration for experiments involving auranofin or Au NPs, as both of their vehicles 
themselves had some significant effects on mediator pr duction. The above statistical 
approach involving analysis of subgroups of samples wa  adapted instead of simply 
applying a one-way ANOVA on all samples at the same ti , because the latter method 
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did not reveal significant effects caused by additional of specific gold agents due to a 
relatively large root mean squared (the measure of deviation across all tested data sets). 
4.2 Effects on Production of Nitric Oxide 
The free radical NO is an important signalling molecul  that acts as a pro-
inflammatory mediator in RA.40 As it is a short-lived species, cellular production f NO 
must be inferred by determining the concentration of its major decay product, NO2‾, using 
the Griess assay.224 Figure 4.1 compares the extent of production of NO2‾ by RAW264.7 
cells after treatment with aurothiomalate, auranofin, Au NPs or LPS. None of the three 
different vehicles resulted in significant NO2‾ production by the macrophages. 
Furthermore, the addition of aurothiomalate, auranofin r Au NPs did not induce any 
formation of NO2‾ at any of the concentrations studied. However, the presence of LPS (0.1 
µg/mL and 1 µg/mL) did induce formation of significant and similar quantities of nitrite. 
In view of the known cytotoxic effects caused by high concentrations of LPS,261 and the 
minimal difference in NO2‾ produced at the two different concentrations used, it was 
decided to use 0.1 µg/mL LPS to induce NO production for the next experiment, as well as 
all other LPS-induced mediator formation experiments described in this chapter. 
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Figure 4.1: Effect of addition of aurothiomalate, auranofin, Au NPs or LPS on nitrite production by 
RAW264.7 macrophages. Cells were incubated with gold c mpounds, Au NPs or LPS at 37 °C under an 
atmosphere of 5% CO2 for 24 h. Nitrite concentration was then measured by the Griess assay. The error bars 
represent one standard deviation calculated from triplicate plates. *** = statistically significant (P < 0.001) 
compared to incomplete medium; ns = not significant compared to corresponding vehicle (P > 0.05).  
Figure 4.2 compares the extent of LPS-induced production of NO2‾ by RAW264.7 
cells, after they had been previously incubated with aurothiomalate, auranofin, or Au NPs. 
Pre-incubation of the macrophages with either the auranofin or Au NP vehicles resulted in 
LPS-induced nitrite production levels that did not vary significantly from when the 
macrophages were pre-incubated with incomplete medium. Pre-incubation of the cells with 
2.5 µM aurothiomalate also failed to produce a statistically significant reduction in 
formation of NO2‾ compared to incomplete medium. When the concentration of 
aurothiomalate in the pre-treatment solution was increased to 60 µM, a 40% drop in the 
amount of produced NO2‾ was recorded. In contrast, when the cells were pre-treated with 
2.5 µM auranofin, almost complete inhibition of NO2‾ production was observed after 
addition of LPS. Pre-incubation of the macrophages with Au NPs at both concentrations 
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resulted in small, (~10%) statistically insignificant decreases in NO2‾ concentration 
compared to what was observed when the cells were first treated with the Au NPs vehicle. 
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Figure 4.2: Effect of pre-incubation with gold compounds or Au NPs on LPS-induced nitrite production by 
RAW264.7 macrophages. Cells were pre-incubated withthe gold compounds or Au NPs at 37 °C under an 
atmosphere of 5% CO2 for 4 h, then 0.1 µg/mL LPS was added, and the cells incubated under the same 
conditions for a further 20 h. Nitrite concentration was then measured by the Griess assay. The error ba s 
represent one standard deviation calculated from triplicate plates. ** = statistically significant (P < 0.01) 
compared to corresponding vehicle; ns = not significant compared to corresponding vehicle (P > 0.05). 
 
The results obtained here with auranofin concur with those obtained in other studies 
using RAW264.7 cells, where similar reductions in the amount of LPS-induced nitrite were 
observed after first treating the cells using 3 and 20 µM solutions of auranofin.257,259 
Previous studies have also shown that pre-treatment with aurothiomalate resulted in 
moderate to large decreases in NO2‾ production for RAW264.7 cells activated by LPS,
262 
as well as for murine H4 chondrocytes activated by IL-1β,263 and non-activated peritoneal 
macrophages isolated from mice.264 Whilst the results obtained using aurothiomalate in the 
current study (Figure 4.2) may not be statistically different from those obtained with the 
vehicle, incomplete medium, they suggest that pre-incubation with even higher 
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concentrations of this gold complex might leads to tatistically relevant decreases in NO2‾ 
production. 
The absence of a significant effect of pre-treatment with Au NPs on the production 
of NO2‾ contrasts results published by Ma et. al in the journal Nitric Oxide.
203 The latter 
authors used a very similar methodology to that followed in this thesis, which involved 
RAW264.7 cells being pre-incubated with Au NPs and subsequently activated using 0.1 
µg/mL LPS. Ma et. al observed a dose-dependent reduction of NO2‾ production with 
increasing Au NPs concentration. Statistically signif cant reductions in the amount of NO2‾ 
produced of 28%, 52% and 76%, were reported in thisliterature study, when the 
macrophages were pre-treated using Au NP solutions c taining 10, 20 and 40 µg Au/mL 
(equivalent to 51, 102 and 203 µM Au, respectively).  
Since two of the three solutions containing Au NPs used in the Ma et. al study had 
much higher concentrations of gold compared to those in the current study, it was decided 
to repeat the experiment, using Au NP pre-treatment solutions with a greater range of 
concentrations. In order to prepare these solutions, newly synthesised Au NPs were 
concentrated by centrifugation. This enabled the prpa ation of Au NP solutions with 
concentrations up to 600 µM without particle aggregation. The results of this set of 
experiments are presented in Figure 4.3. A small drop in NO2‾ production was observed 
for macrophages that were pre-treated with solutions containing 400 or 600 µM Au NPs. 
However, the reduction in NO2‾ levels was still not statistically significant compared to the 
macrophage sample treated with the Au NPs vehicle. As noted in Section 1.4.2, there have 
been a number of conflicting studies in the literatu e concerning the effects of Au NPs on 
macrophages and other cells. In many cases, the physical characteristics of the 
nanoparticles were poorly described, making comparisons difficult. For example, Ma et. al 
indicated in the experimental section of their paper that the Au NPs used were synthesised 
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by the sodium citrate reduction method. However, in another part of the article it is 
mentioned that the Au NPs were coated in PEG, which may account for the difference 
between their results and those presented in this thesis.  
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Figure 4.3: Effect of pre-incubation with Au NPs on LPS-induced nitrite production by RAW264.7 
macrophages. Cells were pre-incubated with various c ncentrations of Au NPs at 37 °C under an atmosphere 
of 5% CO2 for 4 h, then 0.1 µg/mL LPS added and the cells incubated under the same conditions for a further 
20 h. Nitrite concentration was then measured by the Griess assay. The error bars represent one standard 
deviation calculated from triplicate plates. ns = not significant compared to Au NPs vehicle  (P > 0.05). 
Further confusion over the effects of Au NPs arises after reading the results of 
another study that showed pre-treatment of RAW264.7 macrophages with PEG-coated Au 
NPs caused a small increase in NO2‾ production, after subsequent treatment with 0.1 
µg/mL LPS.206 In addition, a letter published in the journal Nitric Oxide stated that in 
contrast to the results reported by Ma et. al, pre-treatment with Au NPs (stabilised with 
citrate or dihydrolipoic acid) caused no significant change in NO2‾ production by NR8383 
cells, a rat macrophage cell line, after they were exposed to LPS.205 The results of this last 
study mirror closely those presented in this thesis. This may be attributable to the Au NPs 
in both cases being stabilised only with low molecuar mass compounds, whereas in some 
of the other studies discussed above the nanoparticles had a protective polymeric 
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coating.203,206 This may have endowed the Au NPs with very different physical and 
chemical properties that could have affected their ab lity to inhibit LPS-induced formation 
of NO2‾. 
The results presented in this section showed that gold compounds and Au NPs can 
vary dramatically in their ability to inhibit LPS-induced formation of NO in RAW264.7 
macrophages. In the next section, experiments are described that sought to determine if 
similar trends were observed when examining the ability of the gold compounds and Au 
NPs to inhibit production of ROS. 
4.3 Effects on Production of Reactive Oxygen Species 
The class of molecules known as ROS play an important biological role through 
their effects on cell signalling pathways, but when produced in large quantities contribute 
to oxidative stress associated with damage to DNA, lipids and proteins alike.34 In patients 
with RA, increased oxidative stress is observed in the synovial fluid,36 and is thought to be 
a major mechanism of disease progression.37 It is possible to quantify ROS produced in 
vitro by measuring the extent of cellular conversion of the dye DCFH2-DA to its 
fluorescent form, DCF, using flow cytometry.  
Figure 4.4 shows exemplar flow cytometry data obtained from experiments 
performed with the three different vehicles and 0.1 µg/mL LPS. For each sample, three 
different sets of data are shown. The first of these (Figure 4.4 a) is a plot of forward scatter 
(cell size) against side scatter (cell granularity) for the cell population analysed, whilst the 
second (Figure 4.4 b) is a plot of forward scatter against fluorescence at 695 nm. 
Fluorescence at this wavelength corresponds to the relative amount of 7AAD present in 
each cell. This dye is similar to trypan blue, in that it is only able to enter cells with
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Figure 4.4: Exemplar flow cytometry data for macrophage samples tr ated with: i) incomplete medium;  ii)  auranofin vehicle;  iii)  Au NPs vehicle;  or iv) 0.1 µg/mL LPS:    
a) dot plots for side scatter (y-axis) vs forward scatter (x axis);  b) dot plots for fluorescence at 695 nm (y-axis) vs forward scatter (x-axis); and c) histograms of relative 
fluorescence at 515 nm for different gated cell populations. DMSO loaded samples are coloured blue and DCFH2-DA loaded samples are coloured red. 
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compromised membranes, which can therefore be classified as ‘non-viable.’ The above 
parameters (forward scatter, side scatter, and fluorescence at 695 nm) allow the viable 
cell population to be selected within a ‘gate’ or region within the plots shown in Figure 
4.4 (shown as an oval or rectangle in the plots). The median fluorescence intensity 
(MFI) at 515 nm of the cell population within the gate is then measured. This 
corresponds to the amount of ROS formed by the cells. The histograms in Figure 4.4 
(c) show the fluorescence at 515 nm for the gated populations shown in Figure 4.4 (b). 
These histograms compare cells loaded (treated) with DCFH2-DA (coloured red in the 
histogram) with those loaded with DMSO (coloured blue in the histogram). The 
administered DCFH2-DA is dissolved in DMSO, and as such, the DMSO loading acts as 
a control to measure whether the cells produce fluorescence at 515 nm that is not a 
result of production of DCF. This usage of DMSO is termed the autofluorescence 
control, because it measures the amount of native fluorescence (i.e. not from ROS) 
generated by the cells. The MFI of the DMSO loading is subtracted from the MFI of the 
DCFH2-DA loading to give the amount of ROS formed. 
Comparison of the data obtained for macrophages treated with the three different 
types of vehicles shows that these had little effect on cell morphology. In contrast, 
treatment with LPS resulted in significant changes to cell size and granularity, as well as 
an increase in fluorescence at 695 nm. The latter increase is typical for cells entering 
either the early or late stages of apoptosis,265 and is consistent with the known 
cytotoxicity of LPS.261 As a result, the LPS treated cell samples were gatd differently 
to the other samples. Examination of the gated population of viable cells remaining after 
treatment with LPS also reveals an increase in relative fluorescence at 695 nm, 
compared to cells treated with the vehicles. This was likely caused by an increase in 
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autofluorescence of the macrophages as a result of being activated by LPS. This has 
been observed previously with monocyte-derived macrophages.266 
Examination of Figure 4.4 c) shows there was little difference between the 
relative fluorescence at 515 nm for DMSO and DCFH2-DA loaded cells for 
macrophages treated with the three different vehicls. This indicates that there was little 
ROS produced as a result of treatment with any of the vehicles, and that the detected 
fluorescence was from other molecules that fluoresce at 515 nm. In contrast, the cells 
treated with 0.1 µg/mL LPS showed a large difference between the relative fluorescence 
of the DMSO and DCFH2-DA loaded samples, indicating that treatment with LPS 
induced formation of a large amount of ROS. The MFI for both the DCFH2-DA and 
DMSO loaded cells was then derived from each of the histograms in Figure 4.4 c). 
Subsequently, the MFI for the DMSO loaded cells was subtracted from that for the 
DCFH2-DA loaded cells to give the amount of ROS produced for each sample. 
Figure 4.5 shows the amount of ROS produced by RAW264.7 cellstr ated with 
aurothiomalate, auranofin, Au NPs or LPS. In each case, the amount of ROS produced 
is expressed as a MFI. Examination of Figure 4.5 shows that none of the gold 
compounds or the Au NPs induced ROS production at any of the concentrations 
studied. In contrast, treatment of the macrophages with LPS resulted in production of a 
large amount of ROS at both concentrations studied, with the MFI for the 1 µg/mL 
treated sample being 1.7 times higher than that for the cells treated with just 0.1 µg/mL 
LPS. As treatment with 0.1 µg/mL LPS produced significant quantities of ROS, this 
concentration was used in all subsequent studies. Thi  also facilitated comparisons with 
the results of investigation into the effects of gold compounds and Au NPs on NO 
formation, which were described in the previous section, and where macrophages were 
also treated with 0.1 µg/mL LPS. 
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Figure 4.5: Effect of treatment with gold compounds, Au NPs or LPS on ROS production by RAW264.7 
macrophages. Cells were incubated with gold compounds, Au NPs or LPS at 37 °C under an atmosphere 
of 5% CO2 for 24 h. ROS was measured by the DCF assay and is presented as a MFI at 515 nm. The error 
bars represent one standard deviation calculated from t iplicate samples. *** = statistically significant (P 
< 0.001) compared to incomplete medium; ns = not significant compared to the corresponding vehicle (P 
> 0.05). 
Figure 4.6 shows the effects of pre-incubation with aurothiomalate, auranofin, 
or Au NPs on production of ROS by RAW264.7 cells subsequently treated with LPS. 
The data presented for each experiment has been normalised by expressing the MFI 
obtained as a percentage of the result obtained when t  cells were treated with 
incomplete medium. This normalisation procedure wasperformed to reduce the impact 
of the variability inherent in the fluorescence inte sities as a result of differences in 
DCFH2-DA loadings from one experiment to another. 
 Examination of Figure 4.6 shows that treatment with 2.5 µM aurothiomalate 
had little effect on the production of ROS by the macrophages. However, when the 
concentration of aurothiomalate was increased to 60 µM, a 44% drop in ROS 
production was observed. As a result of the large standard deviation associated with this 
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result, it was not statistically significant in the ANOVA analysis performed on this 
subset of samples. This is most likely due to the relatively large errors associated with 
the results for the aurothiomalate-treated (as well as other) samples, which are not 
uncommon for experiments of this type. The results, nonetheless, suggest that treatment 
with aurothiomalate can decrease the amount of ROS produced by LPS-induced 
macrophages. 
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Figure 4.6: Effect of pre-treatment with gold compounds or Au NPs on LPS-induced ROS production by 
RAW264.7 macrophages. Cells were pre-incubated withthe gold compounds or Au NPs at 37 °C under 
an atmosphere of 5% CO2 for 4 h, then 0.1 µg/mL LPS was added and incubation continued under the 
same conditions for a further 20 h. ROS was measured by the DCF assay and presented as normalised 
MFI values at 515 nm, relative to incomplete medium. The error bars represent one standard deviation 
calculated from triplicate samples. * = statistically significant (P < 0.05) compared to the corresponding 
vehicle; ns = not significant compared to the corresponding vehicle (P > 0.05). 
Treatment of the macrophages with the auranofin vehicle, consisting of 1% (v/v) 
DMSO/99% (v/v) incomplete medium caused a significant (62%, P < 0.05) drop in 
ROS production relative to that caused by the pre-treatment with incomplete medium. 
Pre-treatment with 2.5 µM auranofin led to almost complete loss of ROS formation (P < 
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0.05), suggesting that this compound may have a much stronger effect on production of 
ROS than aurothiomalate. When the macrophages were pr -treated with the Au NPs 
vehicle, or solutions containing 2.5 µM or 60 µM AuNPs, there was no impact on the 
amount of ROS produced compared to cells pre-treated with incomplete medium. 
The data in Figure 4.6 suggests that pre-treatment with the auranofin vehicle 
may have had a notable impact on the amount of ROS produced, compared to samples 
which were pre-treated with incomplete medium. This is most likely a result of the 
DMSO present in the auranofin vehicle. A similar con lusion was reached in a previous 
study performed using neuroblastoma cells and the DCF assay.267 Figure 4.6 also 
strongly points to a major effect on ROS production by the macrophages as a result of 
pre-treatment with auranofin. This observation is also consistent with results reported 
previously in the literature. While its effect on total ROS production does not appear to 
have been measured previously, auranofin has been shown to inhibit the formation of 
the superoxide ion (O2‾) in a number of studies using phagocytes,
268 polymorphonuclear 
leucocytes,269–271 and neutrophils.272 In addition, auranofin has been shown to quench 
highly reactive singlet oxygen.273 It is also worth noting that the results presented h re 
using aurothiomalate are consistent with literature reports, which show this gold 
compound has a weaker inhibitory effect on the formation of superoxide than 
auranofin.268–271 It has been suggested that one mechanism by which t ese two 
compounds produce their inhibitory effects is through activation of the heterodimeric 
transcription factor Nrf2/small maf, that upregulates anti-oxidant proteins.274 In 
addition, it has been reported that both auranofin and aurothiomalate can suppress the 
pro-inflammatory transcription factor NF-κβ.125 
The lack of a significant effect of Au NPs on production of ROS shown in 
Figure 4.6, appears to contradict the findings of a number of other researchers. For 
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example, one study showed that Au NPs bought from BBI (Cardiff, UK) could reduce 
ROS formation by human PBMCs.275 A luminol-dependent chemiluminescence assay 
was used to measure ROS in this study, which also showed that Au NPs with smaller 
diameters were more effective at inhibiting ROS formation. One key difference between 
this study and that described in this thesis, is that ROS formation was induced using the 
glucan molecule zymosan,275 and not LPS. This is potentially important as zymosan is a 
TLR2 ligand, whilst LPS is a TLR4 ligand, meaning that they may signal their 
inflammatory effects through separate pathways, which in turn, the Au NPs may 
interact differently with. 
Au NPs synthesised by reaction of [AuCl4]‾ with the soil bacterium Bacillus 
licheniformis have also been shown to inhibit ROS formation and lipi peroxidation in 
diabetic mice.276 In this study, treatment of the mice with Au NPs caused upregulation 
of the anti-oxidant molecule glutathione and the anti-oxidant proteins superoxide 
dismutase and glutathione peroxidase. It was concluded that the greater abundance of 
these proteins may have been the cause of the lowerROS levels observed.276 In another 
study ROS production was not changed when RAW264.7 cells were treated with poly-
L-lysine-coated Au NPs for a 24 h period.201 However, exposure to a 100 µM solution 
of the Au NPs for 48 h did result in a significant reduction.201 
Despite the above literature studies suggesting that various types of Au NPs can 
inhibit ROS formation in cells, there are a number of other investigations, which did not 
involve the use of an inflammation-stimulating molecule, which showed they have the 
opposite effect. For example, the DCF assay was used to show that leukaemia and liver 
cell lines treated with 30, 50 and 90 nm Au NPs purchased from CymitQuímica 
(Barcelona, Spain) exhibited an increase in total ROS production, coupled with strongly 
decreased glutathione levels and superoxide dismutase activity.277 In addition, Au NPs 
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(1.4 nm in diameter) stabilised by triphenylphosphine monosulfate caused significant 
ROS formation in leukaemia cells, with the effect becoming more pronounced with 
longer exposure periods.278 Similarly, leukaemia cells exposed to various types of 2 nm 
Au NPs with organic stabilizers of different lengths, showed high levels of ROS 
production, according to measurements performed using the DCF assay.279 
The variety of results in the literature once again highlights the likely 
importance of variations in the size and chemical composition of Au NPs on their 
biological activity. No literature studies appear to have looked at the effect of citrate 
stabilised Au NPs on ROS formation, making the results presented in this thesis distinct 
from those in the literature. The absence of a significa t effect on ROS production, 
together with the minimal influence on NO production shown in Section 4.2, suggests 
that the Au NPs studied here either do not have significant anti-inflammatory properties, 
or that they exert their effects through a different mechanism or mechanisms. In order to 
test the latter hypothesis, the effects of the Au NPs (and gold compounds) on the 
production of the inflammation cytokines TNF and IL-10 was studied next. 
4.4 Effects on Production of Tumor Necrosis Factor 
TNF is a pro-inflammatory cytokine strongly linked to RA progression, as it is 
involved in signalling the release of ROS,22 degradative enzymes,24 and other 
inflammatory cytokines.21 The clinical importance of TNF is highlighted by clinical 
usage of the biologics infliximab and etanercept, which treat RA through inhibition of 
TNF.48 It was decided to investigate the ability of the gold compounds and Au NPs to 
inhibit production of TNF, as this might be a mechanism by which they exert their anti-
arthritic effects. Production of TNF by RAW264.7 cells was assessed using a 
commercial ELISA kit. 
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Figure 4.7 displays the amount of TNF produced by RAW264.7 macrophages in 
response to treatment with aurothiomalate, auranofin, Au NPs or LPS. Treatment of the 
cells with either 0.1 or 1 µg/mL LPS caused release of much larger amounts (~80 times) 
of TNF than that elicited by any of the gold compounds or Au NPs. For example, 
treatment of the cells with 60 µM aurothiomalate only resulted in production of 1.04 
ng/mL of TNF, which was not significantly different (P > 0.05) compared to the amount 
of this cytokine produced when the macrophages were tr ated with incomplete medium 
(0.177 ng/mL). Similarly, treatment of the macrophages with auranofin or Au NPs 
failed to result in statistically significant increases in TNF production.  
 
Figure 4.7: Effect of treatment with gold compounds, Au NPs or LPS on TNF production by RAW264.7 
macrophages. Cells were treated with the gold compounds, Au NPs, or LPS and incubated at 37 °C under 
an atmosphere of 5% CO2 for 24 h, and the amount of TNF produced then measur d by ELISA. The error 
bars represent one standard deviation calculated from t iplicate samples. *** = statistically significant (P 
< 0.001) compared to incomplete medium; ns = not significant compared to the corresponding vehicle (P 
> 0.05). 
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In view of these results, it appeared that the gold c mpounds and Au NPs do not 
induce production of significant amounts of TNF. In contrast, the amount of TNF 
produced after treating the cells with LPS was similar to that observed in other studies 
involving RAW264.7 macrophages, where the cells were treated with 0.01 µg/mL,280 
0.1 µg/mL281 or 0.5 µg/mL LPS.282 
There are very few papers in the literature that discuss the basal effects of 
auranofin and aurothiomalate on TNF production. In co trast, the effects of Au NPs 
have been reported, with differing outcomes being observed depending on the size and 
composition of the nanoparticles. In one study, Au NPs with diameters less than 20 nm 
were used.202 The authors of this study stated that the nanoparticles were produced by 
physical manufacturing and did not contain any surface modifiers or stabilisers. 
Treatment with these Au NPs resulted in an increase in the level of TNF in murine 
J774.A1 macrophages.202 In contrast, another study showed that lysine and poly-L-
lysine coated Au NPs do not affect TNF levels in RAW264.7 macrophages.201 The 
importance of the coating surrounding the Au NPs is further highlighted by another 
study that compared the levels of cytokines produce by bone marrow-derived 
macrophages in response to treatment with either citrate-coated Au NPs or peptide-
coated Au NPs.283 Both TNF and other pro-inflammatory cytokines were p oduced by 
the macrophages after treatment with the peptide coated Au NPs, but not the citrate 
coated Au NPs. 
Figure 4.8 shows the effects of pre-incubation of RAW264.7 macrophages with 
aurothiomalate, auranofin or Au NPs, on TNF production by the cells after treatment 
with 0.1 µg/mL LPS. Pre-incubation with 2.5 µM aurothi malate resulted in no 
significant effects on the amounts of TNF produced. In contrast, when the concentration 
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of aurothiomalate was increased to 60 µM, a statistically insignificant (P > 0.05) 
stimulatory effect was observed.  
 
Figure 4.8: Effect of pre-incubation with gold compounds or AuNPs on LPS-induced TNF production 
by RAW264.7 macrophages. Cells were pre-incubated with the gold compounds or Au NPs at 37 °C 
under an atmosphere of 5% CO2 for 4 h, and then 0.1 µg/mL LPS added and incubation continued under 
the same conditions for a further 20 h. TNF was measured by ELISA. The error bars represent one 
standard deviation calculated from triplicate samples. * = statistically significant (P < 0.05) compared to 
corresponding vehicle; *** = statistically significant (P < 0.001) compared to corresponding vehicle; ns = 
not significant compared to corresponding vehicle (P > 0.05). 
This contradicts some reports in the literature that showed aurothiomalate has a 
small inhibitory effect on LPS-induced TNF production in human PBMCs.118,284,285 A 
possible explanation for this difference could be that the experiments described in this 
thesis were performed using a murine macrophage cell lin , as opposed to PBMCs 
isolated directly from humans118,285 or mice.284 It could also arise from differences in 
methodology, such as the exclusion118,285 or dramatic shortening (< 5 min compared to 4 
h in this thesis)284 of a pre-incubation period for the studied compounds, use of a lower 
LPS concentration (maximum of 0.02 µg/mL compared to 0.1 µg/mL in this 
thesis),118,284,285 or lower aurothiomalate concentrations (maximum of ~27µM compared 
In
co
m
ple
te
 M
ed
ium
M
 A
ur
ot
hio
m
ala
te
µ
2.
5 
M
 A
ur
ot
hio
m
ala
te
µ
60
 
Au
ra
no
fin
 V
eh
icl
e
M
 A
ur
an
of
in
µ
2.
5 Au
 N
Ps
 V
eh
icl
e
M
 A
u 
NP
s
µ
2.
5 
M
 A
u 
NP
s
µ
60
 
0
40
80
120
160
ns
ns
***
ns
**
*
[T
N
F
] 
ng
/m
L
 
Chapter 4 – Inflammation Mediators 136 
to 60 µM in this thesis).118,284,285 It should also be noted even within the literature th re 
are reports that suggest aurothiomalate has no effect on production of TNF. For 
examples, one study that also investigated human PBMCs (from RA patients) showed 
that aurothiomalate does not alter LPS-stimulated TNF production,117 whilst another 
reported that the compound does not affect TNF mRNA levels in LPS-stimulated 
murine macrophages.255  
Figure 4.8 also shows that pre-treatment of the macrophages with 2.5 µM 
auranofin resulted in a significant decrease (~50%, P < 0.001) in TNF production 
compared to the auranofin vehicle. This is consistent with the outcomes from a previous 
study that showed there was inhibition of LPS-induced TNF formation in PBMCs 
following treatment with auranofin.255,284 It should also be noted that Figure 4.8 
indicates that pre-treatment using the 1% DMSO auranofin vehicle may also have a 
significant (P < 0.05) inhibitory effect on TNF formation. A similar effect of DMSO 
upon TNF formation has previously been demonstrated for murine alveolar and 
peritoneal macrophages.286 
Pre-treatment using either 2.5 or 60 µM Au NPs result d in small decreases in 
LPS-induced TNF production that were statistically significant (P < 0.05) when 
compared to the amount of cytokine produced when th pre-treatment was performed 
using the Au NPs vehicle. These results are generally consistent with those reported by 
Ma et. al,203 who indicated that Au NPs had no effect on LPS-induced TNF production. 
In contrast, pre-treatment with Au NPs coated with poly-N-vinylpyrrolidone was shown 
to enhance TNF production by RAW264.7 cells subsequently incubated with LPS.287 
This once again highlights the importance that the composition of the nanoparticle shell 
may play in determining overall biological activity. The absence of a significant effect 
on LPS-induced TNF formation follows on from result presented earlier in this chapter, 
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which revealed an inability of Au NPs to affect thelevels of the inflammatory mediators 
NO and ROS. 
4.5 Effects on Production of Interleukin-10 
The results presented earlier in this chapter showed that pre-treatment of 
RAW264.7 macrophages with Au NPs does not have a significant effect on the levels of 
the pro-inflammatory mediators NO, ROS and TNF. It was therefore decided to 
investigate whether Au NPs might produce anti-inflammatory activity by instead 
upregulating anti-inflammatory cytokines. The cytokine chosen for these experiments 
was IL-10, which has been shown to suppress production of the pro-inflammatory 
mediators IL-1α, IL-6 and IL-8,288 as well as TNF and NO in macrophages.289 Further 
interest in IL-10 stems from previous studies using RAW264.7 cells that showed these 
cells can be converted into one of two subtypes. These are the pro-inflammatory M1 
and anti-inflammatory M2 subtypes of macrophages.18 Therefore, if gold compounds or 
Au NPs were found to lead to increased anti-inflammatory activity, this might be a 
result of conversion of the macrophages to the M2 subtype. 
Figure 4.9 shows the amounts of IL-10 produced by RAW264.7 cells exposed 
to aurothiomalate, auranofin, Au NPs or LPS. The figure shows that when the cells were 
treated with either of the gold compounds or Au NPs, IL-10 production was below the 
detection limit for the assay. This result implies that none of the above gold reagents 
promote an anti-inflammatory process involving IL-10 as a means of biological action. 
In the case of auranofin in particular, this result is not unexpected considering the 
results presented earlier in this chapter where the gold compound was shown to have a 
significant ability to suppress production of the pro-inflammatory mediators NO and 
ROS in LPS-stimulated cells; i.e. auranofin’s mechanism of action involves suppression 
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of pro-inflammatory responses rather than inducing anti-inflammatory responses. 
Aurothiomalate is likely to behave similarly to aurnofin due to similarities in their 
uptake mechanisms and metabolites noted in Section 1.2.  
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Figure 4.9: Effect of gold compounds, Au NPs, or LPS on IL-10 production by RAW264.7 macrophages. 
Cells were treated at 37 °C under an atmosphere of 5% CO2 for 24 h, and IL-10 produced then measured 
by ELISA. The error bars represent one standard deviation calculated from triplicate samples.  = below 
detection limit; * = statistically significant (P < 0.05) compared to incomplete medium; *** = statistically 
significant (P < 0.001) compared to incomplete medium. 
To date there has only been one report in the literature that has discussed the 
effects of aurothiomalate on IL-10 expression. This study showed that treatment with 
this gold compound led to an increase in the total number of PBMCs that had expressed 
IL-10, but also found that this did not result in aincrease in supernatant IL-10 
concentration.290 This is broadly consistent with the results presented in Figure 4.9, as 
no change in supernatant IL-10 was detected in the current study. Similarly, there is 
little literature available regarding the effect of Au NPs on IL-10 production. However, 
one study investigated how 8.8 nm diameter Au NPs prepared in citrate buffer, and Au 
NPs with a mixture of peptide and organic capping agents, affected cytokine production 
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by PBMCs.291 Treatment of the cells with the citrate-stabilised Au NPs led to an 
increase in IL-10 production, whilst the second type of Au NPs had no noticeable 
effect.291 It should be noted that the observed increase in IL-10 levels elicited by the 
citrate-stabilised Au NPs was accompanied by an increase in production of IL-2 and 
interferon-γ. Therefore the observed increase in IL-10 production by the cells may have 
been a regulatory response to the increase in producti n of these two pro-inflammatory 
cytokines. 
The most significant result presented in Figure 4.9 is that treatment of the 
macrophages with LPS, at both 0.1 and 1 µg/mL, resulted in expression of large 
amounts of IL-10. This is most likely a response to LPS inducing the production of pro-
inflammatory mediators such as TNF. It has previously been shown that after 12 – 24 h 
treatment with LPS, bone marrow derived macrophages upregulate IL-10 to suppress 
formation of the pro-inflammatory cytokine IL-1β.292 Since IL-10 is an anti-
inflammatory cytokine, it might be expected that ani-RA drugs could further promote 
its production in cells. To test this hypothesis, a series of experiments were performed 
to see whether pre-treatment with any of the gold cmpounds or Au NPs led to changes 
in the amount of LPS-induced IL-10 produced by the macrophages. Figure 4.10 shows 
the results of these studies. 
Figure 4.10 shows that pre-treatment of the macrophages with the auranofin 
vehicle resulted in a significant decrease (P < 0.01) in IL-10 levels when compared to 
pre-treatment of the cells with incomplete medium. Additionally, pre-treatment with 2.5 
µM auranofin also resulted in a large decrease in IL-10 levels. Whilst it may appear that 
the effect observed for this pre-treatment may be du largely to the effects of the 
DMSO, it should be noted that this decrease was significant (P < 0.01) when compared 
to the auranofin vehicle. This decrease may be explained by considering results 
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presented earlier in this chapter, which showed that pre-treatment with either auranofin 
or the auranofin vehicle led to a reduction in the amount of LPS-induced TNF produced 
by the macrophages. Therefore, the decrease in IL-10 levels may not be a direct result 
of inhibition by either DMSO or auranofin, but may instead be a consequence of 
reduced levels of production of TNF.  
In
co
m
ple
te
 M
ed
ium
M
 A
ur
ot
hio
m
ala
te
µ
2.
5 
M
 A
ur
ot
hio
m
ala
te
µ
60
 
Au
ra
no
fin
 V
eh
icl
e
M
 A
ur
an
of
in
µ
2.
5 Au
 N
Ps
 V
eh
icl
e
M
 A
u 
NP
s
µ
2.
5 
M
 A
u 
NP
s
µ
60
 
0
200
400
600
800
**[
IL
-1
0]
 p
g/
m
L ns ns
nsns
*
**
 
Figure 4.10: Effect of pre-incubation with gold compounds or Au NPs on LPS-induced IL-10 production 
by RAW264.7 macrophages. Cells were pre-incubated with the gold compounds or Au NPs under 37 °C 
under an atmosphere of 5% CO2 for 4 h, and then 0.1 µg/mL LPS added and incubation continued at the 
same conditions for a further 20 h. IL-10 was measured by ELISA. The error bars represent one standard 
deviation calculated from triplicate samples. * = stati tically significant (P < 0.05) compared to 
corresponding vehicle; ** = statistically significant (P < 0.01) compared to corresponding vehicle; ns = 
not significant compared to corresponding vehicle (P > 0.05). 
To test this hypothesis, the data presented in Figure 4.8 and Figure 4.10 that 
were obtained using aurothiomalate can be considered. Figure 4.10 shows that pre-
treatment of the macrophages with 60 µM aurothiomalate resulted in a small, but 
statistically significant decrease in the amount of IL-10 produced. For the explanation 
proposed above to be true, a decrease in production of TNF would also be expected. 
However, Figure 4.8 shows that the opposite result was in fact observed. This is instead 
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consistent with the notion that aurothiomalate inhibits the auto-regulatory production of 
IL-10, thereby causing the observed increase in amount f TNF produced relative to 
incomplete medium. Figure 4.10 shows that treatment of the macrophages with Au NPs 
did not cause any significant change to the amount f IL-10 produced compared to the 
Au NPs vehicle, again indicating a lack of interaction between the Au NPs and the 
macrophages. 
4.6 Studies Using Commercial Au NPs 
The results described in the previous sections showed that the citrate-stabilised 
Au NPs prepared as part of this research project generally failed to have a significant 
effect on the production of various cytokines associated with inflammation, by LPS-
stimulated macrophages. In some instances, these results are consistent with those 
presented in the literature, while in others there was significant disagreement. A 
possible explanation for these differences in behaviour is variation in the size or 
chemical composition of the Au NPs being used. To test his hypothesis, some of the 
assays were repeated using commercial Au NPs with different sizes (2 nm, 20 nm and 
100 nm) or stabilised in different media (PBS or cit ate buffer). The ability of these 
different commercial Au NPs to affect the formation of NO and ROS in LPS-stimulated 
macrophages was compared to that of the citrate-stabili ed Au NPs synthesised as part 
of this project, as well as auranofin. The latter was also included in these experiments as 
a positive control, as it was shown earlier in this chapter to attenuate LPS-induced 
formation of both NO and ROS. 
4.6.1 Effects on Production of Nitric Oxide 
The effects of treating RAW264.7 cells directly with he various types of 
commercial Au NPs on nitrite production are shown in Figure 4.11. Addition of LPS 
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showed once again that the cells were functioning as expected by producing significant 
amounts of NO2‾. None of the different types of commercial Au NPs had a significant 
ability to stimulate production of NO2‾, with the exception of the citrate-buffered Au 
NPs obtained from Sigma, which resulted in formation of approximately one third the 
amount of NO2‾ as that elicited by LPS. This was a surprising result as Figure 4.1 
showed that the citrate-stabilised Au NPs prepared for this project did not show this 
ability. One key reason for the observed difference is that the citrate-buffered Au NPs 
purchased from Sigma are stated to contain a proprietary surfactant as a stabiliser, 
which may affect their biological activity. 
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Figure 4.11: Effect of addition of commercial Au NPs on nitrite production by RAW264.7 macrophages. 
Cells were incubated with the Au NPs at 37 °C under an atmosphere of 5% CO2 for 24 h, and nitrite 
concentration then measured by the Griess assay. All Au NP treatment solutions contained 40 µM gold, 
with the exception of the 2 nm (BBI) Au NPs, which ontained 9 µM gold. The error bars represent one 
standard deviation calculated from triplicate plates. *** = statistically significant (P < 0.001) compared to 
corresponding vehicle; ns = not significant compared to corresponding vehicle (P > 0.05). 
Figure 4.12 shows the effect on production of NO2‾ by LPS-stimulated 
RAW264.7 macrophages, of pre-incubation with various commercial Au NPs, as well 
as auranofin and the Au NPs prepared for this project. Treatment with 2.5 µM auranofin 
resulted in a significant decrease in NO2‾ production, as observed previously (Figure 
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4.2). However, none of the commercial Au NPs resulted in a statistically significant 
decrease in the amount of NO2‾ produced compared to that elicited by the Au NPs 
vehicle, although the 2 nm BBI Au NPs did produce a 20% reduction. This indicates 
that regardless of the size or the identity of the stabilising shell, all of the Au NPs were 
largely ineffectual in altering the amount of LPS-induced NO2‾ produced. This 
included, once again, the citrate-stabilised Au NPs prepared for this project. It should be 
noted that despite producing an increase in basal cellular NO2‾ production, the citrate-
buffered Sigma Au NPs did not elicit a similar increase in NO2‾ with macrophages 
already stimulated with LPS. This suggests that the ability of LPS to increase nitrite 
production was more significant than that of these Au NPs. 
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Figure 4.12: Effect of pre-incubation with commercial Au NPs onLPS-induced nitrite production by 
RAW264.7 macrophages. Cells were pre-incubated withauranofin or Au NPs at 37 °C and under an 
atmosphere of 5% CO2 for 4 h, and then 0.1 µg/mL LPS added and incubation continued under the same 
conditions for a further 20 h. Nitrite concentration was measured by the Griess assay. All Au NP 
treatment solutions contained 40 µM gold, with the exception of 2 nm (BBI) Au NPs, which contained 9 
µM gold, and the Au NP solutions produced as part of this thesis, which contained 60 µM gold. The error 
bars represent one standard deviation calculated from t iplicate plates. ** = statistically significant (P < 
0.01) compared to corresponding vehicle; ns = not significant compared to corresponding vehicle. 
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4.6.2 Effects on Production of Reactive Oxygen Species 
After observing minimal effects of commercial Au NPs upon NO2‾ formation, it 
was of interest to see whether any of the nanoparticles would have an effect on ROS 
formation. Figure 4.13 shows the effect of treating macrophages with commercial Au 
NPs upon ROS formation. Addition of LPS induced formation of large amounts of 
ROS, with no statistically significant difference between the amounts produced in 
response to the two treatment concentrations used. None of the commercial Au NP 
products induced formation of significant amount of ROS, including the citrate-buffered 
Au NPs obtained from Sigma, which were shown in the previous section to stimulate 
production of NO. This suggests that these Au NPs were stimulating formation of NO 
by a pathway specific to NO signalling. 
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Figure 4.13: Effects of addition of commercial Au NPs on ROS production by RAW264.7 macrophages. 
Cells were incubated with the Au NPs at 37 °C under an atmosphere of 5% CO2 for 24 h. ROS was 
measured by the DCF assay and presented as MFI at 515 nm. All Au NP treatment solutions contained 40 
µM gold, with the exception of the 2 nm (BBI) Au NPs, which contained 9 µM gold. The error bars 
represent one standard deviation calculated from triplicate samples. ** = statistically significant (P < 
0.01) compared to incomplete medium; *** = statistically significant (P < 0.001) compared to incomplete 
medium; ns = not significant compared to corresponding vehicle (P > 0.05). 
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The effects of the commercial Au NPs on ROS production in LPS-stimulated 
macrophages are shown in Figure 4.14. Treatment with 2.5 µM auranofin led to 
powerful inhibition of LPS-induced ROS formation, as observed previously (Figure 
4.6). In contrast, none of the commercial Au NPs produce  statistically significant 
changes in the amount of LPS-induced ROS formation, as was also the case for the Au 
NPs synthesised for this project. It is worth noting that addition of the citrate-buffered 
Au NPs obtained from Sigma, and the Au NPs synthesised for this project, had similar 
effects on the amount of ROS produced by the macrophages. In both cases the amount 
of ROS detected was higher than that observed when t  Au NPs vehicle was used. 
However, in view of the variability inherent with experiments of this type, it was not 
possible to determine whether or not this was a real effect with certainty at this stage. 
Overall, the results presented here, along with those in Section 4.6.1 suggest that 
Au NPs do not have a significant effect on the production of either NO or ROS by 
macrophages. Addition of PBS-stabilised Au NPs caused no changes to either NO or 
ROS expression, both in macrophages that had been tr ated with LPS and those that had 
not. In contrast, treatment with the commercial citrate-stabilised Au NPs caused an 
increase in NO2‾ levels for macrophages that had not been treated with LPS. The 20 and 
100 nm diameter BBI Au NPs also caused no changes to NO or ROS expression under 
any circumstances. However, the 2 nm BBI Au NPs result d in a small decrease in LPS-
induced NO production, suggesting that these smaller siz  nanoparticles may have been 
able to interact with the macrophages to a greater extent. This has been suggested by 
other studies, and is usually correlated with increases in other toxicity markers.202,278 
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Figure 4.14: Effect of pre-incubation with auranofin or commercial Au NPs on LPS-induced ROS 
production by RAW264.7 macrophages. Cells were pre-incubated with auranofin or Au NPs at 37 °C 
under an atmosphere of 5% CO2 for 4 h, and then 0.1 µg/mL LPS added and incubation continued under 
the same conditions for a further 20 h. ROS was measur d by the DCF assay and presented as normalised 
MFI values at 515 nm, relative to incomplete medium. All Au NP treatment solutions contained 40 µM 
gold, with the exception of the 2 nm (BBI) Au NPs, which contained 9 µM gold and the Au NPs prepared 
for this thesis, which contained 60 µM gold. The error bars represent one standard deviation calculated 
from triplicate samples. * = statistically significant (P < 0.05) compared to corresponding vehicle; *** = 
statistically significant (P < 0.001) compared to corresponding vehicle; ns = not significant compared to 
corresponding vehicle (P > 0.05). 
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Chapter 5:  
Mass Spectrometric Investigation of the 
Binding of Gold Complexes and Gold 
Nanoparticles to Thioredoxin Reductase 
 
 
This chapter compares the results of binding studies involving either anti-arthritic 
gold(I) compounds or gold nanoparticles, and the redox enzyme thioredoxin reductase. 
These binding studies were initially performed using electrospray ionisation mass 
spectrometry and a mutant form of human thioredoxin reductase. The enzyme was 
obtained by transforming the corresponding mutant ge e into the bacterium Escherichia 
coli, inducing overexpression of the protein, and subsequently purifying it using column 
chromatography. Additional experiments were performed using a commercial sample of 
wild type rat thioredoxin reductase. Selected results presented in this chapter were 
published in: James, L. R. A; et al., J  Inorg. Biochem., 2015, 142, 28-38. 
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5.1 Introduction 
Interest in studying the inhibition of the homodimeric redox enzyme thioredoxin 
reductase (TrxR) using gold compounds stems from research that demonstrated the 
potential of the thioredoxin system to serve as a drug target.174,293 The thioredoxin 
system is essential for normal cellular function, however both Trx and TrxR are 
overexpressed in various types of cancer cells,154–159 as well as synovial cells160 and the 
synovial fluid161 of patients with RA. The presence of an active sit elenocysteine 
residue within the sequence of TrxR makes it an attractive target for compounds 
containing metals such as gold, which show higher levels of reactivity and binding 
selectivity for selenols compared to thiols.162,186 Further interest in TrxR is due to its 
involvement in the redox activity of RAW264.7 macrophages.294–296 Therefore, it was 
of interest to investigate the binding of gold(I) compounds used in the treatment of RA 
to this enzyme, as its inhibition might form part of their mechanism of action.  
Whilst a number of studies have examined the inhibition of TrxR by various 
types of gold compounds, few have provided specific nformation about the 
gold/protein interaction, including how many of the original ligands bound to the metal 
complex are retained after binding. ESI mass spectra are well suited for providing this 
information, so solutions containing different ratios of gold compound or Au NPs, and 
TrxR were analysed in this work. As relatively large quantities of enzyme were required 
to perform these studies, it was decided to obtain the protein by over-expressing it in E.
coli. Since expression of selenocysteine-containing proteins require species specific 
translation machinery, it is difficult to express ma malian selenoproteins in E. coli. 
Therefore, a plasmid containing a mutant form of human TrxR (hTrxR) was selected for 
transformation into E. coli. This mutant form of hTrxR  had been previously used to 
investigate the binding of platinum compounds to TrxR,169 and was kindly provided by 
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Yan-Chung Lo and Andrew Wang (Academia Sinica, Taiwan). The mutant plasmid had 
the selenocysteine codon replaced by that for cysteine, thereby enabling a form of the 
enzyme to be obtained whose active site largely retain d its structure and function.297 
5.2 Characterisation of Human Thioredoxin Reductase 
After initial collection and chromatographic separation of hTrxR from the 
mixture of proteins produced by E. coli, the purity of the collected protein fractions was 
investigated using SDS-PAGE. Figure 5.1 shows the image of an SDS-polyacrylamide 
gel containing purified hTrxR fractions, and a marker lane to indicate the approximate 
molecular mass of the contents of the collected fractions. The majority of fractions in 
the gel show one major component with a molecular mss between 50 and 60 kDa, 
along with a lower abundance component with a molecular mass of ~120 kDa. 
Calculation of the expected molecular mass of hTrxR from its protein sequence 
(Appendix C.1.1) gave a value of 56288.3 Da per monomer, after cleavage of the 
initiating methionine residue.228 It was therefore concluded that the fractions in th s gel 
most likely contain pure hTrxR, with the lower abunda ce band corresponding to 
dimeric hTrxR that did not separate under the denaturing conditions of SDS-PAGE. 
Lanes 22 and 23 in Figure 5.1 also appear to contain a third band corresponding to 
protein molecules with a molecular mass between 60 and 80 kDa. Owing to their lower 
purity, these fractions and those collected after them were not used in any further 
experiments. 
 
Chapter 5 – Thioredoxin Reductase Binding 150 
M 
S
iz
e
 (
k
D
a
) 
10 
15 
20 
30 
40 
50 
60 
80 
110 
160 
260 
1
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23
Lane 
 
Figure 5.1: SDS-PAGE of human TrxR fractions after chromatographic purification. Each lane is 
numbered; M stands for the marker lane. 
After confirming the purity of TrxR by SDS-PAGE, the protein was dialysed 
into solutions containing ammonium acetate for analysis by ESI-MS. Figure 5.2 shows 
the spectra of hTrxR obtained under different conditions of pH and ammonium acetate 
concentration. The spectrum in Figure 5.2 a) was obtained using a solution of hTrxR in 
100 mM ammonium acetate, 5% acetic acid, pH 3.7. It shows several distinct envelopes 
of peaks, with the most abundant being in the range m/z 2400 – 3800. Each peak 
corresponds to a different charge state of the protein, with some of the most prominent 
charge states labelled in the figure. Peaks with an m/z ≤ 3200 are relatively narrow, and 
arise from the monomeric form of the protein. For example, the peak at m/z 2682 
corresponds to [TrxR + 23H]23+. The molecular mass of the protein determined from 
these peaks is 56305 Da, which is close to the calculated molecular mass of 56288.3 Da 
for one hTrxR monomer. This is good agreement given the errors associated with 
molecular mass determination under these conditions.298 
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Figure 5.2: Positive ion electrospray ionisation mass spectra of 5 µM TrxR in: a) 100 mM ammonium 
acetate and 5% acetic acid, pH 3.7 and b) 500 mM ammonium acetate, pH 7.2. M corresponds to a charge 
state arising from monomeric protein, D corresponds to a charge state arising from dimeric protein. 
The spectrum shown in Figure 5.2 b) was obtained using a solution of TrxR in 
500 mM ammonium acetate, pH 7.2, and is very different to that presented in Figure 
5.2 a). It instead features a small number of relatively broad peaks in the range, m/z 
4800 – 5600. These are attributable to the dimeric form of hTrxR, with a molecular 
mass of 114998 Da obtained from the spectrum. For example, the peak at ~m/z 4999 
can be assigned to [2TrxR + 23H]23+. The molecular mass of 114998 Da derived from 
the dimeric protein from Figure 5.2 b) is more than twice that of the monomer, but is 
still within experimental error of the expected value.  
The above results show that solutions containing higher ammonium acetate 
concentrations favour formation of dimeric hTrxR, whilst those with lower ammonium 
acetate concentrations and acidic pH result in some dissociation to the monomer and 
unfolding of the protein. This is more than twice th  mass for the monomer but is within 
the error expected. The broad peaks in Figure 5.2 a) and b) at m/z > 3000 are from 
protein (or dimer) molecules that are folded. Hence, water molecules and salts are 
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included in the protein. As the measured mass is determined from the centre of the peak, 
these included water or salt molecules result in a mass measurement that is greater than 
expected for the native protein. 
Inspection of Figure 5.2 a) reveals the presence of separate envelopes of peaks 
arising from the monomeric and dimeric forms of TrxR. This suggests that separate 
populations of both types of protein molecules that were unfolded to varying extents 
were present in the solution.298 The observation of relatively narrow peaks attributa le 
to the monomeric form of the protein (width at half height ~2.5 Th) identified these 
conditions as being more suitable for binding studies involving metal complexes. This is 
because the difference in m/z for some charge states arising from free protein molecules 
and protein molecules with a single bound gold ion is ~10 Th. The broadness of peaks 
from the dimeric form of the enzyme made it difficult for separate peaks from free 
protein and metallated protein molecules to be resolv d in preliminary experiments. 
Therefore, reactions of gold compounds and hTrxR were carried out in 100 mM 
ammonium acetate where the protein was folded and pre ominantly a dimer, but 
analysis by ESI-MS was carried out after acidification of the mixture. This dissociated 
the dimer and resulted in sharper peaks in the spectra that enabled greater peak 
resolution to be obtained. 
Further attempts were made to optimise conditions towards a mass spectrum 
with sharper peaks. A range of conditions were tested, including dilution of the hTrxR 
to between 1 and 2 µM, as well as lowering the ammonium acetate concentration to 
between 10 and 30 mM. These conditions afforded the spectrum shown Figure 5.3 a), 
which only contained ions attributable to the monomeric form of hTrxR. 
Transformation of the spectrum in Figure 5.3 a) from a m/z scale to one with a mass 
scale afforded the spectrum shown in Figure 5.3 b). Three distinct peaks are present, 
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the most abundant of which is at 56304 Da, and is attributable to monomeric hTrxR. 
The second and third peaks at 56482 and 56562 Da corresp nd to hTrxR molecules 
with mass additions of ~178 and ~258 Da, respectively. The vertical red lines in the 
figure correspond to the calculated mass of hTrxR (56288 Da), as well as hTrxR + 178 
(56466 Da) and hTrxR + 258 (56546 Da). The spectrum re ained essentially 
unchanged when the protein was dialysed against 0.1% formic acid (Appendix C.1.2, 
Figure C.1), consistent with the two heavier hTrxR ions arising from covalently 
modified protein molecules, and not being attributale to contaminants bound 
electrostatically to the protein that survived the el ctrospray process.  
 
Figure 5.3: Positive ion electrospray ionisation mass spectra of 1.5 µM hTrxR in 23 mM ammonium 
acetate and 5% acetic acid. The data are represented in wo different ways: a) raw spectrum and b) the 
spectrum after transformation to a mass scale. The red lines represent the expected masses of each peak, 
which are: A = 56288 mass units; B = 56466 mass units; C = 56546 mass units. 
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It was initially thought that the peak corresponding to hTrxR plus an additional 
178 Da might be from protein molecules that had not been completely cleaved from the 
initiating N-formyl-methionine reside (residue mass 169 Da). However, the mass 
addition observed was slightly too large to be consistent with this explanation. 
Examination of the literature revealed that the twoadditional peaks were likely to be the 
result of a phosphogluconoylation reaction occurring at the amine group of the N-
terminus.299 Geoghegan et al. showed that addition of 6-phosphoglucono-1,5-lactone to 
the N-terminus of ~100 amino acid long fragments of human β-adrenergic receptor 
kinase, expressed in E. coli,  resulted in formation of protein adducts that were heavier 
than the native protein by 258 Da. Furthermore, if the species were dephosphorylated by 
a cellular phosphatase then the masses of the adducte  moieties decreased to 178 Da. 
The authors concluded that the presence of an enginered N-terminal hexa-histidyl tag 
activated the terminal amino group of the proteins to this particular transformation. This 
tag is commonly used when expressing recombinant proteins,300 as it allows a very 
simple purification procedure to be employed in which the required protein is eluted 
through a column containing a divalent metal ion, typically nickel, cobalt or zinc.300 The 
form of hTrxR expressed for this thesis contained an N-terminal hexa-histidyl tag, and 
as such it is likely the observed mass additions are due to the modifications described 
above. 
 To confirm that the two heavier ions were not a result of a contaminating protein 
or proteins with a similar size to hTrxR, a purified nzyme fraction was subjected to 
tryptic digestion to produce a range of peptide fragments, which were then analysed by 
gel electrophoresis followed by LC/MS to separate th  various peptides.* The peptides 
detected by the mass spectrometer were compared to a protein database using the search 
                                                 
* Performed by Dr. Matt Padula (University of Technology, Sydney) 
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engine Mascot, and the proteins present subsequently identified. The results of this 
analysis (Appendix C.1.3, Figure C.2) showed that only peptides belonging to the 
cytoplasmic isoform of human thioredoxin reductase were present in the sample. 
 Having confirmed that the only protein present in he purified hTrxR fractions 
was hTrxR, it is highly likely that the higher mass species in Figure 5.3 were the result 
of phosphogluconoylation. As such, hTrxR containing the gluconoyl group was termed 
G-hTrxR, and hTrxR containing the phosphogluconoyl group was termed PG-hTrxR. A 
mechanism for the addition of these groups is depict d in Figure 5.4. Owing to the 
difficulty associated with trying to separate three v ry similar forms of the same 
enzyme, or removing the gluconoyl group, the protein fractions were used without any 
further purification for gold binding studies.  
 
Figure 5.4: Schematic illustration of N-terminal addition of 6-phosphoglucono-1,5-lactone to hTrxR. 
Adapted from Analytical Biochemistry, 1999, vol. 267 (1), p. 169-184 with permission from Elsevier.299 
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5.3 Gold-Binding Experiments 
The results of binding studies performed using ESI-M , and solutions 
containing different gold compounds or gold nanoparticles and hTrxR are presented in 
this section. All spectra shown here were transformed to a mass scale to facilitate 
identification of protein adducts. The reactions were performed by mixing the required 
quantities of stock metal and protein solutions in ammonium acetate solution, and 
allowing the mixtures to stand on ice for approximately 4 h, thereby allowing sufficient 
time for reaction to occur. The reactions were performed under conditions where the 
protein was predominantly in its dimeric form. Aceti  acid was then added to the 
solutions immediately prior to obtaining ESI mass spectra, to ensure the proteins were 
positively charged, and that peaks in the spectra were relatively sharp and well resolved. 
Initial experiments were performed using solutions containing different ratios of 
aurothiomalate and hTrxrR. The ESI mass spectra of these solutions are presented in 
Figure 5.5. 
The spectrum in Figure 5.5 a) shows hTrxR only, with peak A assigned to 
monomeric hTrxR, peak B assigned to hTrxR containing a gluconoyl group (G-hTrxR), 
and peak C to hTrxR containing a phosphogluconoyl group (PG-hTrxR). Figure 5.5 b) 
shows the spectrum of a solution containing a 1:1 ratio of aurothiomalate : hTrxrR. 
Whilst some new peaks were observed, that arising from hTrxR remained the dominant 
feature. Peak B, which was assigned to G-hTrxR was now broader, most likely as a 
result of overlap of ions from G-hTrxR with those from hTrxR + Au, where a gold ion 
had become bound to the native protein. As these two species are close in molecular 
mass (hTrxR plus 178 or 197), and the resolution of the mass spectrometer under these 
conditions was insufficient to resolve these ions, a ingle broadened peak was observed. 
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Figure 5.5: Positive ion ESI mass spectra of solutions containing different ratios of aurothiomalate and 
hTrxR, after transformation to a mass scale. ) gold : hTrxR = 0:1; b) gold : hTrxR = 1:1; c) gold : hTrxR 
= 3:1; and d) gold : hTrxR = 5:1. In each case, solutions containing aurothiomalate and hTrxR were 
allowed to react for 4 h on ice before the spectrum was obtained. For ESI-MS, each sample contained 1.1 
µM hTrxR in 5% acetic acid and 26 mM ammonium acetate. 
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This peak has therefore also been labelled with D, to signify the presence of ions from 
hTrxR + Au. Another new peak in Figure 5.5 b) is that at 56686 Da (peak E), which 
has been assigned to hTrxR molecules with two bound Au+ ions. 
The ESI mass spectra of solutions containing 3:1 and 5:1 ratios of 
aurothiomalate : hTrxR (Figure 5.5 c and d, respectively) again showed peaks from all 
three forms of the protein, as well as hTrxR + Au, with similar relative abundances to 
those in Figure 5.5 b). However, several new peaks were now present that 
corresponded to protein complexes containing up to eight bound Au+ ions. Only in one 
instance did any of these peaks correspond to protein adducts containing thiomalate 
moieties along with gold ions (peak H in Figure 5.5 d). This suggests that the binding 
of gold to the protein is typically accompanied by the loss of the original ligands bound 
to the metal complex and/or the gold-aurothiomalate bond is readily broken under the 
mass spectrometry conditions used. The spectrum of the solution containing a 5:1 ratio 
of aurothiomalate : hTrxR was noisier than any of the other spectra, particularly in the 
region between 56300 and 56700 Da. This is most likely due to the formation of protein 
adducts containing variable numbers of sodium ions, wing to the presence of a large 
excess of sodium aurothiomalate in solution. The prsence of sodium ions has been 
noted previously to result in poorer quality ESI mass spectra of protein samples.301 
Figure 5.5 d) shows that despite the large excess of gold complex pr sent, peaks from 
free protein remained the most abundant. This observation, along with that of peaks of 
low to medium abundance from protein adducts containing up to eight bound gold ions, 
suggests that the protein contains numerous low affinity binding sites for this metal ion.  
The above result is consistent with a previous MALDI-MS study that showed 
between five to ten moieties of gold(I) and gold(III) compounds can bind to mammalian 
TrxR.187 Some of the most likely positions for gold binding are the two cysteine 
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residues present at each of the N-terminal and C-terminal active sites. There are also an 
additional ten cysteine residues within the protein sequence (Appendix C.1.1), although 
many of these are likely to be present as disulfide bonds maintaining the protein’s 
tertiary structure, and as such, are inaccessible for gold binding. Some lower affinity 
binding sites may be histidine residues, as it has been previously shown by ESI-MS that 
gold may weakly interact with this amino acid.88 hTrxR has a total of nine histidine 
residues, with the mutant form used in these investigations having an additional six 
added to facilitate purification. As such, a significant number of high and low affinity 
sites are available for gold binding. 
It should be noted that none of the spectra in Figure 5.5 provide evidence 
concerning the location of the gold binding sites on the protein. Additional experiments, 
involving the use of reagents that effectively block specific amino acids from binding to 
metallodrugs, or proteomics techniques, would be requi d to provide that information 
for the gold/protein adducts observed in Figure 5.5, as well as all other figures 
presenting mass spectral binding data shown later in this chapter. These experiments 
were not performed owing to time limitations. 
 ESI mass spectra of solutions containing different atios of aurothioglucose and 
hTrxR are shown in Figure 5.6. The spectrum of a solution containing a 1:1 ratio of 
aurothioglucose : hTrxR (Figure 5.6 b) is very similar to that of a solution containing 
the protein only (Figure 5.6 a). However, some broadening and increase in abundance 
of peak B was observed, consistent with formation of pr tein complexes with one Au+ 
ion bound. In addition, Figure 5.6 b) shows a peak with low abundance assigned to 
protein molecules with two Au+ ions bound (peak E). Increasing the ratio of 
aurothioglucose : hTrxR to 3:1 (Figure 5.6 c) resulted in an increase in abundance of  
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Figure 5.6: Positive ion ESI mass spectra of solutions containing different ratios of aurothioglucose and 
hTrxR, after transformation to a mass scale. ) gold : hTrxR = 0:1; b) gold : hTrxR = 1:1; c) gold : hTrxR 
= 3:1; and d) gold : hTrxR = 5:1. In each case, solutions containing aurothioglucose and hTrxR were 
allowed to react for 4 h on ice before the spectrum was obtained. For ESI-MS, each sample contained 1.1 
µM hTrxR in 5% acetic acid and 20 mM ammonium acetate. 
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the latter peak, as well as a new peak from protein adducts in which hTrxR is bound to 
three Au+ ions (peak F). When the ratio of gold complex : protein was increased to 5:1, 
the resulting spectrum (Figure 5.6 d) showed a number of additional peaks with low (< 
20%) relative abundance, corresponding to hTrxR molecules with four, six and seven 
Au+ ions bound. The peaks corresponding to protein molecules with one and two Au+ 
ions bound increased in abundance again, but free hTrxR remained the most abundant 
component of the spectrum. 
Making definitive assignments for some of the peaks in Figure 5.6 was difficult, 
owing to the similar molecular weights of thioglucose (195) and a single gold atom 
(197). For example, peak E in Figure 5.6 c) (56700 Da) could be assigned to hTrxR 
molecules with two bare gold atoms bound, protein molecules containing a single 
aurothioglucose moiety, or a mixture of both types of adducts. In contrast, the spectra of 
solutions containing different ratios of aurothiomalate and hTrxR (Figure 5.5) 
contained many peaks that could be unambiguously assigned to protein adducts 
containing different numbers of bound gold atoms only. Since the bonds between gold 
and sulfur in aurothiomalate and aurothioglucose would be expected to be similar in 
strength, it is reasonable to expect that coordinatio  of aurothioglucose to TrxR would 
also occur concomitantly with cleavage of Au–S bonds, and displacement of the 
original ligands bound to the metal ion. 
The results of mass spectrometric experiments performed using solutions 
containing aurothiosulfate and hTrxR are shown in F gure 5.7. The spectrum of a 
solution containing a 1:1 ratio of aurothiosulfate : hTrxR (Figure 5.7 b) shows that the 
abundance of peak B had increased significantly, compared to what was observed in the 
spectrum of hTrxR alone (Figure 5.7 a). This was most likely due to a greater 
proportion of the protein binding to a single Au+ ion, than what was observed in spectra 
 
Chapter 5 – Thioredoxin Reductase Binding 162 
of the corresponding solutions containing a 1:1 ratio of either aurothioglucose or 
aurothiomalate, and hTrxR, presented earlier in this c apter. The observation of peaks 
in Figure 5.7 b) from protein molecules with two and three Au+ ions bound provides 
further support for the hypothesis that aurothiosulfate more effectively transfers gold 
ions to hTrxR than both aurothioglucose and aurothiomalate.  
 
Figure 5.7: Positive ion ESI mass spectra of solutions containing different ratios of aurothiosulfate and 
hTrxR, after transformation to a mass scale. ) gold : hTrxR = 0:1; b) gold : hTrxR = 1:1; and c) gold : 
hTrxR = 3:1. In each case, solutions containing aurothiosulfate and hTrxR were allowed to react for 4 h
on ice before the spectrum was obtained. For ESI-MS, each sample contained 1.1 µM hTrxR in 5% acetic 
acid and 20 mM ammonium acetate. 
56400 56600 56800 57000 57200
Mass Units
57400 57600 5780056200
100
0
50
100
0
50
100
0
50
R
el
at
iv
e
A
bu
nd
an
ce
 (
%
)
a)
b)
c)
A
B
C
A: hTrxR
B: G-hTrxR
C: PG-hTrxR
A
C
E
A
G
F
E
H
A: hTrxR
B: G-hTrxR
C: PG-hTrxR
D: hTrxR + Au
E: hTrxR + 2 Au
F: hTrxR + 3 Au
A: hTrxR
B: G-hTrxR
C: PG-hTrxR
D: hTrxR + Au
E: hTrxR + 2 Au
F: hTrxR + 3 Au
G: hTrxR + 4 Au
H: hTrxR + 5 Au
I: hTrxR + 6 Au
J: hTrxR + 7 Au
BD
F
C
BD
J
I
 
Chapter 5 – Thioredoxin Reductase Binding 163 
When the ratio of aurothiosulfate : hTrxR was increas d to 3:1, the spectrum 
obtained (Figure 5.7 c) showed a number of substantial differences compared to that in 
Figure 5.7 b). To begin with, the peak assigned to free hTrxR was no longer the most 
abundant in the spectrum, with peaks from both hTrxR + 2 Au and hTrxR + 3 Au of 
markedly greater abundance. In addition, peaks of low to medium abundance 
corresponding to complexes of hTrxR with four to seven Au+ ions bound were also 
observed. 
When aurothiosulfate was reacted with hTrxR in a 5:1 ratio, a dramatic shift in 
the position of the entire envelope of ions in the conventional mass spectrum (i.e. before 
transformation to a mass scale) was observed, as shown in Figure 5.8. For both the 
spectrum of the solution containing only the protein, and that of the solution containing 
a 3:1 ratio of aurothiosulfate : hTrxR (Figure 5.8 a and b, respectively), peaks of high 
abundance (i.e relative abundance > 70%) were found between m/z 1300 – 1500. In 
contrast, the most abundant peaks in the spectrum of a s lution containing a 5:1 ratio of 
aurothiosulfate : hTrxR (Figure 5.8 c) were found between m/z 1700 and 1850. This 
shift to higher m/z was observed repeatedly for different solutions containing a 5:1 ratio 
of aurothiosulfate : hTrxR.  In addition, these spectra featured a lower signal-to-noise 
ratio than spectra containing lower ratios of aurothiosulfate : hTrxR, most likely due to 
the higher concentration of Na+ ions in solution from having dissolved greater quantities 
of sodium aurothiosulfate. Owing to these factors, it was not possible to accurately 
transform the spectrum to a mass scale. 
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Figure 5.8: Raw positive ion ESI mass spectra of solutions containing different ratios of aurothiosulfate 
and hTrxR. a) gold : hTrxR = 0:1; b) gold : hTrxR = 3:1; and c) gold : hTrxR = 5:1. In each case, 
solutions containing aurothiosulfate and hTrxR were allowed to react for 4 h on ice before the spectrum 
was obtained. For ESI-MS, each sample contained 1.1 µM hTrxR in 5% acetic acid and 20 mM 
ammonium acetate.  
It is worth noting that the majority of the ions inFigure 5.7 b) and c) 
correspond to protein molecules with one or more bound gold ions that did not retain 
any of their original thiosulfate ligands. This again suggests that binding of the gold 
complexes to hTrxR occurs concomitantly with ligand displacement. The observation of 
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contains many as yet unidentified amino acid side chains capable of binding to 
aurothiosulfate. 
Figure 5.9 shows the ESI mass spectra of solutions containing the 
chrysotherapy metabolite [Au(CN)2]‾, and hTrxR. Examination of the spectrum of the 
solution containing a 1:1 ratio of [Au(CN)2]‾ to hTrxR (Figure 5.9 b), reveals that 
unlike the other gold(I) compounds discussed earlier in this chapter, addition of 
[Au(CN)2]‾ resulted in very little change to the spectrum of the protein. Similarly, the 
only notable difference in the spectrum of the soluti n containing a 3:1 ratio of 
[Au(CN)2]‾ : hTrxR (Figure 5.9 c) was some broadening of peak B, which is again 
attributable to the presence of hTrxR molecules with one Au+ ion bound. However, the 
spectrum of the solution containing a 5:1 ratio of [Au(CN)2]‾ : hTrxR (Figure 5.9 d), 
showed more substantial changes. Three new peaks were observed, with one (labelled 
E) corresponding to the protein with one Au(CN) moiety bound, appearing as a 
shoulder on the high mass side of peak D. The other two types of peaks were of low 
relative abundance (~20% relative abundance), and were assigned to G-hTrxR with 
either one Au+ ion, or one Au(CN) moiety bound (peaks F and G, respectively). The 
reason for the lower amount of gold binding observed h re is likely related to the very 
high affinity of the cyanide ligands in [Au(CN)2]‾ for the metal ion.
57,90 Since the Au-
CN bonds do not undergo ligand exchange reactions as readily as the Au-S bonds in the 
three gold complexes discussed previously in this capter, it is far less likely for 
[Au(CN)2]‾ to bond to the cysteine residues in hTrxR. It is also worth noting that 
Figure 5.9 d) suggests that a significant proportion of the gold bound to the protein has 
retained one of its two original cyanide ligands. This is also likely to be a consequence 
of the greater stability of Au-CN linkages compared to Au-S bonds, which also enables 
the former to survive the ionisation conditions present in the mass spectrometer source. 
 
Chapter 5 – Thioredoxin Reductase Binding 166 
 
Figure 5.9: Positive ion ESI mass spectra of solutions containing different ratios of [Au(CN)2]‾ and 
hTrxR, after transformation to a mass scale. ) gold : hTrxR = 0:1; b) gold : hTrxR = 1:1; c) gold : hTrxR 
= 3:1; and d) gold : hTrxR = 5:1. In each case, solutions containing [Au(CN)2]‾ and hTrxR were allowed 
to react for 4 h on ice before the spectrum was obtained. For ESI-MS, each sample contained 1.1 µM 
hTrxR in 5% acetic acid and 10 mM ammonium acetate. 
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Figure 5.10 shows the mass spectra of solutions containing various ratios of 
auranofin and hTrxR. In the spectrum of the solution c ntaining a 1:1 ratio of auranofin 
: hTrxR (Figure 5.10 b), there is some evidence of broadening of peak B compared to 
the spectrum shown in Figure 5.10 a). This suggests that some of the protein molecules 
are now bound to a single Au+ ion. More convincing evidence of this is provided by the 
presence of peak E, attributable to ions from hTrxR with one AuPEt3 moiety bound. 
Increasing the ratio of auranofin to hTrxR to 3:1 gave the spectrum shown in Figure 
5.10 c). This shows that the relative abundance of hTrxR + AuPEt3 had increased 
markedly. In addition, peaks from several other new types of protein adducts were 
observed, including hTrxR + Au + AuPEt3 and hTrxR + 2 AuPEt3. The spectrum of a 
solution containing a 5:1 ratio of auranofin to TrxR (Figure 5.10 d) showed evidence of 
further complexation of the protein by Au+ ions and AuPEt3 moieties, with the peak 
corresponding to hTrxR + AuPEt3 now the most abundant (peak E). In addition, the 
peak assigned to hTrxR + Au + 2 AuPEt3 (peak J) was now of substantial abundance. 
The total number of gold ions or Au-ligand moieties derived from auranofin that 
became bound to hTrxR was not as great as was previously observed in reactions with 
aurothiomalate, aurothioglucose or aurothiosulfate. This suggests that there may not be 
as many binding sites on the protein accessible to auranofin as there are for the other 
three gold complexes. Despite this, the relative abundance of the peak corresponding to 
free hTrxR in Figure 5.10 d) was lower than in the corresponding spectra of solutions 
containing a 5:1 ratio of aurothiomalate, aurothioglucose or [Au(CN)2]‾, and hTrxR. 
This suggests that the smaller number of auranofin binding sites on the protein exhibit a 
higher affinity towards this gold complex. 
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Figure 5.10: Positive ion ESI mass spectra of solutions containing different ratios of auranofin and 
hTrxR, after transformation to a mass scale. ) gold : hTrxR = 0:1; b) gold : hTrxR = 1:1; c) gold : hTrxR 
= 3:1; and d) gold : hTrxR = 5:1. In each case, solutions containing auranofin and hTrxR were allowed to 
react for 4 h on ice before the spectrum was obtained. For ESI-MS, each sample contained 1.3 µM hTrxR 
in 5% acetic acid and 20 mM ammonium acetate. 
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The results presented in Figure 5.10 highlight the strength of the Au-P bond in 
auranofin, an observation that is supported by other studies involving this gold 
complex.74,109 For example, previous ESI-MS investigations into the interactions of 
human serum albumin (HSA) with AuPEt3Cl, a model complex for auranofin, showed 
that each of the protein adducts observed consisted of HSA molecules bound to one or 
more AuPEt3 moieties.
88 In the case of reactions between auranofin and hTrxR, the 
most abundant ions observed in the ESI mass spectra were those attributable to protein 
molecules with at least one or two AuPEt3 moieties bound. In contrast, ions from 
protein adducts containing only Au+ ions were of low abundance. The results obtained 
here are also consistent with those derived from investigations into the binding of 
auranofin to serum albumin, performed using 1HNMR spectroscopy,87 31P NMR 
spectroscopy82 and EXAFS.82 Each of these studies also provided evidence for the 
binding of AuPEt3 moieties to the protein. 
All of the gold(I) compounds studied showed similar binding behaviour towards 
hTrxR. Each reacted with the protein to form a mixture of different adducts, with some 
hTrxR molecules binding to multiple Au+ ions or gold/ligand fragments, or a mixture of 
both. There were, however, differences in the extent to which the compounds interacted 
with the protein that could be related to differencs in the lability of the metal-ligand 
bonds in the initial complex. For example, the dicyanoaurate ion interacted to a limited 
extent with hTrxR owing to the strength of the Au-CN bonds. In contrast, the polymeric 
compounds aurothiomalate and aurothioglucose showed more extensive binding than 
[Au(CN)2]‾ to the protein. However, this was not as extensive as what was observed 
with the discrete gold(I) compounds aurothiosulfate and auranofin. These latter 
observations may be attributable to slower rates of bond dissociation in the polymeric 
molecules limiting the availability of free Au+ ions or Au-ligand moieties for binding to 
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the protein. Overall, based on the mass spectrometric r sults shown in this section, the 
reactivity of the gold(I) compounds towards hTrxR follows the sequence: 
[Au(CN)2]‾ < aurothiomalate ≈ aurothioglucose < auranofin < aurothiosulfate 
It has previously been suggested that the strength of a gold-sulfur bond increases 
as the acidity of the thiol increases.302,303 Accordingly, the complex containing the most 
acidic thiol ligand should be expected to be the most stable and therefore exhibit the 
lowest degree of reactivity towards hTrxR. Comparing the pKSH values reported in 
literature for the thiol-containing ligands of the aforementioned complexes gives the 
following order: thiomalic acid (9.9302) > thioglucose (7.6302) > acetylthioglucose 
(6.4303) > thiosulfuric acid (0.6/1.74304). If the above hypothesis is correct, then 
thiosulfuric acid would be expected to show the least degree of reactivity towards 
hTrxR, and thiomalic acid the highest level of reactivity. These predictions are the 
opposite of what was observed, and instead suggest that the most important factor in 
determining the strength of the Au-S bonds, and therefore their reactivity, may be the 
basicity of the thiolate anions.  
To determine whether the addition of acid prior to ionisation might be causing 
dissociation of the complexes, experiments were performed where solutions of gold 
complexes were prepared without protein present, bu under similar solution and 
instrumental conditions. It was not possible to give definitive assignments to the signals 
observed for all five complexes. However, there were no noteworthy differences 
between spectra of the gold complexes that had beenacidified and spectra of those that 
had not been acidified. This implies that bond dissociation that leads to hTrxR binding 
is occurring due to either the ionisation process or the inherent kinetic lability of Au-S 
bonds. As such, while acidification may be favouring bond dissociation at a non-cellular 
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pH, the conditions that the reactions were initially performed do approximate normal 
cellular conditions, and did enable significant binding of gold to the protein to occur. 
In order to qualitatively examine the kinetics of the binding interactions between 
aurothioglucose and TrxR, a 3:1 mixture of the gold complex and hTrxR was prepared 
and aliquots removed and analysed by mass spectrometry at different time points. The 
results of this experiment are shown in Figure 5.11. After 30 min (Figure 5.11 a) peaks 
attributable to adducts of hTrxR with between two and four Au+ ions bound were 
present in relatively low abundance. When the reaction ime was increased to 1 h 
(Figure 5.11 b), and 4 h (Figure 5.11 c), peaks corresponding to adducts of the protein 
with even larger numbers (up to seven) of Au+ ions bound were observed, and increased 
in abundance at the longer reaction time. This trend continued when the reaction 
mixture was analysed again after 24 h (Figure 5.11 d). At this point peak J, 
corresponding to ions consisting of hTrxR with seven Au+ bound, was perhaps the most 
abundant protein adduct in the solution. When a similar experiment was performed 
using auranofin (Appendix C.1.4, Figure C.3), time appeared to have less of an 
influence on the extent of binding, with the majority of protein adducts containing Au+ 
or AuPEt3 forming after just 1 h of reaction. The contrast be ween the kinetics of these 
two reactions is most likely attributable to differences in the rates of ligand dissociation 
in the initial gold complexes, noted earlier. In summary, the rate of dissociation of the 
bridging thioglucose ligands in aurothioglucose was probably slower than for the 
acetylthioglucose ligand in auranofin. This would result in free gold ions being made 
available more slowly in the case of the former comp und, resulting in changes to the 
mass spectra occurring over a much longer period of time. 
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Figure 5.11: Positive ion ESI mass spectra of a solution containing a 3:1 ratio of aurothioglucose to 
hTrxR obtained after different periods of time, and transformed to a mass scale. Spectra were obtained 
after the gold complex and protein had reacted for: a) 30 min;  b) 1 h;  c) 4 h; and  d) 24 h. For ESI-MS, 
each sample contained 1.2 µM hTrxR, 20 mM ammonium acetate and 5% acetic acid. 
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Having established that each of the gold complexes selected for investigation 
could bind to hTrxR, it was of interest to see whether or not Au NPs might also interact 
with the protein. However, treatment of TrxR with up to 5 equivalents of Au NPs for as 
long as 24 h failed to give rise to any new peaks in ESI mass spectra (Appendix C.1.4, 
Figure C.4). There are several possible reasons for this outcome, including that the 
Au(0) atoms present in Au NPs are unlikely to form bonds with the protein that are 
sufficiently stable to survive the ESI process. Alternatively, the size of the nanoparticles 
may be sufficiently large to prevent them from approaching cysteine residues exposed 
on the surface of hTrxR. 
A number of literature studies have also examined th  interactions between Au 
NPs and proteins. One of the earliest such studies us d zeta potential measurements and 
quartz crystal microbalance techniques to examine the binding of Au NPs to bovine 
serum albumin.207 It was tentatively concluded that electrostatic forces, possibly 
involving the carboxylate groups of citrate anions on the surfaces of the Au NPs, and 
protonated amines of surface lysine residues of the protein, were responsible for the 
interactions. In a separate study, a combination of techniques including circular 
dichroism spectroscopy and dynamic light scattering, was used to perform 
measurements on systems containing citrate-stabilized Au NPs of various sizes, and a 
range of proteins found in human blood.208 The results of these investigations led to the 
development of a model in which the proteins formed an outer layer, or “corona” on the 
surface of the Au NPs, and a hypothesis that the overall strength of the interactions 
increased in accordance with nanoparticle size. Binding constants ranging from 104 to 
107 M–1 were obtained for these systems, indicating that te overall strength of the 
binding interactions could vary significantly. 
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Evidence of interactions between thioredoxin reductase and nanoclusters 
composed of 25 gold atoms stabilized by a tridecapeptid  has also been reported.209 The 
positively charged peptide was believed to enhance the solubility of the gold clusters, 
and also facilitate electrostatic binding interactions with a number of negatively charged 
amino acid residues near the active site of the enzyme. Molecular docking studies and 
molecular dynamics simulations were used to further probe the nature of the binding 
interactions, and improve understanding of the origins of the stability of the resulting 
assembly. It was also shown that the gold nanoclusters inhibit the activity of TrxR, 
leading to higher levels of reactive oxygen species and apoptosis in HeLa cells. Silver 
nanoparticles have also been reported to inhibit selenoprotein synthesis, and the activity 
of TrxR in vitro, resulting in an increase in oxidative stress.211 However, it should be 
noted that the mechanism of inhibition was proposed to involve Ag+ ions leaching from 
the nanoparticles, as opposed to being a consequence of binding of the nanoparticles 
themselves to the protein. 
The above studies highlight the ability of Au NPs and nanoclusters, as well as 
nanoparticles composed of other metals, to interact with proteins including TrxR.  Each 
of the techniques used in these literature studies was non-destructive, and therefore well 
suited for probing weak binding interactions between molecules. In contrast, whilst ESI-
MS is known to employ one of the “softer” ionization methods available for obtaining 
mass spectra, the ability of non-covalent assemblies of molecules to be analysed by this 
technique does vary depending on the experimental conditions (e.g. desolvation 
temperature). It is therefore possible that electrostatic interactions were occurring 
between the Au NPs and TrxR in samples prepared for the mass spectrometry 
experiments performed as part of this thesis project, but were not sufficiently stable for 
the resulting complexes to survive the conditions inside the mass spectrometer. 
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5.4 Experiments Involving Rat Thioredoxin Reductase 
All of the results presented earlier in this chapter were obtained from 
experiments performed using a mutant form of hTrxR in which the active site 
selenocysteine residue had been replaced by a cysteine. Although both amino acids 
show a significant degree of affinity towards soft metal ions such as gold(I), it has been 
reported that the binding interaction exhibited by selenol-containing amino acids and 
peptides is particularly strong.162,174,186 Therefore, when it became possible during the 
later stages of this project to obtain a commercial (Sigma-Aldrich) sample of the native 
selenol-containing form of TrxR (wild type rat TrxR, rTrxR), a further series of binding 
experiments was performed using ESI-MS and auranofin. The positive ion ESI mass 
spectrum of rTrxR after dialysis in ammonium acetate, and subsequent addition of 
acetic acid and methanol, is shown in Figure 5.12. The most abundant peak in the 
transformed spectrum was at 54514 Da (peak B), withadditional peaks of medium 
abundance at 54330 (peak A) and 54698 Da (peak C), and a number of other peaks of 
low abundance also present at higher masses. The number of different types of peaks 
present suggests that a number of different protein species were present in this solution. 
Calculation of the expected molecular mass of this protein from its sequence (Appendix 
C.2.1) gave a value of 54539.3 Da per monomer, after cleavage of the initiating 
methionine residue.228 This value matches closely to that of the most abundant peak 
(peak B) in the spectrum, confirming that there were significant amounts of rTrxR 
present. However, the differences in mass between pak B on the one hand, and peaks A 
and C on the other, could not be rationalised by proposing a specific amino acid had 
been lost/gained, or by common post-translational modifications or amino acid 
mutations. 
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Figure 5.12: Positive ion ESI mass spectrum of 1 µM rTrxR in 18 mM ammonium acetate, 1% acetic 
acid and 10% methanol. The spectrum has been transformed to a mass scale. Peak B is consistent with the 
expected mass of rTrxR, whilst peaks A and C are due to as yet unidentified protein species. 
In order to elucidate the identity of the protein species giving rise to peaks A and 
C, a sample of rTrxR was subjected to tryptic digestion and subsequent analysis by 
LC/MS/MS.* The results of this analysis (Appendix C.2.2, Figure C.5) showed that 
there were peptides present that were attributable to two completely different proteins. 
The first of these was the expected rat thioredoxin reductase 1 (cytoplasmic isoform). 
Surprisingly, however, rat pyruvate kinase (liver tissue isoform) was also found to be 
present and in approximately an equal quantity. Pyruvate kinase has a similar mass and 
isoelectric point to TrxR, which means that it was likely that they were eluted together 
during purification steps employing size and ion chromatography that would probably 
have been used by the commercial supplier. Whilst the proteomic analysis identified 
that rat pyruvate kinase was present in the supplied sample of rTrxR, neither peak A nor 
peak C in Figure 5.12 could be assigned to this protein. This indicates that there was 
likely to be at least three different proteins present in the commercial sample of rTrxR. 
One potential explanation for peaks A and/or C might be pyruvate kinase (molecular 
weight 58661.6 Da228,305) that was partially proteolysed during the purificat on 
procedure. Since it would be difficult to separate ll of the proteins present in the 
                                                 
* Performed by Dr. Matt Padula (University of Technology, Sydney) 
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sample of rTrxR in the time remaining at this stage of the PhD project, it was decided to 
perform a small number of gold binding experiments using the protein as supplied. 
Figure 5.13 shows the transformed mass spectra obtained after reaction of 
various ratios of auranofin with rTrxR. In the spectrum of the solution containing only 
the protein (Figure 5.13 a) peaks A and C have been assigned as contaminants, while 
peak B is attributed to rat thioredoxin reductase (rTrxR). When the protein was reacted 
with an equivalent amount of auranofin, the spectrum shown in Figure 5.13 b) was 
obtained. This also contained a peak of medium abundance at 54832 Da (peak D), 
which is attributable to rTrxR molecules with one AuPEt3 moiety bound. An additional 
peak of medium abundance was observed at 55014 Da (peak E), which was assigned to 
the protein contaminant responsible for peak C with one AuPEt3 group bound. This 
indicates that there was at least one contaminating protein present with an exposed 
amino acid side chain suitable for binding to this gold drug.  
When the ratio of auranofin : rTrxR was increased to 3:1, the resulting spectrum 
(Figure 5.13 c) showed more dramatic changes. In this spectrum, the peak assigned to 
rTrxR + AuPEt3 was now the most abundant, with an additional peak of medium 
abundance at 55147 Da (peak F) attributable to protein molecules with two AuPEt3 
moieties bound also present. Peak E corresponding to a contaminant protein with one 
AuPEt3 group bound was now also of high abundance, and an additional peak at 55330 
Da (peak G) corresponding to contaminant protein molecules with two AuPEt3 moieties 
bound was also present. Numerous other new peaks are also present in this spectrum, 
but were difficult to assign conclusively, although it is likely that some correspond to 
protein molecules with even larger numbers of AuPEt3 groups, and possibly bare Au
+ 
ions bound. 
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Figure 5.13: Positive ion ESI mass spectra of solutions containing different ratios of auranofin and 
rTrxR, after transformation to a mass scale. ) gold : rTrxR = 0:1; b) gold : rTrxR = 1:1; and c) gold : 
rTrxR = 3:1. In each case, solutions containing auranofin and rTrxR were allowed to react for 4 h on ice 
before the spectrum was obtained. For ESI-MS, each s mple contained 1.1 µM rTrxR in 1% acetic acid, 
10% methanol and 18 mM ammonium acetate. 
When the protein was reacted with five equivalents of auranofin, the resulting 
spectrum exhibited a very poor signal-to-noise ratio, preventing meaningful assignment 
of ions. Figure 5.14 illustrates the origin of the poor signal-to-noise ratio in this 
spectrum as the amount of auranofin was increased. It shows the raw ESI mass spectra 
(i.e. not transformed) of solutions containing various ratios of auranofin : rTrxR.  
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Figure 5.14: Raw positive ion ESI mass spectra of solutions containing different ratios of auranofin and 
rTrxR: a) gold : rTrxR = 0:1; b) gold : rTrxR = 3:1; and c) gold : rTrxR = 5:1. Solutions containing 
auranofin and rTrxR were allowed to react for 4 h on ice before a spectrum was obtained. For ESI-MS, 
each sample contained 1.1 µM rTrxR in 1% acetic acid, 10% methanol and 18 mM ammonium acetate.  
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For both the spectrum of the solution containing only the protein, and that of the 
solution containing only the 3:1 ratio of auranofin : rTrxR (Figure 5.14 a and b, 
respectively), characteristic envelopes of peaks associated with the various charge states 
of the protein are clearly visible and separate from each other. However, for the 
spectrum of the solution containing a 5:1 ratio of auranofin : rTrxR (Figure 5.14 c), 
there is no longer a distinct separation between peak envelopes corresponding to the 
different charge states of the various proteins and protein adducts. As a consequence, it 
was not possible to obtain a transformed mass spectrum of sufficient quality. While a 
similar problem was observed previously for spectra of reaction mixtures containing 
hTrxR and aurothiosulfate (Figure 5.8), it was further exacerbated here due to the 
presence of one or more contaminating protein species of high relative abundance. 
Therefore, further studies involving solutions contai ing higher Au : protein ratios 
would only be worthwhile after obtaining access to a purer sample of the protein. 
One of the most important conclusions to be drawn from this study is that the 
binding interaction between auranofin and rTrxR is very similar to that observed 
between this gold drug and hTrxR. In both cases the gold drug largely retained the PEt3 
moiety in its coordination sphere after binding to the protein. In addition, the spectra 
suggest that a series of dynamic equilibria were establi hed in solution, involving free 
protein molecules, as well as protein adducts containi g different numbers of AuPEt3 
moieties. Under the conditions used in these experiments, it did not appear that the 
presence of the selenol residue significantly affected the extent of binding to the protein 
by auranofin. 
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6.1 Conclusions 
The research presented in this thesis compares a number of aspects of the 
biological chemistry of gold(I) compounds used for the treatment of rheumatoid 
arthritis, with those of gold nanoparticles (Au NPs). There have been many studies that 
focussed solely on the biological activity of one or more anti-arthritic gold(I) 
compounds, and other studies have examined exclusive y the biological effects of 
various types of Au NPs. However, there have been fw, if any, investigations that set 
out to comprehensively compare the interactions of both classes of gold agents. These 
comparisons formed the overall aim of this project.  
Interest in studying Au NPs stemmed from two studies that reported they 
elicited powerful in vivo anti-inflammatory activity after administration to rats or 
humans; however, the mechanisms through which these effects occurred were unclear. 
Conflicting results in the literature concerning the biological activity of Au NPs also 
provided a focus and impetus for the research present d in this thesis. Most previous 
studies did not examine the effects of Au NPs prepared using the classical citrate-
reduction approach, or on a wide range of inflammation markers, as has been reported 
here. In addition, prior work did not set out to explore the importance of the shell 
surrounding and stabilising the nanoparticles on their biological activity. Many of the 
studies performed in this project focussed on the int ractions of the gold compounds 
and Au NPs with the mouse macrophage cell line, RAW264.7. Macrophages were 
chosen for these studies due to their integral rolein the immune system, and their 
contribution to rheumatoid arthritis progression. 
One specific aim of this project was to compare the cytotoxicity and cellular 
uptake of Au NPs to that of the gold compounds. Thetoxicity determined for auranofin 
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(IC50 = 4 µM) was found to be in good agreement with other cytotoxicity values widely 
reported in the literature. In contrast, the toxicity of aurothiomalate has not been 
previously studied as extensively, with the lack of toxicity reported here (IC50 > 1000 
µM) the first measure of cytotoxicity obtained using the MTT assay and macrophage 
cells. This result is in general agreement with thelow toxicity exhibited by this 
compound in other cytotoxicity assays. The cytotoxicity of aurothiosulfate had been 
investigated to a lesser degree than aurothiomalate, wi h the IC50 of 650 µM reported 
here being the first such value determined, and reflecting a low level of toxicity for this 
compound. Au NPs proved to be essentially non-toxic to the macrophages at 
concentrations up to 60 µM. The MTT assay could not be performed using higher 
concentrations of Au NPs as this would have required addition of such large volumes of 
stock Au NP solution, that substantial dilution of the cellular medium used to culture the 
macrophages would have occurred. Despite this, it was still possible to conclude that Au 
NPs were far less toxic than auranofin to the macrophages.  
Although treatment of macrophages with Au NPs did not lead to any cytotoxic 
effects, it still resulted in the incorporation of significant quantities of gold into the 
cells. Macrophages treated with solutions containing 2.5 µM or 60 µM Au NPs showed 
higher levels of intracellular gold than cells treaed with equivalent amounts of 
auranofin, aurothiomalate or aurothiosulfate. This was a significant result, as although 
the cellular uptake of various types of Au NPs had been studied previously, no prior 
investigation had directly compared the extent of uptake of Au NPs to that of anti-
arthritic gold compounds under the same conditions. In addition, the results of this study 
demonstrated that it was likely sufficient gold was incorporated into cells to elicit a 
biological response. 
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Another specific aim of this project was to compare, for the first time, the 
cellular distribution of Au NPs and gold(I) compounds after uptake by macrophages, 
using microprobe synchrotron radiation X-ray fluoresc nce (SR-XRF) imaging. This 
aim was achieved through experiments performed at two different synchrotrons. Images 
obtained at the Advanced Photon Source (Argonne National Laboratory, USA) of 
macrophages treated with aurothiomalate or Au NPs showed that the gold accumulated 
within the cells in discrete regions. This result was consistent with previous studies that 
showed that gold(I) compounds used for chrysotherapy become localised in lysosomal 
bodies, referred to as aurosomes in view of their high gold content. Similarly, Au NPs 
are taken up by cervical cancer, fibroblast, brain tumour and osteoblast cells through 
endocytosis, and become localised in lysosomes. SR-XRF images of large numbers of 
macrophages exposed to Au NPs were also obtained, using the XFM beamline at the 
Australian Synchrotron (Melbourne). These images showed that the gold was more 
extensively and evenly distributed between cells than gold incorporated into the cells 
after exposure to auranofin or aurothiomalate. Furthermore, field emission scanning 
electron microscopy experiments performed on macrophages treated with Au NPs 
confirmed that gold localised with the cells was inter alised, and not simply surface-
bound. 
A further aim of this project was to compare the effects of Au NPs and gold(I) 
compounds on the levels of specific inflammation mediators, in the hope of gaining 
insights into their mechanisms of action. The effects of auranofin have been 
documented thoroughly in the literature, with some pr vious studies having also 
focussed on the effects of aurothiomalate. Auranofin was shown to have powerful 
inhibitory effects on production of nitric oxide (NO), reactive oxygen species (ROS), 
and tumor necrosis factor (TNF), in macrophages activ ted using lipopolysaccharide 
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(LPS). In contrast, aurothiomalate had a much weaker inhibitory effect on the 
production of NO and ROS in macrophages treated with LPS. These results were in 
concordance with those available in the literature, which indicate that auranofin is in 
general a stronger inhibitor of the production of inflammation mediators than 
aurothiomalate. This may be due in part to auranofin being incorporated into cells to a 
greater extent than aurothiomalate, as demonstrated by the results of the GFAAS 
experiments presented here. However, it must be remembered that aurothiomalate is 
generally regarded as a more effective drug than auranofin for the treatment of 
rheumatoid arthritis. This suggests that the mechanism of anti-arthritic action of 
aurothiomalate may involve effects on pathways involving other types of inflammation 
mediators, and/or activity with other classes of cells or biological targets such as 
enzymes. 
Prior to commencement of this thesis, there was already a significant literature 
on the effects of Au NPs on inflammation markers. The results of these studies were 
variable, with Au NPs eliciting either a pro- or anti-i flammatory effect. One probable 
reason for these differences is variations in the identity of the stabilising agent used to 
prepare the nanoparticles and/or the size of the nanoparticles. As part of the current 
thesis research program, experiments were carried out in order to try to resolve this 
unanswered question. The citrate-stabilised Au NPs studied had no significant effect on 
the LPS-stimulated production of NO, ROS, or the anti-inflammatory cytokine 
interleukin-10 (IL-10), in macrophages stimulated by LPS. In addition, the Au NPs had 
only a small inhibitory effect on the production of the pro-inflammatory cytokine TNF. 
These results were surprising in view of the substantial uptake of gold revealed by 
GFAAS experiments, and supported by the results of electron microscopy experiments. 
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In addition, SR-XRF experiments provided evidence that the gold from Au NPs 
becomes widely distributed throughout individual macrophage cells. 
There are several possible explanations for the lack of biological activity 
exhibited by the Au NPs. First, Au NPs may interact with cells by a mechanism or 
mechanisms that do not involve the inflammation mediators investigated here. 
Secondly, the conditions under which the in vitro studies presented in this thesis were 
performed may be a poor approximation for in vivo conditions; and some key 
inflammation processes with which the Au NPs might either interfere or enhance may 
be absent. Finally, the Au NPs used may not have produced any substantial changes to 
macrophage function owing to the inertness of the Au(0) atoms. An additional set of 
studies performed using five different types of commercially available Au NPs, with 
different sizes and stabilising agents, did not shed any further light on the factors 
affecting their biological activity. In all cases, the Au NPs were unable to affect the 
production of the inflammation markers NO and ROS. Further work is therefore 
required to confirm that Au NPs are efficacious anti- rthritic agents in vivo, and if so, 
how those effects are elicited. 
The final specific aim of this thesis was to investigate the binding of gold(I) 
compounds and Au NPs to the redox enzyme thioredoxin reductase (TrxR). A 
motivation for investigating this enzyme was the uncommon selenocysteine residue 
normally present at the C-terminal active site, which has been reported to be a potent 
target for gold(I) ions, such as those present in most chrysotherapeutic agents and their 
metabolites. While this enzyme has been studied extensively as a drug target in recent 
years, few of these investigations attempted to directly probe its interactions with 
gold(I) compounds. For example, the question of whether any of the initial ligands 
bound to the metal ion remained after binding to the protein was still unanswered. The 
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studies presented in this thesis, performed using electrospray ionisation mass 
spectrometry (ESI-MS) and two forms of TrxR, were able to address this question.  
Addition of aurothiomalate, aurothioglucose or aurothi sulfate to solutions 
containing TrxR resulted in the formation of multiple protein adducts containing 
between one and seven bare gold ions bound to the enzyme. Little, if any, evidence for 
retention of any of the initial ligands bound to the metal was found in these 
experiments. In contrast, when the initial metal complex contained less labile Au-CN 
and Au-P bonds, protein adducts were formed in which one of the two original ligands 
was still also bound to the gold ion. Furthermore, th  extent of gold binding was lower 
in these instances. The results obtained with both types of TrxR revealed that there is 
likely to be a number of suitable binding sites for the gold compounds, in addition to the 
cysteine and selenocysteine residues at the C-terminus. Further experiments will be 
required to identify these additional binding sites. 
The interactions between Au NPs and TrxR were also investigated for the first 
time by ESI-MS. The Au NPs showed no sign of binding to the protein. Whether such 
interactions do occur, and whether ESI-MS is a suitable technique for investigating such 
interactions, remain open questions. For example, any interactions that might have 
occurred are unlikely to have been covalent in nature, and therefore may not have 
survived the ionisation conditions present in the mass spectrometer. Further work using 
alternative techniques is therefore required to provide a definitive answer to the question 
of the nature of any interactions between Au NPs and TrxR. 
6.2 Future Directions 
Despite the number of investigations performed intothe biological interactions 
of Au NPs, there remain a number of areas that needfurther work. The most important 
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area concerns the apparent lack of effect Au NPs have upon inflammation mediators. 
This could be investigated further in a number of ways. One is by expanding the studies 
to include other inflammation mediators. Such experim nts might shed light on whether 
the biological activity of Au NPs arises from interactions with other classes of 
inflammation mediators, including pro-inflammatory interleukins, transcription factors, 
or cell-surface receptors. Additional insight into why the Au NPs had no effect on the 
production of the inflammation mediators could be obtained from experiments 
performed using alternative methods of stimulating the macrophages. One such 
alternative method involves the pro-inflammatory cytokine interferon-γ. This would 
induce inflammation in the macrophages by a different pathway, which might serve as a 
better model for inflammation in patients with rheumatoid arthritis. For example, 
interferon-γ might lead to higher levels of production of the inflammation mediators 
examined in this thesis, or of other mediators thathave not yet been explored. If the 
latter were subsequently shown to be affected significa tly by prior treatment with any 
of the gold compounds or Au NPs, valuable clues might be obtained about the 
mechanism of action of the gold agents. 
The variability in results obtained from in vitro investigations into the biological 
effects of Au NPs also highlights the need for additional in vivo studies to confirm or 
disprove literature reports indicating they exhibit similar or improved levels of anti-
inflammatory activity compared to established chrysotherapeutic agents. These studies 
should be performed using Au NPs with known and different stabilising agents and/or 
particle sizes. In addition, they should be performed using different agents to induce 
symptoms of inflammation in the test animals. Examples of inflammation-inducing 
agents include Mycobacterium tuberculosis, collagen, pristane and LPS. Comparison of 
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the results of these studies will establish the most promising lead therapeutic agents, and 
will aid the design of future in vitro investigations. 
Whilst the effects of a range of Au NPs on production of NO and ROS were 
studied as part of this research project, in many cases it was not known what the identity 
of the stabilising molecules were, as this is the proprietary information of the chemical 
suppliers. This remains a key issue in understanding the biological chemistry and 
interactions of Au NPs, as variations in the identity of the stabilisers is one of the few 
possible reasons for different results reported in the literature, and here. It would also be 
of considerable interest to examine the biological nteractions of alloy nanoparticles, 
such as gold-silver nanoparticles containing known and varying amounts of gold and 
silver. Studies such as these might provide insight into the importance of the identity of 
the metal in determining the ability of nanoparticles to impact upon the inflammatory 
response. 
Although a number of useful results were obtained from the inflammation 
mediator experiments, these required careful interpretation. One reason for this is that 
the auranofin vehicle (1% DMSO/99% (v/v) incomplete medium) itself resulted in 
significant inhibition of LPS-induced ROS and TNF formation. If further experiments 
investigating the effects of auranofin were to be performed, it would be valuable to 
perform them using a vehicle containing a much lower (e.g. 0.1% (v/v)) concentration 
of DMSO.  
Some issues were also encountered whilst determining the effects of the gold 
compounds and Au NPs on ROS production. These experiments were performed using 
a flow cytometry method, which typically resulted in large variations between replicate 
samples, making meaningful interpretation of the data difficult. It would therefore be 
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worthwhile to repeat these investigations using an alternative method that involves 
plate-based fluorescence measurements, instead of flow-cytometric measurements of 
dichlorofluorescin concentration. Such an approach might provide more concrete 
evidence of effects being exerted by the gold compounds and Au NPs, which are only 
being hinted at in the data currently available.  
There are now a number of reports, including this tesis, which describe the 
effects of LPS on the production of cytokines by macrophages, and how this can be 
affected by pre-treating the cells with gold drugs. However, there still remains a lot to 
be learnt about the timing of the different cellular responses. In Chapter 4 of this thesis, 
the production of the anti-inflammatory cytokine IL-10 was described as an auto-
regulatory response to increased TNF levels, which resulted from the initial treatment of 
macrophages with LPS. While it has been shown conclusively in the literature that LPS-
stimulated macrophages produce interleukin-1β, which in turn leads to higher levels of 
IL-10, the same is not true for TNF. Perhaps more importantly, an unanswered question 
is whether treatment of RAW264.7 cells with LPS leads first of all to elevated levels of 
TNF or interleukin-1β, or both. In addition, do increases in IL-10 levels correlate more 
closely to a spike in the levels of just one or both interleukin-1β and TNF? One way to 
answer this question would be to treat the macrophages with LPS, and then measure the 
concentrations of all three cytokines at various time points. If, for example, the IL-10 
concentration was found to increase rapidly in respon e to a spike in TNF 
concentration, and not a change in interleukin-1β levels, this would suggest that the 
production of IL-10 is being induced as an auto-regulatory response to the sudden 
increase in TNF levels. 
A further question that remains from this work is why the Au NPs used in this 
thesis did not alter the production of the various inflammation mediators. One possible 
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explanation is that after entry into the cells, the gold remains in the elemental oxidation 
state, and is therefore not able to participate readily in reactions with various cellular 
components. In order to address this possibility, synchrotron radiation X-ray absorption 
spectroscopic measurements could be performed on macrophages after they have been 
exposed to gold compounds or Au NPs. This technique enables determination of the 
oxidation state of a metal atom or ion and also provides information about the ligand 
donor atoms directly bonded to it. Whilst this technique has previously been used to 
examine the metabolism of aurothiomalate in rats, it does not appear to have been used 
to explore the cellular fate of Au NPs and other gold compounds.  
Another area of future work involves expansion of the microprobe SR-XRF 
imaging experiments performed as part of this thesis project. A consequence of the 
overlap of the gold M line with the sulfur K line in these experiments was that it was 
not possible to determine whether gold from aurothiomalate or Au NPs was co-localised 
with sulfur inside the macrophages. This problem was exacerbated by the use of high 
concentrations of aurothiomalate or Au NPs in experim nts involving these gold 
reagents. Therefore one potential method for overcoming this issue, and determining if 
Au/S co-localisation does in fact occur, would be to use lower treatment concentrations. 
It would also be extremely worthwhile to perform additional experiments using thin-
sections or three-dimensional tomography of whole cells treated with Au NPs in order 
to determine whether the internalised gold was located entirely in the cytosol and 
excluded from the cell nucleus. 
Another question that lacks a definitive answer is whether Au NPs can interact 
with TrxR. Although ESI-MS failed to provide any evidence for such interactions, this 
may have been a result of the fragile nature of such complexes. It would therefore be 
worthwhile to explore these systems using other techniques. For example, the 
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interactions of Au NPs with proteins have previously been probed using circular 
dichroism spectroscopy and dynamic light scattering.  
Although ESI-MS did prove suitable for characterising the binding of the anti-
arthritic gold(I) compounds to TrxR, a number of additional experiments involving ESI-
MS could be performed to yield further information about these systems. For example, 
the ESI-MS results presented here did not provide any evidence for the exact location of 
the gold binding sites. This could potentially be accomplished by first reacting the 
protein with selective blocking agents such as iodoacetamide, which alkylates free 
cysteine residues, and then observing by ESI-MS whether gold binding behaviour is 
altered. This information could also be obtained by using a proteomics approach in 
which TrxR is reacted with a gold complex, and the resulting mixture of protein adducts 
subjected to digestion with trypsin, after which the resulting peptide fragments are 
analysed by mass spectrometry to determine which amino acids the gold has become 
bound to. 
The most important factor that limited the information that could be obtained 
from the ESI-MS results was the presence of protein molecules containing N-terminal 
gluconoyl and phosphogluconoyl groups in engineered human TrxR samples. These 
additional species made unambiguous assignment of some ions to specific gold-TrxR 
adducts problematic. There are two ways to attempt to rectify this problem. One is to 
investigate whether a chemical reagent could be used to selectively cleave the amide 
bond between these additional moieties and the N-terminus of the protein, without 
hydrolysing any of the other amide bonds in the rest of the protein. Alternatively, it may 
be possible to take advantage of the observation that the existence of these N-terminal 
modifications is very dependent on the identity of the amino acids between the hexa-
histidyl tag and the initiating methionine residue. Therefore, it may be possible to 
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engineer plasmids that prevent these modifications from occurring. A final area for 
improvement concerns the ESI-MS experiments performed using rat TrxR. The spectra 
of this protein were not as informative as hoped owing to the presence of additional 
peaks from as yet unidentified protein contaminants, which were present in significant 
quantities. It will therefore be necessary to purify these protein samples, for example, by 
chromatographic separation, or to obtain protein with a higher level of purity from 
another commercial source, before additional information can be obtained from ESI 
mass spectra concerning the ability of TrxR to bind to different gold complexes or Au 
NPs. 
In conclusion, the work presented in this thesis has contributed to our knowledge 
of the differences between how gold anti-arthritic compounds and gold nanoparticles 
interact with biological systems. Despite this, there remains much to be learnt about the 
origin of these differences in interactions, which s the key to the development of new 
gold therapeutic agents with improved efficacy. It is hoped that the experiments 
described in this thesis will guide future research efforts in this area, and thereby pave 
the way to future discoveries concerning anti-inflammatory gold compounds and 
nanoparticles.
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Appendix A:  
Preparation of Solutions used in Cell Assays and 
Graphite Furnace Operating Conditions 
 
 
A.1 PBS 
PBS solution was prepared by dissolving one Oxoid (Thermo Fisher) PBS tablet 
in Milli-Q H 2O and diluting to a final volume of 100 mL. This solution was then 
sterilized by autoclaving and stored at 4 °C. 
A.2 Saline Solution 
Trace metals pure saline solution was prepared by dissolving 0.90 g of trace 
metals pure NaCl in Milli-Q H2O, which was diluted to a final volume of 100 mL and 
stored at 4 °C. 
A.3 D-PBS 
D-PBS was prepared by dissolving 0.20 g KCl, 0.20 g KH2PO4, 8.00 g NaCl and 
1.14 g of Na2HPO4 in Milli-Q H 2O, which was diluted to a final volume of 1.00 L and 
stored at 4 °C. 
A.4 10×D-PBS 
10×D-PBS was prepared by dissolving 0.20 g KCl, 0.20 g KH2PO4, 8.00 g NaCl 
and 1.14 g of Na2HPO4 in ~90 mL of Milli-Q H2O, and adjusting the pH to 7.4 if 
necessary, before being  diluted to 100 mL and stored at 4 °C. 
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A.5 ELISA Wash Buffer 
ELISA wash buffer was prepared similarly, by adding 500 µL of TWEEN to D-
PBS solution prior to the final dilution to a volume of 1.00 L. This resulted in a solution 
with a final concentration of 0.5% v/v TWEEN/D-PBS, which was passed through a 20 
µm filter before use. 
A.6 Incomplete NaCl Medium 
Incomplete NaCl medium was prepared by first dissolving 0.20 g NaOH, 0.38 g 
KCl, 2.39 g HEPES and 8.18 g NaCl in ~900 mL of Milli-Q H2O, and adjusting the pH 
to 7.5 with 1 M NaOH solution. The solution was then diluted to a final volume of 1.00 
L using Milli-Q H2O and stored at 4 °C.  
A.7 Complete NaCl Medium 
Complete NaCl medium was prepared by addition of 0.09 g of glucose to 100 
mL of incomplete NaCl medium, then re-adjusting thepH to 7.5 if required. The 
solution was stored at -20 °C.  
A.8 TrxR Dialysis Buffers 
TrxR dialysis buffers were prepared by first dissolving 3.85 g (100 mM) or 
19.27 g (500 mM) ammonium acetate in ~450 mL of Milli-Q H2O. The pH of the 
solution was then adjusted to 7.2 with 1 M ammonia and acetic acid solution as required 
and diluted to a final volume of 500 mL using Milli-Q H2O before being stored at 4 °C. 
For buffers containing DTT, 77.1 mg of DTT was adde to the final solution 
immediately prior to dialysis. 
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A.9 Graphite Furnace AAS Operating Conditions 
Table A.1: Operating conditions for analysis of gold in digested cell samples using GFAAS. 
Stage 
Temperature 
(°C) 
Ramp 
Time (s) 
Hold 
Time (s) 
Gas Flow 
(mL/min) 
Dry 1 110 1 30 250 
Dry 2 130 15 30 250 
Ash 800 10 20 250 
Atomization 1800 0 5 0 
Clean Out 2450 1 3 250 
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Appendix B:  
SR-XRF Images & Spectra 
 
 
B.1 Microprobe SR-XRF Images 
B.1.1 Advanced Photon Source 
All samples were prepared by incubating the cells with the treatment solution at 37 °C 
under an atmosphere of 5% CO2 for 24 h. All maps were collected with the following 
operating conditions: beam energy = 13.450 keV; beam size = 0.5 μm; step size = 0.5 
μm; and dwell time = 0.5 s/pt. All elemental concentrations below each map have the 
units µg/cm2. 
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Figure B.1: Microprobe SR-XRF elemental maps obtained from RAW264.7 cells treated with treatment 
medium only. Scan dimensions (H x V) were 18.5 µm × 18.5 µm. 
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Figure B.2: Microprobe SR-XRF elemental maps obtained from RAW264.7 cells treated with 2.5 µM 
auranofin. Scan dimensions (H x V) were 50.5 µm × 50.5 µm. 
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Figure B.3: Microprobe SR-XRF elemental maps obtained from RAW264.7 cells treated with 1000 µM 
aurothiomalate. Scan dimensions (H x V) were 20.5 µm × 52.5 µm. 
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Figure B.4: Microprobe SR-XRF elemental maps obtained from RAW264.7 cells treated with 100 µM 
HAuCl4. Scan dimensions (H x V) were 30.5 µm × 28.5 µm. 
 
 
 
 
 
 
 
 
Appendix B: SR-XRF Images & Spectra 211 
     
P 
0.0-10.9 
S 
0.0-10.3 
Cl 
0.07-1.14 
K 
0.000-0.975 
Ca 
0.000-0.108 
     
Fe 
0.0000-0.0706 
Cu 
0.0000-0.00937 
Zn 
0.000-0.116 
Au 
0.0-87.4 
Scatter 
78-873 
Min  Max 
Figure B.5: Microprobe SR-XRF elemental maps obtained from RAW264.7 cells treated with 60 µM Au 
NPs. Scan dimensions (H x V) were 13.5 µm × 50.5 µm. 
 
 
 
Appendix B: SR-XRF Images & Spectra 212 
     
P 
0.0-16.5 
S 
0.0-13.0 
Cl 
0.13-1.83 
K 
0.00-1.12 
Ca 
0.000-0.140 
     
Fe 
0.0000-0.0805 
Cu 
0.0000-0.0107 
Zn 
0.000-0.163 
Au 
0-138 
Scatter 
210-1159 
Min  Max 
Figure B.6: Microprobe SR-XRF elemental maps obtained from a second set of RAW264.7 cells treated 
with 60 µM Au NPs. Scan dimensions (H x V) were 20.5 µm × 40.5 µm. 
 
B.1.2 Australian Synchrotron 
All samples were prepared by incubating the cells with the treatment solution at 37 °C 
under an atmosphere of 5% CO2 for 24 h. All maps were collected with the following 
operating conditions: beam energy = 12.055 keV; beam size = 2 μm; step size = 2 μm; 
dwell time = 1 s/pt; and scan dimensions (H × V) 120 μm × 120 μm. All values below 
each map represent relative quantifications of the elements and are unitless. 
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Figure B.7: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with treatment medium 
only. 
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Figure B.8: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 2.5 µM auranofin. 
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Figure B.9: Microprobe SR-XRF elemental maps for a second set of RAW264.7 cells treated with 2.5 
µM auranofin. 
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Figure B.10: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 2.5 µM 
aurothiosulfate. 
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Figure B.11: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 500 µM 
aurothiosulfate. 
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Figure B.12: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 2.5 µM 
aurothiomalate. 
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Figure B.13: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 1000 µM 
aurothiomalate. 
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Figure B.14: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 2.5 µM Au NPs. 
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Figure B.15: Microprobe SR-XRF elemental maps for RAW264.7 cells treated with 60 µM Au NPs. 
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B.2 SR-XRF Spectra 
Below are the integrated SR-XRF spectra for the corresponding SR-XRF images 
presented in Sections B.1.1 and B.1.2. In each image, the black spectrum is the 
integrated spectrum, the green spectrum is the fitted spectrum, and the red spectrum is 
the assigned Kα lines. Vertical lines indicate the expected energy positions of gold L or 
M lines. 
B.2.1 Advanced Photon Source 
 
Figure B.16: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with treatment medium. Vertical lines indicate the expected positions 
of Au L and M lines. 
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Figure B.17: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 2.5 µM auranofin. Vertical lines indicate the expected positions 
of Au L and M lines. 
 
Figure B.18: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 1000 µM aurothiomalate. Vertical lines indicate the expected 
positions of Au L and M lines. 
 
 
Appendix B: SR-XRF Images & Spectra 224 
 
Figure B.19: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 100 µM HAuCl4. Vertical lines indicate the expected positions 
of Au L and M lines. 
 
Figure B.20: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 60 µM Au NPs. Vertical lines indicate the expected positions of 
Au L and M lines. 
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Figure B.21: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 60 µM Au NPs. Vertical lines indicate the expected positions of 
Au L and M lines. 
B.2.2 Australian Synchrotron 
 
Figure B.22: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with treatment medium. Vertical lines indicate the expected positions 
of Au L and M lines. 
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Figure B.23: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 2.5 µM auranofin. Vertical lines indicate the expected positions 
of Au L and M lines. 
 
Figure B.24: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of a second set of RAW264.7 cells treated for 24 h wit 2.5 µM auranofin. Vertical lines indicate the 
expected positions of Au L and M lines. 
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Figure B.25: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 2.5 µM aurothi sulfate. Vertical lines indicate the expected 
positions of Au L and M lines. 
 
Figure B.26: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 500 µM aurothi sulfate. Vertical lines indicate the expected 
positions of Au L and M lines. 
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Figure B.27: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 2.5 µM aurothi malate. Vertical lines indicate the expected 
positions of Au L and M lines. 
 
Figure B.28: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 1000 µM aurothiomalate. Vertical lines indicate the expected 
positions of Au L and M lines. 
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Figure B.29: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 2.5 µM Au NPs. Vertical lines indicate the expected positions f 
Au L and M lines. 
 
Figure B.30: Integrated (black), fitted (green) and assigned Kα lines (red) of microprobe SR-XRF spectra 
of RAW264.7 cells treated for 24 h with 60 µM Au NPs. Vertical lines indicate the expected positions of 
Au L and M lines. 
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Appendix C:  
Thioredoxin Reductase Sequences, Spectra and 
Proteomics 
 
C.1 Human Thioredoxin Reductase 
C.1.1 Amino Acid Sequence 
Below is the full sequence of the mutant human TrxR plasmid as provided by 
Yan-Chung Lo and Andrew Wang (Academia Sinica, Taiwan). It is presented in a 
monospace font. 
MAHHHHHHVDDDDKMNGPEDLPKSYDYDLIIIGGGSGGLAAAKEAAQYGKKVMVLDFVT
PTPLGTRWGLGGTCVNVGCIPKKLMHQAALLGQALQDSRNYGWKVEETVKHDWDRMIEA
VQNHIGSLNWGYRVALREKKVVYENAYGQFIGPHRIKATNNKGKEKIYSAERFLIATGE
RPRYLGIPGDKEYCISSDDLFSLPYCPGKTLVVGASYVALECAGFLAGIGLDVTVMVRS
ILLRGFDQDMANKIGEHMEEHGIKFIRQFVPIKVEQIEAGTPGRLRVVAQSTNSEEIIE
GEYNTVMLAIGRDACTRKIGLETVGVKINEKTGKIPVTDEEQTNVPYIYAIGDILEDKV
ELTPVAIQAGRLLAQRLYAGSTVKCDYENVPTTVFTPLEYGACGLSEEKAVEKFGEENI
EVYHSYFWPLEWTIPSRDNNKCYAKIICNTKDNERVVGFHVLGPNAGEVTQGFAAALKC
GLTKKQLDSTIGIHPVCAEVFTTLSVTKRSGASILQAGCCG 
 
 
 
 
Appendix C: Thioredoxin Reductase 231 
C.1.2 ESI Mass Spectrum of hTrxR in Formic Acid 
Figure C.1 below shows the positive ion ESI mass spectrum of hTrxR after it 
had been transformed to a mass scale. The solution of the protein was dialysed three 
times for 3 hours each against 0.1% formic acid prior to mass spectral analysis. 
 
Figure C.1: Positive ion ESI mass spectrum of 1.1 µM hTrxR in 0.1% formic acid. 
 
C.1.3 Proteomics Results 
Figure C.2 shows the list of highest abundance fragments obtained from a 
trypsin digest of recombinant hTrxR. The digestion was analysed by LC/MS/MS, and 
after identification of the peptide fragments, was compared to a protein database using 
the search engine Mascot.230 This work was performed by Dr. Matt Padula of the 
University of Technology, Sydney. 
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Figure C.2: Protein identification results for hTrxR obtained using the search engine Mascot. Obtained 
by personal communication from Dr. Matt Padula, University of Technology, Sydney on 12/03/2015. 
 
C.1.4 Gold Binding Results 
Figure C.3 shows the positive ion ESI mass spectra obtained using a solution 
containing a 3:1 ratio of auranofin : hTrxR that had been allowed to react for different 
periods of time. Figure C.4 shows the positive ion ESI mass spectra obtained of a 
solution containing a 5:1 ratio of Au NPs : hTrxR after it had been allowed to react for 1 
h, 4 h and 24 h. The spectrum of a solution containing hTrxR only is included for 
comparison. 
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Figure C.3: Positive ion ESI mass spectra of a solution containing a 3:1 ratio of auranofin : hTrxR, 
transformed to a mass scale. The solution was analysed after being allowed to react for: a) 30 min; b) 1 h; 
c) 4 h; and d) 24 h. For ESI-MS, each sample contained 1.2 µM hTrxR, 20 mM ammonium acetate and 
5% acetic acid. 
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Figure C.4: Positive ion ESI mass spectra of a solution containing a 5:1 ratio of Au NPs : hTrxR, after 
transformation to a mass scale: a) is a spectrum of a solution containing hTrxR only, included for 
comparison. The solution reaction mixture was analysed after being allowed to react for: b) 1 h and c) 24 
h. For ESI-MS, each sample contained 1.2 µM hTrxR, 20 mM ammonium acetate and 5% acetic acid. 
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C.2 Rat Thioredoxin Reductase 
C.2.1 Amino Acid Sequence 
Below is the full sequence of rat TrxR obtained by searching the UniProt 
database for rat thioredoxin reductase (http://www.uniprot.org/ accessed 14/10/2014). It 
is presented in a monospace font. 
MNDSKDAPKSYDFDLIIIGGGSGGLAAAKEAAKFDKKVMVLDFVTPTPLGTRWGLGGTC
VNVGCIPKKLMHQAALLGQALKDSRNYGWKLEDTVKHDWEKMTESVQNHIGSLNWGYRV
ALREKKVVYENAYGKFIGPHKIMATNNKGKEKVYSAERFLIATGERPRYLGIPGDKEYC
ISSDDLFSLPYCPGKTLVVGASYVALECAGFLAGIGLDVTVMVRSILLRGFDQDMANKI
GEHMEEHGIKFIRQFVPTKIEQIEAGTPGRLKVTAKSTNSEETIEDEFNTVLLAVGRDS
CTRTIGLETVGVKINEKTGKIPVTDEEQTNVPYIYAIGDILEGKLELTPVAIQAGRLLA
QRLYGGSTVKCDYDNVPTTVFTPLEYGCCGLSEEKAVEKFGEENIEVYHSFFWPLEWTV
PSRDNNKCYAKVICNLKDNERVVGFHVLGPNAGEVTQGFAAALKCGLTKQQLDSTIGIH
PVCAEIFTTLSVTKRSGGDILQSGCUG 
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C.2.2 Proteomics Results 
Figure C.5 shows the list of highest abundance fragments obtained from  a 
trypsin digest of commercially obtained rTrxR. The digestion was analysed by 
LC/MS/MS, and after identification of the peptide fragments, was compared to a protein 
database using Mascot.230 This work was performed by Dr. Matt Padula of the 
University of Technology, Sydney. 
 
Figure C.5: Protein identification results for rTrxR obtained using the search engine Mascot. Obtained by 
personal communication from Dr. Matt Padula, University of Technology, Sydney on 12/03/2015. 
 
 
